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This doctoral research program comprised three separate prospective studies. Data 
collection was completed on 139 participants. 
Study 1: 
Two-minute walk test (2MWT): measurement properties and comparison of the 
cardiorespiratory and symptom responses with the six-minute walk test 
(6MWT) in people with moderate to severe chronic obstructive pulmonary 
disease (COPD) 
Background: Although the 6MWT is commonly used to measure functional 
exercise capacity in people with COPD, it does not appear to be routinely used 
among clinicians involved in the management of patients hospitalised with an acute 
exacerbation of COPD (AECOPD). This may be because clinicians consider the 
6MWT to be an inefficient use of their time as the severe dyspnoea that accompanies 
an exacerbation results in patients often need to rest frequently, or for prolonged 
periods during the test. Therefore, in the context of patients who experience severe 
dyspnoea on exertion, such as in some of those with moderate to severe COPD who 
are clinically stable or in those who are hospitalised for an AECOPD, the 2MWT 
may be an appropriate alternative to the 6MWT for assessing functional exercise 
capacity. However, there is a paucity of data pertaining to the measurement 
properties of the 2MWT and no studies have compared the cardiorespiratory 
responses between the 2MWT and the 6MWT. Aims: In people with moderate to 
severe COPD who experience severe dyspnoea exertion, to; (i) report the 
measurement properties of the 2MWT (i.e. effect of test repetition, coefficient of 
repeatability [COR] and validity), (ii) determine whether or not the two-minute walk 
distance (2MWD) is interchangeable with one third of the six-minute walk distance 
(6MWD) and, (iii) compare the cardiorespiratory responses and levels of symptoms 
elicited during the 2MWT with the 6MWT. Methods: Participants were recruited 
from patients who had been referred to the out-patient pulmonary rehabilitation 
program at Sir Charles Gairdner Hospital, Perth, Western Australia. All participants 
attended two testing sessions that were separated by a minimum of 48 hours and a 
maximum of 14 days. The sessions included completing three 2MWTs during the 
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first testing session, and one 2MWT and one 6MWT during the second testing 
session. Results: Twenty participants (nine [45%] males; age [mean ± SD] 72.5 ± 
8.3yr) with moderate to severe COPD (forced expiratory volume in one second 
[FEV1] 28 ± 13% predicted) completed this study. The 2MWD increased by a mean 
of 6m; 95% confidence interval (CI), 2m to 9m between walk 1 and walk 2, and by a 
mean of 4m; 95% CI, 2m to 6m between walk 2 and walk 3. When expressed as a 
percentage of difference from baseline, the 2MWD increased by a mean of 4%; 95% 
CI, 1% to 7% between walk 1 and walk 2 and a mean of 3%; 95% CI, 1% to 4% 
between walk 2 and walk 3. The bias and COR for the 2MWD were 1m and 14m, 
respectively. There was a strong linear relationship (r = 0.67, p < 0.01) between the 
2MWD and the 6MWD. The participants walked 31 ± 22m (27%) further during the 
2MWT than one third of the 6MWD (p < 0.001). Two (11%) participants rested 
during the 2MWT and 13 (72%) rested during the 6MWT (p < 0.001). Compared 
with data collected during the 6MWT, the 2MWT elicited significantly lower 
cardiorespiratory responses, demonstrated by lower peak heart rate (HR [107 ± 
13bpm vs. 112 ± 15bpm]) and higher nadir percutaneous oxygen saturation (SpO2 
[86 ± 6% vs. 82 ± 7%]) and less peak dyspnoea (Borg, 4.1 ± 2.0 vs. 5.0 ± 1.8) (all p 
< 0.05). Discussion and conclusions: The 2MWT had a very small learning effect 
which appears to be smaller than the learning effect for the 6MWD reported in 
previous studies. Therefore, a practice walk for the 2MWT may be less important 
and may not be necessary in people who may not be able to complete two 2MWTs 
within a day. The COR of 14m indicates that clinicians can be 95% confident that a 
difference of greater than 14m in response to an intervention is likely to represent a 
‘true’ change in this outcome as it exceeds measurement error and the natural 
variability inherent in this test. The strong relationship between the 2MWD and the 
6MWD supports the concurrent validity of the 2MWT as a measure of functional 
exercise capacity. The finding that the participants walked significantly further 
during the 2MWT than one third of the 6MWD indicates that these two values are 
not interchangeable. This information is particularly important for clinicians who 
evaluate the effect of an intervention (e.g. exercise program) using the 6MWT at 
baseline and are tempted to use the 2MWT on completion of the program in patients 
who develop an exacerbation or because the clinicians are under time pressure. Even 
though the 6MWT is three times as long as the 2MWT, comparing one third of the 
distance walked during the 6MWT performed at baseline with the 2MWD measured 
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post-intervention will lead to an over-estimation of the effects of the intervention on 
this outcome. The findings that a smaller proportion of participants rested during the 
2MWT compared with the 6MWT and the 2MWT elicited a lower peak HR, less 
oxygen desaturation and lower peak dyspnoea responses compared to the responses 
during the 6MWT, provides some evidence that the 2MWT is better tolerated than 
the 6MWT in people with moderate to severe COPD.  
Study 2: 
Regression equations to estimate the 2MWD in Malaysian adults aged 40 to 75 
years 
Background: The use of the 2MWT to assess functional exercise capacity has 
recently risen in popularity. However, the distance achieved during the test (i.e. the 
2MWD) may be difficult to interpret in the absence of normative data in a healthy 
local population. To date, there are only two regression equations available to 
estimate the 2MWD; one was derived from a sample of Brazilian adults and the other 
one was derived from a sample of American adults. Earlier studies that established 
equations to estimate the 6MWD in one ethnicity appear to be of limited accuracy in 
other ethnicities. Therefore, it is likely that the two equations previously published to 
estimate the 2MWD will be of limited accuracy in a sample of Malaysian adults. 
Aim: In Malaysian adults aged between 40 and 75 years who present with no 
significant disease, to (i) develop regression equations to estimate the 2MWD and, 
(ii) ascertain differences between the measured 2MWD with that estimated using the 
two previously published regression equations. Methods: Participants were 
volunteers who responded to flyers distributed in four villages located in the Batu 
sub-district, Gombak, Malaysia. All participants attended a single 3-hour session and 
completed two 2MWTs. Using a stepwise linear regression analysis, the best 2MWD 
was used as the dependent variable and age, gender, height, weight and change in HR 
(ΔHR) during the test were used as independent variables. Results: Eighty seven 
participants (43 [49%] males; age 57.1 ± 9.6yr) completed this study. The 2MWDs 
measured during the two consecutive 2MWTs were 193 ± 33m and 199 ± 34m, 
respectively, with the best 2MWD being 200 ± 34m. Males achieved a greater 
2MWD compared with females (217 ± 31m vs. 184 ± 28m; p < 0.001). The predictor 
variables that explained the largest proportion of variance in the 2MWD were 
gender, age and ΔHR during the test. The following equation explained 73% of the 
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variance in 2MWD, m: 196 - (1.1 × age, yr) + (1.0 × ΔHR) + (31.2 × gender [males 
= 1, females = 0]). When ΔHR was excluded from the equation, age and gender 
explained 47% of the variance in 2MWD, m: 279 - (1.7 × age, yr) + (35.9 × gender 
[males = 1, females = 0]). The 2MWD estimated using the equation derived from an 
American sample significantly under-estimated the 2MWD measured in the sample 
of Malaysian adults by 23 ± 27m (p < 0.001). Although the average 2MWD 
estimated using the equation derived in a sample of Brazilian adults was similar to 
the 2MWD measured in Malaysian adults, the Bland and Altman plots showed the 
presence of proportional error between the 2MWD measured in the sample of 
Malaysian adults and the 2MWD estimated using both existing equations. 
Discussion and conclusions: The equations derived in this study allow the main 
outcome of the 2MWT (i.e. the 2MWD) in clinical populations in Malaysia, as well 
as countries with similar cultural backgrounds and anthropometric characteristics to 
Malaysia, such as Indonesia, Singapore and Southern Thailand to be interpreted as a 
percentage of the value estimated in a person without significant disease (i.e. % 
predicted). Expressing the 2MWD as a % predicted value provides individuals and 
healthcare professionals with an indication of the magnitude of functional exercise 
capacity lost as the consequence of their condition. Inclusion of ∆HR in the first 
regression model explained an additional 26% of the variance in the 2MWD and is 
therefore likely to produce a more accurate estimate than the equation that does not 
include ∆HR. However, the second regression equation, which does not include ∆HR 
is more likely to be appropriate when interpreting the 2MWD in clinical populations 
who have factors known to influence the HR response during exercise, such as 
certain cardiovascular medications. Disparity between the measured 2MWD with 
that estimated using both of the existing equations highlights the importance of using 
regression equations derived in a local sample.  
Study 3:  
A randomised controlled trial of exercise training in people hospitalised with an 
AECOPD 
Background: Acute exacerbations of COPD are important events in the clinical 
course of people with COPD and they represent a major burden to patients as well as 
healthcare systems. Severe AECOPDs which necessitate hospitalisation have been 
demonstrated to impair functional exercise capacity, quadriceps muscle force (QMF) 
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and levels of physical activity (PA). Most importantly, one exacerbation increases 
the risk of recurrent exacerbations and the frequency of AECOPDs is associated with 
worse prognosis in this population. Therefore, strategies are needed to minimise the 
negative consequences of severe AECOPDs and the risk of further AECOPDs. In 
people with stable COPD, exercise training reduces dyspnoea and fatigue, feelings of 
anxiety and depression, improves exercise capacity, health-related quality of life 
(HRQoL) and reduces healthcare utilisation. However, in contrast to the large body 
of evidence supporting exercise training in people with stable COPD, evidence to 
support its benefits in people hospitalised for an AECOPD is limited. Aims: In 
people hospitalised with an AECOPD, to; (i) evaluate the effects of an exercise 
program comprising walking and resistance exercises, initiated within two days of 
hospitalisation, on exercise capacity (2MWD), QMF, functional performance (i.e. Sit 
to Stand Test [STST] and Timed Up and Go [TUG]) test and PA and, (ii) compare 
the level of adherence to supervised and unsupervised training sessions. Methods: 
Participants were recruited from patients who were hospitalised for an AECOPD in 
two general hospitals in Kuala Lumpur, Malaysia (Hospital Selayang and Institute of 
Respiratory Medicine). Within two days of hospital admission, participants 
completed baseline testing and were randomised to either a control group (CG) or an 
exercise group (EG). Participants in the CG received standard usual care (e.g. 
medical and nursing care, airway clearance and encouragement to mobilise). In 
addition to standard usual care, participants in the EG performed individualised, 
progressive walking and functional resistance exercises throughout the 
hospitalisation period. They were prescribed with one supervised and one 
unsupervised training session each day. Primary outcomes were 2MWD and QMF. 
Secondary outcomes were the STST, TUG test and daily steps recorded using a 
Stepwatch Activity Monitor. Results: Thirty two participants (31 males [97%]; age 
64.2 ± 7.8yr; FEV1 33 ± 14% predicted) completed all the measurements during 
baseline and re-assessment. Median [interquartile range] hospital length of stay in the 
EG and CG were 8 [6 to 9] and 7 [6 to 8] days, respectively (p = 0.64). Those in the 
EG completed 4 ± 1 (range 2 to 6) supervised and 4 ± 1 (range 2 to 7) unsupervised 
exercise sessions. Compared with changes seen in the CG group, those in the EG 
demonstrated greater gains in 2MWD (33 ± 15m vs. 20 ± 13m; p = 0.01) and QMF 
(5.9 ± 3.4kg vs. 3.1 ± 3.6kg; p = 0.03). No between-group differences were seen in 
the magnitude of change in the STST or TUG test. Compared with the CG, the EG 
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spent less time being sedentary (median [interquartile range] 1154 [1082 to 1275] 
min per day vs. 1261 [1177 to 1342] min per day; p = 0.04) and more time walking 
at a low intensity (248 [143 to 307] min per day vs. 126 [84 to 221] min per day; p = 
0.03). No between-group differences were observed in the amount of time they spent 
walking at a moderate intensity or the average number of steps taken per day. 
Adherence to supervised and unsupervised sessions was similar (96 ± 9% vs. 92 ± 
13%; p = 0.22). Discussion and conclusions: In people hospitalised with an 
AECOPD, an individualised, progressive exercise program that comprised walking 
and resistance exercises significantly reduced the deleterious effects of an AECOPD 
on exercise capacity and QMF. In contrast with other randomised controlled trials of 
exercise training in people hospitalised with an AECOPD which demonstrated no 
effect on exercise capacity, the program prescribed in this study used a combination 
of both walking and resistance training and was powered to detect between-group 
differences in exercise capacity and QMF. The lack of between-group difference in 
STST and TUG test may reflect the fact that participants in this study did not present 
with substantial impairment in these outcomes at the time of recruitment. The 
training program also appears to have positive effect on levels of PA. The EG spent 
less time being sedentary and more time walking at low intensity compared to the 
CG. The lack of between-group difference in the average number of steps taken per 
day over the hospitalisation period may reflect a Type II error in the analysis. The 
high level of adherence to the training sessions as well as the similar adherence to 
supervised and unsupervised exercise sessions suggest that exercise intervention 
initiated within two days of hospital admission was well tolerated. 
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CHAPTER 1  
INTRODUCTION 
 
This program of research focuses on the assessment and rehabilitation of people with 
chronic obstructive pulmonary disease (COPD), who are characterised by profound 
dyspnoea on exertion. Two prospective cross-sectional studies and one randomised 
controlled trial (RCT) were conducted in a total of 139 participants. Study 1 
evaluated the measurement properties of the two-minute walk test (2MWT), 
including the effect of test repetition, coefficient of repeatability and validity, the 
difference between the distance walked during the 2MWT and one third of the 
distance walked during the six-minute walk test (6MWT) and compared the 
cardiorespiratory responses and the severity of dyspnoea and leg fatigue reported 
during the 2MWT and the 6MWT. Study 2 developed regression equations to 
estimate the two-minute walk distance (2MWD) in Malaysian adults who presented 
with no significant disease. Study 3 evaluated the effectiveness of an exercise 
program in people hospitalised with an acute exacerbation of COPD (AECOPD) in 
Malaysia. The exercise program comprised both walking and resistance exercise and 
was evaluated in terms of its effect on outcomes such as functional exercise capacity, 
quadriceps muscle force (QMF), functional performance and levels of physical 
activity (PA). 
This chapter provides a rationale for the development of each research question. The 
hypotheses for each research question are described (where appropriate) and the 
significance of the research program is discussed. The order of the research questions 
described is consistent with the order in which Chapters 3 to 5 are presented. 
 




1.1 Study 1  
2MWT: measurement properties and comparison of the cardiorespiratory and 
symptom responses with the 6MWT in people with moderate to severe COPD 
1.1.1 Background 
The 2MWT and the 6MWT were introduced in 1982 as alternatives to the original 
twelve-minute walk test (12MWT) as they were considered to be less burdensome 
for patients with respiratory disease and less time consuming for clinicians (1, 2). 
The 6MWT was subsequently proposed as the test of choice as it was better tolerated 
by patients with cardiorespiratory diseases than the 12MWT, and was believed to 
more accurately reflect the requirements of daily living activities than the shorter 
2MWT (1). Nevertheless, the uptake of this test is poor among people hospitalised 
with an AECOPD (3). This may be because clinicians consider the 6MWT to be an 
inefficient use of their time as the severe dyspnoea that accompanies an exacerbation 
results in patients taking frequent and/or prolonged rests during the test. Earlier work 
has shown that at least 20% of those who are clinically stable require between one 
and four rests during the 6MWT (4-6). It seems likely that this proportion would be 
greater in those hospitalised with an AECOPD. Therefore, in the context of patients 
who experience severe dyspnoea on exertion, such as those who are hospitalised for 
an AECOPD or even in some of those with moderate to very severe disease, the 
2MWT may be an appropriate alternative to the 6MWT in measuring functional 
exercise capacity.  
The first study conducted in this program of research sought to investigate several 
measurement properties of the 2MWT and compare the cardiorespiratory and 
symptom responses elicited during the 2MWT and the 6MWT in people with 
moderate to severe stable COPD. 
This study reported the effect of test repetition on 2MWD. Earlier work has reported 
inconsistent findings with respect to the effect of test repetition on the 2MWD (1, 2, 
7, 8), with some, but not all reporting a small but significant increase in the 2MWD 
with test repetition (1, 2, 7). Information regarding whether or not the 2MWD 
increases significantly with test repetition is important to clinicians who wish to use 
the 2MWT to evaluate change in functional exercise capacity following an 
intervention. If the 2MWD is found to increase significantly with test repetition, 




practice test(s) would then be necessary at baseline. Failure to account for the 
influence of test repetition (if present) on 2MWD would result in an over-estimation 
of the effect any intervention has on this outcome. 
This study also reported the coefficient of repeatability (COR) for the 2MWD. These 
data are important in order to understand how much the 2MWD may differ with test 
repetition simply due to inherent error in the test. That is, a change in the 2MWD 
following an intervention that exceeds the COR means that the clinician can be 95% 
confident that a difference of this magnitude was due to the intervention as it exceeds 
the threshold of error inherent in the test.  
Data collected in this study also allowed for comparison of measures collected 
during the 2MWT (i.e. the 2MWD) with measures collected during the 6MWT (i.e. 
six-minute walk distance [6MWD]). Specifically, these analyses allowed the validity 
of the 2MWD as an assessment of functional exercise capacity to be explored by 
determining the strength of the association between the 2MWD and 6MWD. Further, 
the 2MWD was also compared with one third of the distance in the 6MWD. 
Determining whether or not these two measurements are interchangeable with each 
other is important for clinicians who evaluate the effect of an intervention, such as an 
exercise training program, using the 6MWT. That is, given that the 6MWT is exactly 
three times as long as the 2MWT, in the event that a patient develops an AECOPD or 
when time is limited, clinicians might be tempted to use the 2MWT on completion of 
the program and one third of the 6MWD performed at baseline as the baseline 
2MWD. If these two measurements are not interchangeable with each other, 
comparing one third of the distance walked during the 6MWT performed at baseline 
with the 2MWD measured post-intervention will lead to either an over- or under-
estimation of the effects of the intervention on this outcome. 
Finally, this study compared the cardiorespiratory and symptom responses elicited 
during the 2MWT with those elicited during the 6MWT. Although earlier work (8) 
suggests that people with stable COPD report a significantly higher rating of 
perceived exertion (RPE) on completion of the 6MWT compared to the 2MWT, no 
studies have compared the cardiorespiratory responses (heart rate [HR] and 
percutaneous oxygen saturation [SpO2]) elicited during the 2MWT with the 6MWT 
in people with moderate to severe COPD. Understanding whether or not the 2MWT 




elicits less cardiorespiratory and symptom burden when compared with the 6MWT 
will support the use of the 2MWT as an alternative to the 6MWT in people who 
experience severe dyspnoea on exertion, such as in some of those with moderate to 
severe stable COPD or in patients who are hospitalised with an AECOPD.  
While all the results in this study are most relevant to patients with moderate to 
severe stable COPD, it is also possible that the results could be extended to those 
who are hospitalised for an AECOPD. This is because this study specifically 
recruited patients who were likely to have similar characteristics as those 
experiencing an AECOPD, such as profound dyspnoea and oxygen desaturation on 
exertion and marked impairment in exercise capacity (90% of the participants had 
severe to very severe COPD, 80% requiring wheeled walker and 80% were on long 
term oxygen therapy).  
1.1.2 Research questions and hypotheses (where appropriate) 
1.1.2.1 Primary research question and hypothesis 
i) Research question: 
What is the magnitude of change in the 2MWD with test repetition? 
Hypothesis:  
The 2MWD will change (i.e. increase) significantly with test repetition. 
1.1.2.2  Secondary research questions and hypotheses 
ii) Research question: 
What is the COR for the 2MWD measured over two days? 
Hypothesis:  
No hypothesis will be tested. The research question will be answered with 
a descriptive statistic. 
 
iii) Research question: 
Is the 2MWD associated with the 6MWD? 
Hypothesis:  
There will be a positive strong association between the 2MWD and the 
6MWD. 
 
iv) Research question: 




Is the distance walked during the 2MWT different to one third of the 
6MWD? 
Hypothesis:  
The distance walked during the 2MWT is different (i.e. greater) than a 
distance equivalent to one third of the 6MWD. 
 
v) Research question: 
Does the 2MWT elicit different cardiorespiratory responses and levels of 
symptoms when compared with the 6MWT? 
Hypothesis:  
The 2MWT will elicit different (i.e. less) cardiorespiratory responses and 
different (i.e. lower) levels of symptoms when compared with the 6MWT. 
1.2 Study 2 
Regression equations to estimate the 2MWD in Malaysian adults aged 40 to 75 
years 
1.2.1 Background 
The 2MWT has been used in people with respiratory diseases (1, 2, 7-9), as well as 
in other clinical populations, such as in people with poliomyelitis (10), multiple 
sclerosis (11, 12) and stroke (13), in those undergoing cardiac surgery (14), lower 
limb amputation (15), and in the healthy elderly (16). However, despite the 
increasing use of the 2MWT, regression equations to estimate the main outcome of 
the test (i.e. 2MWD) are still limited. Such equations allow clinicians to estimate the 
2MWD in the general population and thereby express the 2MWD in a clinical 
population as a percentage of the estimated value. Expressing the 2MWD as a 
percentage of the value estimated in general population allows clinicians to provide 
people with a health condition with an indication of the degree of impairment in 
functional exercise capacity that was due to their condition. 
To date, there are only two regression equations available to estimate the 2MWD; 
one was derived from a sample of Brazilian adults (17) and the other one was derived 
from a sample of American adults (18). This is in contrast to the 6MWT, where at 
least 20 regression equations are available to estimate the 6MWD in healthy 
individuals (19-38). Of note, the regression equations published to estimate the 




6MWD use different predictors, different coefficients for the same predictors, and 
produce 6MWDs that differ by as much as 200m for any given individual (23, 26, 
27). In addition to differences in the test protocol (i.e. track length, use or not of 
encouragement), differences in the predictors retained in each equation, and the 
influence of each predictor in these equations reflects, at least in part, discrepancies 
in sample characteristics. For example, in two studies where the 6MWT was 
performed using an identical protocol, by the same team of investigators but in two 
samples of different ethnicities, the equation derived to estimate the 6MWD in 
Chinese Singaporean retained different predictors and different coefficients for the 
same predictors to the equations derived to estimate the 6MWD in Caucasian 
Australian (21, 39). Factors such as disparities in body composition, cultural and 
lifestyle differences between Asian and Caucasian populations may explain these 
differences. Given the fact that the two previously published regression equations 
(17, 18) that estimate the 2MWD were derived in American (18) and Brazilian 
samples (17), it is likely that these equations will not be appropriate to estimate the 
2MWD in a sample of Malaysian adults. Therefore, the second study conducted in 
this program of research sought to develop regression equations to estimate the 
2MWD in Malaysian adults. This study is important because, in the absence of 
normative data derived from a local population, the distance achieved during the 
2MWT (i.e. the 2MWD) for an individual patient may be difficult to interpret. 
1.2.2 Research questions and hypotheses 
1.2.2.1 Primary research question and hypothesis 
i) Research question: 
Can age, gender, height, weight and change in HR (∆HR [i.e. peak measured 
HR during the 2MWT - resting HR]) explain at least 50% of variance in the 
2MWD? 
Hypothesis:  
Age, gender, height, weight and ∆HR will account for at least 50% of variance 
in the 2MWD.  
1.2.2.2 Secondary research questions and hypotheses 
ii) Research question:  




Is the 2MWD measured in Malaysian adults similar to the 2MWDs estimated 
using the equations derived from Brazilian and American samples? 
Hypothesis:  
The 2MWD in Malaysian adults is different (i.e. smaller) than the 2MWD 
estimated using the regression equations derived from Brazilian and American 
samples. 
1.3 Study 3 
An RCT of exercise training in people hospitalised with an AECOPD 
1.3.1 Background 
Acute exacerbations of COPD that necessitate hospitalisation (i.e. severe AECOPD) 
are important events in the clinical course of people with COPD and account for the 
largest component of the treatment cost for this condition (40-42). When compared 
with people who are clinically stable, those who are hospitalised for an AECOPD are 
characterised by an increase in dyspnoea and fatigue (43, 44), a greater impairment 
in quadriceps muscle force (QMF) (45-47), worse exercise capacity (48-50), lower 
levels of PA (47, 51), and poorer health-related quality of life (HRQoL) (40). There 
is also evidence suggesting that, in some patients, the decrease in exercise capacity 
and PA levels, and the loss in QMF during hospitalisation for AECOPD have not 
recovered to the pre-exacerbation values two to three months following hospital 
discharge (46-48, 52, 53).  
 
Hospitalisation for an AECOPD has also been identified as the single best predictor 
for both recurrent AECOPDs as well as hospitalisations for AECOPDs (40, 54-56). 
In a longitudinal study of 295 people with COPD, Hurst et al. (55) found that at least 
30% of the 2,189 exacerbations recorded over their 2-year study period were 
recurrent exacerbations. They also found that AECOPDs were not random events, 
instead clustering together in time, with the high-risk period for recurrent 
exacerbation to be within the first 8 weeks after an exacerbation (55). Importantly, 
hospitalisations for AECOPD are associated with worse prognosis in this population 
(57-59). Specifically, hospitalisation for an AECOPD has been identified as one of 
the independent predictors of mortality in people with COPD (57), with the mortality 
rates amongst those who survive the hospital admission ranging from 22% (57, 58) 
to 43% (59) at one year following hospital discharge. Therefore, strategies are 




needed to minimise the negative consequences of AECOPD and the risk of recurrent 
exacerbation. 
 
In people with stable COPD, there is strong evidence demonstrating that pulmonary 
rehabilitation programs (PRPs), which include an exercise training component, lead 
to an improvement in multiple outcomes including dyspnoea and fatigue, feelings of 
anxiety and depression, exercise capacity and health-related quality of life (60, 61). 
There is also evidence demonstrating that PRPs reduce hospitalisations for 
AECOPDs (62-64).  Despite this evidence in people with stable COPD, the evidence 
to support the role of exercise training during hospitalisation for AECOPD is limited. 
This is somewhat surprising as it is possible that implementing a program of exercise 
training during hospitalisation for AECOPD maybe assists in reducing the 
deleterious effects of an AECOPD and thereby assists in reducing the risk of future 
AECOPDs. Studies that have explored the effects of exercise training during 
hospitalisation for an AECOPD have often initiated the exercise program between 
four and eight days following hospital admission (i.e. once clinical status had been 
stabilised) (65-67). This limits the generalisability of the results of these studies to 
countries, such as Malaysia and Australia in which the length of stay for an 
AECOPD is often less than one week (68, 69).  
To date, only three RCTs have explored the effects of exercise training commenced 
within two to three days of hospitalisation for an AECOPD and evaluated the effect 
of the intervention prior to hospital discharge (70-72). These RCTs showed that 
exercise training commenced within two to three days of hospitalisation was safe and 
feasible (70-72). However, despite the evidence for the benefits of walking-based 
training on outcomes such as exercise capacity and HRQoL in people in with stable 
COPD (73, 74), two of these three studies prescribed an exercise training program 
that comprised exclusively resistance exercise (71, 72). Studies that prescribed a 
resistance only exercise program reported inconsistent effects on exercise capacity 
and QMF at the time of discharge from the hospital (71, 72). The only RCT that 
investigated the effects of an exercise training program that comprised both walking 
and resistance exercise, initiated within two days of hospitalisation, did not 
demonstrate significant between-group differences in favour of the intervention 
group on exercise capacity or QMF (70). The lack of between-group differences was 




presumably due to the small sample size available for analyses (n ≤ 11 per group). 
Further, none of the three RCTs have investigated the effect of exercise training 
commenced within two to three days of hospitalisation for an AECOPD on 
functional outcomes such as the Sit to Stand test (STST) and the Timed Up and Go 
(TUG) test or have monitored PA on a daily basis throughout the hospitalisation 
period. Therefore, the third study conducted in this program of research sought to 
determine the effects of an exercise program that comprised both walking and 
resistance exercise, initiated within two days of hospitalisation for an AECOPD, on 
outcomes including QMF, exercise capacity, level of PA, STST and TUG. This RCT 
was conducted in two general hospitals in Kuala Lumpur, Malaysia. Data collected 
in this RCT also allowed the level of adherence to supervised and unsupervised 
training sessions to be compared. Such information is important, as it will allow 
clinicians to appreciate whether supervision of the training sessions is essential to 
optimise adherence. 
1.3.2 Research questions and hypotheses 
1.3.2.1 Primary research question and hypothesis 
i) Research question: 
Does an exercise program, initiated within two days of hospital admission, that 
comprises walking and resistance exercise, produce additional benefits in 
exercise capacity, QMF, functional performance and PA, over and above any 
changes seen with usual care? 
Hypothesis: 
Participation in the exercise training will produce significant positive changes in 
exercise capacity, QMF, functional performance and PA, over and above any 
changes seen with standard usual care. 
1.3.2.2 Secondary research questions and hypotheses 
ii) Research question: 
Is there a difference in the level of adherence between supervised and 
unsupervised exercise training sessions? 
Hypothesis: 
The level of adherence to supervised exercise sessions will be different (i.e. 
higher) than the level of adherence to unsupervised exercise sessions. 




1.4 Significance and novelty of the research 
This program of research will contribute novel and important information pertaining 
to both the assessment and rehabilitation of people with COPD who are characterised 
by profound dyspnoea on exertion, such as those hospitalised for an AECOPD.  
The first study in this program of research investigated the measurement properties 
of a simple field-based test of functional exercise capacity, the 2MWT. This 
information can be used by clinicians to guide implementation of this test and 
interpretation of its results and is most likely to be of use to those working with 
people with COPD who are characterised by profound dyspnoea on exertion. This is 
because, in this group of people, the 6MWT may be considered burdensome and in 
those who need to rest frequently or for long periods, the 6MWT is an inefficient use 
of both the patient’s and clinician’s time. This limits the uptake of the 6MWT in 
people hospitalised with an AECOPD (3). The use of the 2MWT in people for whom 
the 6MWT is perceived to be burdensome or inefficient, offers clinicians the 
opportunity to evaluate the effectiveness of interventions, such as exercise training, 
using an objective measure of functional exercise capacity, the 2MWD. Further, 
similar to the way in which the 6MWD has been used to prescribe the initial intensity 
of walking-based exercise training (75), the 2MWD may provide a basis for exercise 
prescription in those for whom the 6MWT is perceived to be burdensome or 
inefficient.  
The second study in this program of research developed regression equations to 
estimate the 2MWD in Malaysian adults. These equations are the first to estimate the 
2MWD in adults living in the Asian region, and therefore are likely to be the most 
appropriate to facilitate interpretation of the 2MWD in clinical populations in 
Malaysia as well as in other Asian countries with similar cultural backgrounds and 
anthropometric characteristics to Malaysia, such as Indonesia, Singapore and 
Southern Thailand.  
The third study in this program of research evaluated the effects of an exercise 
program in people hospitalised with an AECOPD on important outcomes such as 
functional exercise capacity, QMF, functional performance and daily PA. The 
intervention investigated in this study was initiated within two days of hospital 
admission and included both walking and resistance exercise. The exercise training 




program required minimal equipment and could be easily replicated in areas of low 
healthcare funding. If the exercise intervention is found to be effective, this study 
will be the first to demonstrate that an exercise training program initiated early 
during hospital admission, using minimal equipment, can mitigate the negative 
consequences of AECOPD on exercise capacity, QMF, functional performance and 
PA. These findings will contribute importantly to the current evidence for such 
interventions. Data collected during this RCT also builds on information presented in 
the first study performed in this program of research by exploring the responsiveness 
of the 2MWD following exercise training in people hospitalised for an AECOPD. 
Finally, this program of research is particularly novel given that two of the studies 
were conducted in Malaysia, a country where very little work in the area of 
pulmonary rehabilitation has been done in the past.




CHAPTER 2  
LITERATURE REVIEW 
 
This literature review is divided into four parts.  
Part 1 provides information pertaining to the definition, prevalence, classification of 
severity, causes, risk factors and cost associated with chronic obstructive pulmonary 
disease (COPD) and an acute exacerbation of COPD (AECOPD). Part 2 discusses 
the pulmonary and extra-pulmonary impairments of people with COPD, and includes 
a description of their clinical characteristics such as dyspnoea and fatigue, decreased 
exercise capacity, low levels of physical activity (PA) and impaired health-related 
quality of life (HRQoL), and the impact of hospitalisation for an AECOPD. This 
section also provides a summary of the assessment techniques commonly used to 
measure dyspnoea and fatigue, muscle force and endurance, exercise capacity, PA 
and HRQoL in people with COPD. Part 3 focuses on the literature which has 
reported data pertaining to the measurement properties of the two-minute walk test 
(2MWT) as an assessment of functional exercise capacity in people with COPD and 
tolerance when compared to tests such as the six-minute walk test (6MWT) and the 
twelve-minute walk test (12MWT). This section also describes the literature which 
has reported data pertaining to the interpretation of the primary outcome of the 
2MWT (i.e. the two-minute walk distance [2MWD]). Part 4 reviews studies which 
have reported the effects of exercise training in people hospitalised for an AECOPD. 
Specifically, this section discusses the quality of the studies and the effects of 
exercise training on exercise capacity, quadriceps muscle force (QMF), PA, HRQoL 
and healthcare utilisation. This part of the literature review is the longest as; (i) it 
reviews earlier work related to the most complex study undertaken in this program of 
research (i.e. the randomised controlled trial which investigated the effects of 
exercise training initiated in people hospitalised with an AECOPD) and, (ii) there 
was considerably more literature to review in this area than other topics related to 
this thesis such as the use of the 2MWT to measure exercise capacity in people with 
COPD. 




2.1 Part 1 
Chronic obstructive pulmonary disease is a common and costly condition mostly 
associated with cigarette smoking (76). Unlike many other common chronic diseases, 
the prevalence and burden of COPD are predicted to rise due to the continuous 
exposure to COPD risk factors such as cigarette smoking and air pollution and the 
ageing of the world’s population (76-78). Section 2.1.1 provides the definition and an 
overview of the prevalence of COPD in Australia and Malaysia. Section 2.1.2 
describes the methods used to diagnose and classify the severity of COPD and 
AECOPDs. Section 2.1.3 provides an overview of the causes and risk factors for 
COPD and AECOPDs. Section 2.1.4 provides information regarding the cost 
associated with the management of COPD as well as AECOPD. 
2.1.1 Definition and prevalence of COPD 
Chronic obstructive pulmonary disease is a preventable and treatable lung disease 
characterised by persistent airflow obstruction that is usually progressive. The 
chronic airflow obstruction characteristic of COPD is caused primarily by a 
combination of small airway diseases (chronic bronchitis) and parenchymal 
destruction (emphysema), each of which contributes to a varying degree from 
individual to individual (76). Chronic obstructive pulmonary disease was reported as 
the sixth leading cause of death worldwide in 1990 (79), fifth in 2002 and is 
projected to be the third leading cause of death by 2020 (80). The prevalence of 
individuals with at least moderate COPD in Australia was estimated to be 7.5% for 
those aged 40 years and over and 29.2% in those aged 75 years and over (81). In 
2008, the disease was estimated to affect more than 2.1 million Australians (i.e. 
nearly 1 in 5 individuals aged > 40 years) (82). Data reporting the prevalence of 
COPD in Malaysia are limited. Based on model projections, using the prevalence of 
risk factors for COPD, the prevalence of moderate to severe COPD in Malaysia was 
estimated to be 4.7% for individuals aged 30 years and over (83). However, this 
prevalence is likely to be an under-estimation as spirometric data collected in similar 
regions (i.e. the Philippines) has demonstrated the prevalence of COPD among those 
aged ≥ 40 years to be 12.5% (84).  
2.1.2 Diagnosis and classification of severity of COPD and AECOPD 
The diagnosis of COPD is confirmed by spirometry, with the most important 
measures being the forced vital capacity (FVC) and the forced expiratory volume in 




one second (FEV1) (76). The exact criteria for the diagnosis and classification of the 
disease severity vary in the literature (Table 2.1). The British Thoracic Society (BTS) 
(85), National Institute of Health and Clinical Excellence (NICE) (86) and Thoracic 
Society of Australia and New Zealand (TSANZ) (87) define airway obstruction 
based on a fixed FEV1/FVC ratio < 0.70 and FEV1 below 80% of predicted value in 
healthy individuals (i.e. % predicted). In contrast, the Global Initiative of Obstructive 
Lung Disease (GOLD) (76), American Thoracic Society/European Respiratory 
Society (ATS/ERS) (88) and Malaysia Clinical Practice Guidelines (CPG) (89) 
define airflow obstruction based only on the fixed FEV1/FVC ratio < 0.70 with no 
criteria based on the measurement of FEV1 expressed as a % predicted.  
 
Table 2.1: Classification of severity of COPD 
  FEV1 % predicted 
GOLD 
grade 
Description GOLD, ATS/ERS and 
Malaysia CPG 
BTS, NICE and TSANZ  
I Mild  ≥ 80%  60% to 80% 
II Moderate  ≥ 50% to < 80%  40% to 59 % 
III Severe  ≥ 30% to < 50%  < 40% 
IV Very severe < 30% or < 50% with 
chronic respiratory failure 
 
Abbreviations: ATS/ERS, American Thoracic Society/European Respiratory Society; 
BTS, British Thoracic Society; CPG, Clinical Practice Guidelines; FEV1, forced expiratory 
volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; 
NICE, National Institute for Health and Care Excellence; TSANZ, Thoracic Society 
Australia and New Zealand. 
 
The clinical course of COPD includes periods of clinical stability punctuated by 
periods of acute worsening, known as AECOPDs. An AECOPD is defined as a 
period during which people with COPD experience a sustained (i.e. ≥ 24 hours) 
worsening of symptoms beyond their normal day-to-day variation, that is acute in 
onset and necessitates a change in their regular medications (90). Symptoms of an 
AECOPD vary between individuals (91), with the most common being increased 
dyspnoea, cough, wheezing and chest tightness and increased sputum volume and 
purulence. Non-specific symptoms such as fatigue and general malaise are also 
common during an AECOPD (76). The severity of an AECOPD is often classified 
based on the utilisation of healthcare resources by patients (90). A mild exacerbation 
is characterised when a patient has an increased need for medication but he/she can 
manage the condition in own normal environment. A moderate exacerbation is 




characterised when a patient has an increased need for medication and feels the need 
to seek additional medical assistance. A severe exacerbation is characterised when a 
patient or caregiver recognises obvious and/or rapid deterioration in condition which 
requires hospitalisation (90). 
2.1.3 Causes and risk factors for COPD and AECOPD  
Both environmental and genetic risk factors have been identified in the development 
and progression of COPD (76). With regard to the environmental risk factors, 
exposure to cigarette smoke has been estimated to account for approximately 85% of 
the risk of developing COPD (92), and thus is the most important risk factor. 
However, it is important to note that that not all people with the same smoking 
history will develop COPD. Thus, there are factors other than exposure to cigarette 
smoke that play a role in the development of COPD. Genetic factors such as 
deficiency of the serine protease α1-antitrypsin enzyme, exposure to other 
environmental hazards (e.g. air pollution or occupational dusts) and advancing age 
have also been shown to increase the risk of COPD (93). 
 
Regarding the causes and risk factors for AECOPD, published data suggest that 50 -
70% of exacerbations are due to bacterial or viral infections, 10% are from 
environmental pollution and about 30% are of unknown aetiology (94). Several other 
factors have also been demonstrated to increase the risk of an AECOPD. These 
include a history of exacerbations in the previous year (54, 56, 95, 96), more severe 
airflow limitation (40, 54, 95, 96), older age (54, 96), winter season (40, 55), poor 
quality of life (40, 95) and underlying comorbidities (e.g. diabetes mellitus, 
ischaemic heart disease) (96). Of all these risk factors, a history of exacerbation in 
the previous year has been consistently identified as the single best predictor for both 
an AECOPD as well as hospitalisation for an AECOPD (40, 54, 56, 95). 
2.1.4 Cost of COPD and AECOPD 
Chronic obstructive pulmonary disease is associated with a large direct and indirect 
economic burden. Direct costs are costs that directly relate to the disease such as the 
costs for in-patient care, physician services, prescription drugs, out-patient visits, 
special care visits, home healthcare and nursing home care (97). Indirect costs of 
COPD are costs primarily related to reduced labour force participation such as lost 
wages of the patient, lost wages of the caregivers, and employer-borne costs such as 




absenteeism and sick leave, disability and impaired work performance costs (97). In 
Australia, the total cost of COPD in 2008 was estimated to be AUD $8.9 billion 
(approximately USD $6.7 billion). Of this, AUD $0.9 billion (USD $681 million) 
was reported from direct healthcare expenditure and the remaining AUD $8 billion 
(USD $6.1 billion) was reported from indirect costs such as lost productivity due to 
lower employment, absenteeism and premature death (82). Data reporting the direct 
and indirect costs of COPD in Malaysia are limited. As estimated from the 
prevalence of COPD National Burden of Disease Study, Ministry of Health Malaysia 
(98), the total cost of COPD was estimated to be approximately RM2.25 billion 
(USD $560 million) per annum. This cost includes out-patient visits, travelling costs, 
annual visits for primary care, specialist care visits and hospitalisation costs. Chronic 
obstructive pulmonary disease also results in a high economic burden in countries 
like the United States of America (USA) and the European Union (EU). It was 
estimated that the direct and indirect costs of COPD in the USA in 2010 were USD 
$29.5 billion and USD $20.4 billion, respectively (76). Whereas, in the EU, the total 
direct and indirect costs associated with COPD in 2011 were €23.3 billion (USD $26 
billion) and €25.1 billion (USD $28 billion), respectively (99).  
 
The higher costs of COPD in countries like the USA and EU when compared to the 
costs of COPD in countries like Malaysia and Australia may be partly explained by 
the differences in the prevalence of the disease as well as the size of the population 
between these countries. For example, the prevalence of COPD in the USA and EU 
were estimated to be higher than that estimated for both Malaysia and Australia (i.e. 
15.2% and 13.7% (100) vs. 4.7% (83) and 7.5% (81), respectively). Thus, it can be 
appreciated that the costs would be greater in countries with more people with 
COPD. In addition to the higher prevalence of COPD, the size of the population in 
the USA and EU were also at least 10 times greater than the size of the population in 
Malaysia and Australia. This means that, there would be more people with COPD for 
every percentage of increase in prevalence in the USA and EU than in Australia and 
Malaysia. Of note, several studies have reported that the management of an 
AECOPD accounts for the largest component of the treatment costs of COPD (40-
42), representing between 50% and 75% of the total treatment costs of COPD (88).  





Chronic obstructive pulmonary disease is a preventable and treatable chronic lung 
disease, characterised by persistent airflow obstruction that is usually progressive. 
The prevalence of COPD is high in developing countries such as Malaysia as well as 
in developed countries like Australia. The diagnosis of COPD is usually confirmed 
by spirometry. The clinical course of COPD includes periods of clinical stability (i.e. 
periods where there have been no change in respiratory symptoms that required a 
change in medication for ≥ 4 weeks) and periods of acute worsening of respiratory 
symptoms, known as an AECOPD. The severity of an AECOPD is usually classified 
based on healthcare utilisation. Severe AECOPD (i.e. exacerbations that necessitate 
hospitalisation) represent a major burden to patients as well as healthcare systems. 
2.2 Part 2 
Chronic obstructive pulmonary disease is increasingly recognised as a systemic 
disease rather than a disease of the respiratory system alone. It is characterised by 
pulmonary and extra-pulmonary impairments and associated with several chronic 
comorbidities such as cardiovascular disease, osteoporosis, and anxiety and 
depression. Section 2.2.1 provides an overview of the pulmonary pathology and its 
physiological consequences (i.e. pulmonary hyperinflation and gas exchange 
abnormalities). Section 2.2.2 provides an overview of the systemic pathology that 
occurs during COPD and describes one extra-pulmonary consequence (i.e. skeletal 
muscle dysfunction) that has been demonstrated in people with COPD. A detailed 
discussion of other systemic manifestations and comorbidities described in this 
clinical population is beyond the scope of this thesis. Section 2.2.3 reviews the 
clinical characteristics of people with COPD, which include symptoms of dyspnoea 
and fatigue, impairments in exercise capacity, low levels of PA and poor HRQoL. 
This section also provides a summary of the assessment techniques commonly used 
to measure dyspnoea and fatigue, muscle force and endurance, exercise capacity, PA 
and HRQoL in this population. 
2.2.1 Pulmonary pathology and pathophysiology in COPD  
2.2.1.1 Pulmonary pathology 
Pulmonary pathology in COPD occurs as a result of exposure to noxious particles 
(e.g. cigarette smoke and/or environmental pollution) which trigger a series of 




protective inflammatory responses in the lungs. Repeated injury and repair amplifies 
the normal protective inflammatory response and results in changes to the central and 
peripheral airways, lung parenchyma and pulmonary vasculature (93, 101).  
 
Inflammation within the central airways is associated with epithelial, squamous and 
goblet cell metaplasia, mucous gland hypertrophy, ciliary dysfunction, degeneration 
of airway cartilage, increased smooth muscle and connective tissue in the airway 
wall and mucus hypersecretion (93). These changes are responsible for the symptoms 
of chronic cough and sputum production in people with COPD (102). Inflammation 
within the peripheral airways results in smooth muscle hypertrophy, remodelling, 
fibrosis and airway narrowing, and is responsible for airflow obstruction in people 
with COPD (93). Of note, the structural changes in the wall of the peripheral airway 
are an important cause of the increase in peripheral airway resistance, which 
contributes to pulmonary hyperinflation, ventilation-perfusion (V/Q) mismatch and 
gas exchange abnormalities in COPD (102).  
 
Lung parenchyma includes the area for gas exchange of the lung (i.e. respiratory 
bronchioles and alveoli) and the pulmonary capillary system. The damage within the 
lung parenchyma (i.e. dilatation and destruction of the respiratory bronchioles, 
alveolar walls and pulmonary capillary bed) seen with COPD contributes further to 
expiratory airflow limitation and gas exchange abnormalities (93, 102). Inflammation 
within the pulmonary vasculature results in thickening of the vessel wall and is 
associated with an increase in pulmonary vascular pressure that develops first with 
exertion and then at rest, and, late in the course of the disease, the development of 
pulmonary hypertension and cor pulmonale (93). During an episode of AECOPD, the 
inflammatory response in people with stable COPD is triggered by viral or bacterial 
infections or air pollutants to further increase the production of eosinophils, 
neutrophils and several other inflammatory mediators such as cytokines and 
chemokines and leads to greater respiratory impairments and symptoms (102).  
2.2.1.1.1 Pulmonary hyperinflation  
In people with COPD, the pulmonary pathology within both the peripheral airways 
and lung parenchyma reduces lung elastic recoil, which in turn leads to a reduction in 
the driving pressure for expiratory flow through narrowed airways (102). 




Consequently, during resting spontaneous breathing, the end-expiratory lung volume 
(EELV) increases, a process known as static lung hyperinflation (103). This process 
worsens during exercise as the increased respiratory demand (i.e. increased minute 
ventilation) results in insufficient time to allow for a complete expiration because it 
is interrupted by the next inspiratory effort before the respiratory system has reached 
the static equilibrium volume. This process is known as dynamic hyperinflation (DH) 
of the lungs (104). As an AECOPD is often characterised by worsening airway 
obstruction, both static and dynamic hyperinflation worsen during an AECOPD 
(103). Regarding measurement, whole body plethysmography is the gold standard 
for measuring static EELV (103), whereas the rate and magnitude of DH is generally 
measured in the laboratory by making serial measures of inspiratory capacity during 
a cycle ergometry test (105). Dynamic hyperinflation is the main factor contributing 
to the sensation of dyspnoea (see subheading 2.2.3.1.1) and exercise limitation in 
COPD (103, 104). 
2.2.1.1.2 Gas exchange abnormalities 
In addition to causing lung hyperinflation, pulmonary pathology within the 
peripheral airways and lung parenchyma also leads to problems with gas exchange 
(i.e. V/Q mismatching). For example, in people with a predominantly 
emphysematous phenotype, there is a greater destruction of parenchyma compared to 
the changes in peripheral bronchioles, which in turn results in increased ventilation 
of poorly perfused lung units (i.e. high V/Q ratio) (106). In contrast, people with 
COPD who have a substantial magnitude of impairment in the airways, are more 
likely to have a low V/Q ratio resulting from hypoventilation (106). 
Ventilation/perfusion abnormalities are also one of the most important causes of 
arterial hypoxemia in people with COPD, which is measured as the partial pressure 
of oxygen in arterial blood (PaO2) or indirectly via pulse oximetry (107). The 
prevalence and magnitude of hypoxemia appear to increase with disease progression 
and during exertion or an AECOPD (106-108). Rodriguez-Roisin et al. (107) found 
that the prevalence of mild to moderate hypoxemia (i.e. PaO2 of < 80mmHg to ≥ 
60mmHg) increased from 40% to 72% from mild to severe COPD. During an 
AECOPD, the worsening of the V/Q mismatch or the increase in gas exchange 
abnormalities is often explained by the increase in airway obstruction due to 
worsening of airway inflammation, bronchospasm or mucus secretions. These 




changes result in a greater proportion of blood flow diverted through the poorly-
ventilated lung units and a decrease in mixed venous oxygen tension due to greater 
oxygen consumption by the respiratory muscles (108). The presence of hypoxaemia 
in COPD has been associated with the development of pulmonary hypertension and 
polycythaemia as well as skeletal muscle dysfunction in people with COPD (106). 
2.2.2 Systemic pathology 
Chronic obstructive pulmonary disease is associated not only with an abnormal 
inflammatory response in the lungs, but also with evidence of systemic 
inflammation. That is, when compared to healthy controls, people with COPD have 
an increased in systemic oxidative stress (109, 110), enhanced chemotaxis in the 
circulating inflammatory cells (e.g. neutrophils) (111) and increased plasma levels of 
inflammatory cytokines in their peripheral circulation. These abnormal systemic 
inflammatory responses have been shown to be further increased during an AECOPD 
(110, 112). The origin of the systemic inflammation in people with COPD is still 
unclear. However, it could be due to the spill-over of inflammatory molecules from 
the inflamed pulmonary parenchyma through the pulmonary circulation (113). 
Systemic inflammation has been demonstrated to be associated with several systemic 
consequences such as nutritional abnormalities, weight loss, skeletal muscle 
dysfunction, cardiovascular disease, glucose intolerance, osteoporosis and depression 
(114).  
2.2.2.1 Skeletal muscle dysfunction  
Although dysfunction of various skeletal muscles has been described in the literature, 
arguably one of the most important is the dysfunction seen in the quadriceps muscle. 
Reduced QMF has been identified as a significant predictor for important outcomes 
such as impaired exercise capacity, number of hospital admissions due to AECOPD 
(115), number of out-patients visits to pulmonary clinics (115) and survival (116).  
2.2.2.1.1 Changes in structure 
Changes within the quadriceps muscles of people with COPD include profound 
muscle atrophy. Relative to data collected in healthy controls, people with COPD 
have a lower mean ± standard deviation (SD) cross-sectional area of rectus femoris 
muscle (348 ± 78mm2 vs. 463 ± 137mm2; p = 0.001), measured by ultrasound (117). 
In addition to having smaller quadriceps muscle, there is evidence that the quality of 




the muscles is also impaired as several cellular morphological modifications have 
also been observed in quadriceps muscle of people with COPD (118, 119). For 
example, following biopsy of the vastus lateralis muscle, people with COPD 
demonstrated a marked reduction in the proportion of Type I muscle fibres (34 ± 
14% vs. 58 ± 16%; p < 0.0005) with a corresponding increase in Type IIb muscle 
fibres (15 ± 12% vs. 5 ± 5%; p = 0.015) when compared with healthy controls (119). 
The cross-sectional area of Type I, IIa and IIb fibres were found to be smaller and the 
number of capillary contacts across these three fibre types were reduced in people 
with COPD when compared to healthy controls (119). Mitochondrial function has 
also been shown to be altered in the quadriceps muscle of people with COPD (120-
123). When compared with healthy controls, both the mitochondrial volume density 
as assessed by mitochondrial enzyme activities (120-122) and expression of key 
transcription factors for mitochondrial biogenesis (123) have been shown to be 
reduced in the quadriceps muscle of people with COPD. The activity of citrate 
synthase in the vastus lateralis muscle fibres of people with COPD was shown to be 
reduced by approximately 40% when compared with healthy controls (120-122).  
 
The cause of the quadriceps muscle dysfunction is likely to be multi-factorial and 
includes deconditioning, corticosteroid use, weight loss, gas exchange abnormalities 
and hormone and electrolyte imbalances (124, 125). 
2.2.2.1.2 Impairments in strength 
The changes described above result in several impairments in the way the quadriceps 
muscle functions in people with COPD. Earlier work has demonstrated a reduction in 
the force-generating capacity of the quadriceps muscle in people with COPD (126-
129). This impairment relates to the reduction in the muscle’s cross-sectional area 
(126, 127). A retrospective study involving a large cohort of participants with COPD 
(n = 591) conducted in the United Kingdom and the Netherlands reported that 
quadriceps muscle weakness was evident in approximately 30% of participants 
(127).  
The prevalence of quadriceps muscle weakness increases with an increase in disease 
severity (126-128). In one example, Seymour et al. (127) found that at least 25% of 
people with mild disease demonstrated with quadriceps muscle weakness and the 
number increased to 38% in those with very severe disease. Quadriceps muscle force 




has been shown to be further compromised during episodes of AECOPDs (46, 47). 
Spruit et al. (46) found that QMF was the lowest in people hospitalised for an 
AECOPD when compared with those who were clinically stable as well as with 
healthy controls (66 ± 22% vs. 86 ± 16% vs. 103 ± 20% predicted). The mean 
reduction in QMF was reported to be between 5% (46) and 8% (47) within only five 
days of hospitalisation. More importantly, both of these studies demonstrated that the 
reduction in QMF during the hospitalisation period took a very long time to recover. 
Pitta et al. (47) found that QMF did not return to pre-exacerbation values even after a 
month following hospital discharge. Spruit et al. (46) demonstrated that QMF had 
improved only by 8% 90 days following hospital discharge. Possible mechanisms for 
the greater reduction in QMF during hospitalisation for an AECOPD include 
increased systemic inflammation (46) and oxidative stress (45), the administration of 
oral corticosteroids (130) and inactivity and bed rest (47). One clear example, when 
compared to healthy controls, Crul et al. (45) found that the levels of markers that 
indicate muscle disuse (e.g. MyoD protein and IGF-I) were significantly lower in 
people hospitalised with an AECOPD, and MyoD protein in particular was shown to 
have a moderate association with QMF (r = 0.45; p < 0.05).  
Regarding measurement, several methods have been described to assess QMF, such 
as manual muscle testing (MMT), one-repetition maximum (1-RM), the use of a 
hand-held dynamometer (HHD) and devices such as an isokinetic dynamometer or a 
system which allows participants to perform an isometric maximal voluntary 
contraction against a fixed resistance, with the QMF measured using a force 
transducer or strain gauge. Devices which allow participants to perform an isometric 
maximal voluntary contraction against a fixed resistance are considered gold 
standards. This is because, compared to HHD and MMT, these methods have been 
shown to provide very sensitive measurements of strength and have the ability to 
detect small differences in isometric forces (131, 132). 
2.2.2.1.3 Impairments in endurance 
In addition to a reduction in QMF, several studies have demonstrated lower 
quadriceps muscle endurance (i.e. increased quadriceps fatigability) in people with 
COPD when compared to healthy controls (129, 133-136). Muscle fatigue has been 
defined as the inability of a muscle to maintain a certain force or power output (125). 
Earlier work has shown that, when compared with healthy controls, the time to task 




failure for the quadriceps muscle contracting against a constant submaximal load (i.e. 
10% of maximum voluntary contraction) was reduced by 77% in people with COPD 
(129). The mechanisms that predispose people with COPD to early fatigue, 
especially in cycle based exercise, can be explained, at least in part, by the relative 
loss of fatigue-resistant Type I fibres in addition to concurrent structural alterations 
in capillary density and mitochondrial function (119-122). Similar to the prevalence 
of quadriceps muscle weakness that has been shown to increase with the increase in 
disease severity (126-128), quadriceps muscle endurance was also found to be 
associated with the degree of airflow obstruction (r = 0.52; p < 0.05) (134). Although 
data pertaining to the impact of an AECOPD on muscle endurance are not available, 
earlier work has demonstrated a significant relationship between elevated plasma 
levels of an inflammatory biomarker (e.g. C-reactive protein [CRP]) and endurance 
time, measured via a cycle ergometer test in people with severe to very severe COPD 
(137). The (median [range]) endurance time was significantly lower (8min [2 - 
30min] vs. 13min [3 - 30min]) in people with COPD who presented with an elevated 
CRP compared to those with normal CRP levels (137). Of note, inflammatory 
markers (e.g. CRP, IL-6, IL-8) have been consistently shown to be elevated during 
an AECOPD (46).  
Regarding measurement, muscle endurance can be assessed as the time to task failure 
for the quadriceps muscle whilst contracting against a constant submaximal load, 
usually 10% to 20% of a maximum voluntary contraction (129, 134), the rate of 
decline in peak torque during a sequence of maximal contractions against an 
isokinetic dynamometer (135) or a reduction in force generation in response to 
magnetic femoral nerve stimulation following cycle-based exercise (136).  
2.2.3 Clinical characteristics and measurement methods 
This section describes the symptoms of dyspnoea and fatigue, impairment in exercise 
capacity, low levels of PA and poor HRQoL in people with COPD. A summary is 
provided of the assessment techniques commonly used to measure these outcomes. 




2.2.3.1 Dyspnoea and fatigue  
2.2.3.1.1 Dyspnoea 
Dyspnoea is defined by the ATS as a subjective experience of breathing discomfort 
that is comprised of qualitatively distinct sensations that vary in intensity (138). It is 
the most common symptom especially during activity in people with COPD, and is 
often the main reason that an individual with this condition seeks medical attention 
(139). In a large survey (n = 3,265) involving people with COPD in North America 
and Europe, Rennard et al. (140) found that dyspnoea was associated with a 
considerable burden of disease, affecting several aspects that are fundamental to 
daily life. They found that people with COPD reported dyspnoea even when just 
sitting or lying, and the number of patients who reported dyspnoea increased with an 
increase in the intensity of activity (140). The mechanisms underpinning dyspnoea in 
COPD are multifactorial. Primarily, dyspnoea occurs when there is a mismatch 
between the central neural drive and the incoming afferent information from the 
peripheral mechanical and chemical receptors (141). The presence of DH has been 
identified as one of the most important contributors to dyspnoea (44, 142, 143). This 
is because DH increases the elastic and threshold loads on the inspiratory muscles, 
thereby increasing the work of breathing. It also shortens and flattens the diaphragm, 
thereby reducing its mechanical advantage and causing functional inspiratory muscle 
weakness. These consequences of DH contribute to the alteration of the afferent 
activity and cause mismatching between the respiratory effort and the mechanical 
response of the respiratory system (141). The severity of dyspnoea has been 
demonstrated to increase with an increase in disease severity as well as during an 
AECOPD (53, 144, 145). This could be explained by the fact that DH is further 
increased as a result of the increased airflow obstruction during an AECOPD (103). 
In a 2-year follow-up study of 101 people with moderate to severe COPD, 
Seemungal et al. (53) reported that 64% of the 504 exacerbations within the 2-year 
period were associated with an increase in dyspnoea. They also demonstrated that the 
increase in dyspnoea at the onset of an AECOPD was associated with prolonged 
recovery time. Specifically, they found that most of the patients who presented with 
increased dyspnoea at the onset of an exacerbation still reported increased dyspnoea 
35 days after the onset of the exacerbation (53). 
 




Regarding measurement, dyspnoea is most often measured using the Borg category 
ratio scale or in the context of HRQoL (146). The Borg scale has ratio properties 
with values ranging from zero to 10 together with simple verbal descriptors of 
intensity such as ‘very, very slight’ and ‘severe’ (147). Borg scores are simple to 
collect, reliable over short periods of times and sensitive to evaluate change in 
dyspnoea following interventions (e.g. pulmonary rehabilitation program [PRP]) in 
people with COPD (148, 149). Dyspnoea is also measured as a construct within the 
assessment of HRQoL using tools such as the Chronic Respiratory Questionnaire 
(CRQ) (150). In addition to these methods, the other scale commonly reported to 
assess the impact of dyspnoea during daily life is the modified Medical Research 
Council (mMRC) scale (151, 152). This scale comprises five statements each of 
which is assigned a grade that ranges from zero “I only get breathless with strenuous 
exercise” to four “I am too breathless to leave the house or I am breathless when 
dressing”. The participant selects the statement which best describes their functional 
limitation resulting from their dyspnoea. 
2.2.3.1.2 Fatigue 
Another common symptom for people with COPD is general fatigue, defined as a 
subjective perception of generalised tiredness, exhaustion or lack of energy (146). In 
a cross-sectional study evaluating the presence of fatigue among people with 
moderate to severe COPD who had participated in a PRP, Baltzan et al. (153) found 
that high fatigue was present in 39% of the 251 participants. They also found that 
those who presented with high fatigue had more depressive symptoms, greater 
dyspnoea, poorer health status and lower exercise capacity compared to those with 
low fatigue (153). The mechanism of general fatigue in people with COPD involves 
the interaction between physiological factors (e.g. hypoxemia and skeletal muscle 
dysfunction) and psychological factors (e.g. anxiety and depression) (146, 153, 154). 
For example, in a cross-sectional study of 80 individuals with COPD, depression, 
QMF and arterial oxygen saturation were identified as being able to explain 62% of 
the variance in the measurement of general fatigue (154). The severity of general 
fatigue has also been demonstrated to increase with an increase in disease severity 
(153-155) as well as during an AECOPD (43). Baghai-Ravary et al. (43) 
demonstrated that fatigue, measured using the FACIT-Fatigue questionnaire, 
increased during an AECOPD in as many as 31 (97%) of the 32 patients. The 




increased fatigue during an AECOPD is most likely explained by the increase in 
symptoms of depression, the greater impairment in QMF and worsening of 
hypoxemia during an exacerbation (43, 46, 108). Increased inflammatory markers 
(e.g. tumour necrosis factor α) during an AECOPD have also been shown to induce 
‘sickness behaviour’ like lethargy and tiredness (156). With regard to the recovery 
time for fatigue, Baghai-Ravary et al. (43) found that fatigue had recovered by six 
weeks following an AECOPD. Recovery time for fatigue within this 6-week period 
is unknown. Although several scales and questionnaires have been developed to 
assess general fatigue, in people with COPD general fatigue is commonly assessed as 
a construct within the assessment of HRQoL using tools such as the CRQ (150). 
Other than dyspnoea and general fatigue, people with COPD also report significant 
leg fatigue, particularly during cycle-based exercise (157-159). For example, when 
compared to healthy controls, Killian et al. (157) reported a greater proportion of 
people with COPD stopped their exercise test performed on a cycle ergometer due to 
intolerable leg fatigue (43% vs. 36%). Among those with COPD, leg fatigue was also 
more frequently cited (n = 42 [43%]) as symptom limiting exercise than dyspnoea (n 
= 25 [26%]) (157). Factors contributing to leg fatigue and the impact of AECOPD on 
muscle fatigue were described in subheading 2.2.2.1.3. Similar to dyspnoea, leg 
fatigue is often measured using the Borg category ratio scale (147) or a visual 
analogue scale (160).  
2.2.3.2 Decreased exercise capacity 
People with COPD have impaired exercise capacity, irrespective of whether exercise 
capacity is expressed as the maximum work rate achieved during cycle ergometry 
testing (142, 143), peak rate of oxygen consumption (VO2 peak) (142, 161), or as the 
distance walked during a field-based walking test (6, 162, 163). Earlier work has 
demonstrated that the reasons for terminating exercise tests in people with COPD 
were either intolerable dyspnoea, leg fatigue or a combination of both dyspnoea and 
leg fatigue (157-159). In addition to the impairments in lung function, the reduction 
in exercise capacity is also explained by the reduced oxidative capacity of the 
quadriceps muscle in this population. Specifically, the reduction in Type I muscle 
fibres, number of capillary contacts across all muscle fibres as well as the reduction 
in mitochondrial enzyme activity serve to reduce the oxidative capacity of the muscle 
and increase its reliance on the anaerobic energy system (161). These changes result 




in unusually early increases in arterial lactate, which is a potent respiratory stimulant 
and increases the ventilatory demand associated with exercise. Consequently, the 
increased ventilatory demand results in a worsening of lung hyperinflation and 
contributes to the experience of intolerable dyspnoea and reduced exercise capacity 
in this population (104).  
Exercise capacity has also been shown to be further reduced with an AECOPD (48-
50). For example, Carr et al. (50) found that the six-minute walk distance (6MWD) 
in 29 individuals with COPD was significantly lower two to four weeks following an 
AECOPD when compared to measurements made during a period of clinical stability 
(299 ± 99m vs. 359 ± 85m; p < 0.001). Of note, the mean reduction of 59 ± 80m 
reported in this study was greater than the threshold established previously to be 
considered as the minimal clinically important difference (MCID) for the 6MWD 
(164). The reduction in exercise capacity during an AECOPD also appears to take a 
very long time to recover. In another study by the same authors, Carr et al. (165) 
found that, without any intervention, the 6MWD measured three months following 
an AECOPD was approximately 30m lower when compared to the pre-exacerbation 
6MWD (314 ± 112m vs. 342 ± 87m). The possible mechanisms that explain the 
reduction in exercise capacity during an AECOPD include an increase in both 
pulmonary impairments (e.g. DH) and extra-pulmonary impairments (e.g. skeletal 
muscle dysfunction) during an AECOPD (46, 103).  
Regarding measurement, exercise capacity can be assessed using either laboratory-
based exercise tests, done on a cycle ergometer or a treadmill, or via field-based 
exercise tests such as the 6MWT and the incremental shuttle walk test (ISWT) (166-
168). Although laboratory-based tests are considered the gold standard for 
quantifying exercise capacity and provide information which assists in determining 
the mechanism of limitation, field-based tests are a popular choice as they can be 
performed at low cost in the clinical setting, require less technical expertise and are 
more representative of activities of daily living compared to laboratory-based 
exercise tests (169, 170). Moreover, the measurement properties of field-based tests 
have been studied extensively (171). 
In addition to these laboratory and field-based walking tests, there are emerging data 
to support the use of other tests of functional performance in people with COPD, 




such as the Sit to Stand Test (STST) and the Timed Up and Go (TUG) test. Several 
variations of the STST protocol are available. These include the original ‘timed-
stands’ test that measures the time taken to perform 10-STS (172), the shorter 
version of the original ‘timed-stands’ test (i.e. the 5-STS) (173), and the number of 
sit to stands (i.e. STST) performed within 30s or one minute (174, 175). Measures 
obtained during the STST demonstrated a moderate and strong association with the 
6MWD (r = 0.69 to 0.75; p < 0.001) (176, 177)and the ISWT (r = -0.59; p < 0.001) 
(178). Measures obtained during the STST have also demonstrated high test-retest 
repeatability with intraclass correlation coefficient (ICC) values ranging from 0.84 to 
0.92 (179) and the STST appears to be responsive to change with several studies 
demonstrating significant improvements in the test outcome following exercise 
training in people with stable COPD (175, 180, 181). 
Regarding the TUG test, this involves measuring the time required for an individual 
to get up from a chair, walk to a 3m mark, turn around, walk back to the chair and sit 
down (182). Two variations of instructions used during this test have been reported 
in the literature. In the original protocol developed by Podsiadlo and Richardson 
(182), participants are instructed to perform the task ‘at a comfortable and safe pace’. 
In the second protocol by Shumway-Cook et al. (183), participants are instructed to 
perform the task ‘as quickly as they could’ (i.e. at maximum effort). Kamide et al. 
(184) found that the TUG performed using instruction that asked for a maximum 
effort resulted in the task being performed at least 2s faster and appeared to be more 
reliable than the TUG performed at a comfortable pace. In people with COPD, the 
time required to perform the TUG test has demonstrated a strong association with the 
6MWD (r = -0.74; p < 0.001) (185). The TUG test has good test-retest reliability 
with the kappa coefficient and the ICC reported for repeated TUG tests in people 
with COPD being 0.62 and 0.85, respectively (186). The performance in the TUG 
test has also been shown to be able to detect change following an exercise training 
program in people with stable COPD (187, 188). 
2.2.3.3 Low levels of PA 
Physical activity is defined as any bodily movement produced by skeletal muscles 
that results in energy expenditure (189). There is a considerable amount of evidence 
showing that people with COPD have a low level of PA compared to their age-
matched healthy counterparts (190-193). For example, Pitta et al. (190) found that 




people with COPD spent, on average, less time walking (44 ± 26 vs. 81 ± 26 
minutes/day) and standing (191 ± 99 vs. 295 ± 109 minutes/day) and walked at a 
slower speed (1.8 ± 0.3 vs. 2.4 ± 0.5m/s2) compared to age-matched healthy controls. 
In another example, Singh et al. (193) found that people with COPD recorded 
significantly lower counts of PA even on light activity such as slow walking when 
compared to healthy controls (17 ± 13 counts/min vs. 28 ± 10 counts/min). The 
reasons underpinning the reduced PA levels in people with COPD can be explained 
in part by the increased symptoms of dyspnoea on exertion, general fatigue as well as 
the reduced exercise capacity in this population. People with COPD often adopt a 
sedentary lifestyle as strategy to minimise their experience of dyspnoea (190, 194). 
The reduction in daily activity levels from adopting a more sedentary lifestyle in turn 
results in further deconditioning of muscles, particularly the muscles of locomotion 
(e.g. quadriceps) which increases the reliance on anaerobic metabolism at lower 
work rates (195). This leads to the sensation of dyspnoea at lower levels of PA and 
the dyspnoea-inactivity cycle continues. In addition to dyspnoea, Todt et al. (196) 
reported that those with severe fatigue, as measured using the Fatigue Impact Scale 
(197), had nearly a six-fold higher probability of having low levels of PA.  
 
A gradual reduction in several measures of PA, such as average daily steps, total 
time spent on walking and level of PA (i.e. total daily energy expenditure/whole-
night sleeping energy expenditure), has been reported between people grouped 
according to GOLD grades (198-200) as well following an AECOPD (47, 51, 201-
203). When compared to measurements made during periods of clinical stability, 
Pitta et al. (47) found that those hospitalised for an AECOPD spent less time in 
weight bearing activities (e.g. standing and walking) and more time sitting and lying. 
Importantly, they also found that the time these patients spent on weight bearing 
activities (median, 19% [interquartile range, 10 to 34%]) a month after hospital 
discharge was lower than those with stable COPD (33 ± 16%) as well as the healthy 
elderly (52 ± 16%) (47). The mechanisms that most likely explain the decline in PA 
during an AECOPD are the increase in dyspnoea and fatigue, the greater impairment 
in QMF as well as the ‘sickness behaviour’ that can be induced from the increase in 
inflammatory markers during an AECOPD (43, 53, 156).  
 




Regarding measurement of PA, subjective or self-reported methods as well as 
objective methods have been described (204). Questionnaires and diaries are 
examples of subjective measures used to quantify the level of PA in daily life (205). 
Quantifying PA through these methods has the advantage of being inexpensive and 
easy to administer. However, factors such as recall bias, cognitive ability and 
interviewer attitudes have been shown to affect the reliability and validity of 
measures obtained using subjective methods of assessment (206). In order to 
overcome some of the limitations associated with subjective measures of PA, the use 
of devices objectively measure PA has increased. Devices available for this purpose 
include pedometers which are used for measuring steps, accelerometers for detecting 
body acceleration and metabolic monitors such as the SenseWear armband 
(BodyMedia Inc., Pittsburgh, Philadelphia, USA). Pedometers are usually small and 
simple instruments used to measure the number of steps taken by an individual. They 
are often inexpensive and the output of the device (i.e. steps) is easily understood. 
However, pedometers can be affected by artefact, in which any vertical movement, 
such as that associated with car travel, is counted as a step (204). Further, they often 
lack of sensitivity to detect slow or shuffling gait patterns (207-209). In contrast, 
accelerometers, which measure movement in one or more planes, have the capacity 
to detect slow walking, with some providing more varied and detailed information 
regarding PA undertaken in daily life. There are also hybrid devices, such as the 
StepWatchTM Activity Monitor (SAM) (Modus Health IIc, Washington, USA) which 
is a microprocessor-driven pedometer with a multi-level sensor that responds to time, 
position and acceleration information to record the number of steps in a detailed 
minute by minute profile. The SAM has shown to be valid, reliable and responsive 
for measuring steps in people with COPD (210, 211). Two studies that investigated 
the accuracy of the SAM in people with COPD found that the SAM had more than 
90% accuracy in 99% of the participants (210) and there was no significant 
difference between steps recorded by the device and steps counted via direct 
observation (p = 0.63) (211). The major advantages of the SAM over other devices 
are that the SAM is easy to use (waterproof and unobtrusive for the wearer), is 
highly-durable (the battery lasts for 7 years of continuous use) and can continuously 
record data for up to two months (212). More importantly, the device has been 
shown to be sensitive in detecting changes in walking speed and accurate in 
recording steps in people who walk with a walking aid (211). 




2.2.3.4 Impaired HRQoL 
The term HRQoL refers to the impact of disease on daily life and well-being (213). 
Compared with healthy individuals, people with COPD have demonstrated lower 
HRQoL (214-216). For example, Peruzza et al. (214) compared the HRQoL 
measured using the St George's Respiratory Questionnaire (SGRQ) between 60 
people with COPD and 58 healthy controls and found that the score in each domain 
of the SGRQ was significantly higher (i.e. worse) in people with COPD. The mean 
differences in the scores for each item were also greater than the threshold 
established previously as the MCID (i.e. 4 units) for the SGRQ (217). Specifically, 
the differences in SGRQ were 56.5 vs. 11.8 for the total score, 65.7 vs. 13.6 for the 
activity domain, 51.1 vs. 10.6 for the impact domain and 56.6 vs. 12.4 for the 
symptom domain in those with COPD vs. healthy controls (all p < 0.01). The low 
HRQoL in people with COPD can be explained by several clinical characteristics of 
people with COPD such as disease severity, symptoms of dyspnoea and fatigue, 
decreased exercise capacity, low levels of PA as well as feelings of anxiety and 
depression (40, 214, 218, 219). For example, in addition to demonstrating lower 
HRQoL in people with COPD when compared with healthy controls, Peruzza et al. 
(214) found that FEV1, mMRC dyspnoea scale as well as the 6MWD were 
significantly correlated with the total SGRQ score in people with COPD. 
Health-related quality of life has also been shown to be further reduced during an 
AECOPD (50). When compared to measurements made during a period of clinical 
stability, Carr et al. (50) found that the presence of an AECOPD was associated with 
significant reductions in the fatigue, emotional function and mastery domains of the 
CRQ by a mean of 1.0 ± 1.3 unit, 0.6 ± 1.0 unit and 0.5 ± 1.4 unit, respectively (all p 
< 0.05). Of note, the mean reduction in the score for each domain was also greater 
than the threshold established previously as the MCID (i.e. 0.5 unit) for the CRQ 
(220). Factors such as increased severity of airflow obstruction, symptoms of 
dyspnoea and fatigue, and anxiety and depression during an exacerbation as well as 
the greater impairment in skeletal muscle, reduction in exercise capacity and PA 
levels may explain the greater impairment in HRQoL during an AECOPD (43, 47, 
50, 53) 
Regarding measurement, HRQoL can be measured either using general/generic or 
disease-specific questionnaires (221). Generic questionnaires such as the 36-item 




(SF-36) survey and the Sickness Impact Profile allow comparisons of HRQoL among 
individuals with a wide range of diseases. On the other hand, disease-specific 
questionnaires were developed to measure the key impact a specific condition or 
disease has on HRQoL (221). The SGRQ and CRQ are the two examples of disease-
specific HRQoL questionnaires for people with COPD (222, 223). Both 
questionnaires measure domains considered to be important in determining HRQoL 
in individuals with COPD. These include dyspnoea, fatigue, emotional function and 
mastery in CRQ, and symptom, impact and activity in the SGRQ (222, 223). The 
main advantage of disease-specific HRQoL questionnaires is that they are more 
responsive to small changes in health status (221). 
2.2.4 Summary 
Chronic obstructive pulmonary disease is associated with both pulmonary and 
systemic consequences. Pulmonary pathology in COPD includes changes (i.e. 
destruction and repair) throughout the central and peripheral airways, lung 
parenchyma and pulmonary vasculature. One of the most important systemic 
consequences of COPD is quadriceps muscle dysfunction. When compared to 
healthy controls, people with COPD demonstrated a reduction in QMF and 
endurance, lower exercise capacity, and low levels of PA and HRQoL. 
Hospitalisation for AECOPDs have been shown to further impair the negative 
consequences associated with COPD. That is, when compared to people with COPD 
who are clinically stable, those hospitalised for an AECOPD demonstrated a greater 
impairment in QMF, worse exercise capacity, lower levels of PA and poorer 
HRQoL. Importantly, the impact of hospitalisation for an AECOPD on some of these 
outcomes (e.g. QMF, exercise capacity and PA) appears to take a very long time to 
recover. 
2.3 Part 3  
Although the 6MWT is a popular assessment of exercise capacity in people with 
COPD, in some populations, such as those hospitalised for an AECOPD, people are 
likely to need to rest frequently, or for prolonged periods during the test, due to 
intolerable dyspnoea. Therefore, the 2MWT may be an appropriate alternative to the 
6MWT for measuring functional exercise capacity, particularly in patients 
characterised by profound dyspnoea on exertion. In contrast to the 6MWT where 
data pertaining to the measurement properties and interpretation of the test outcome 




(i.e. the 6MWD) have been extensively reported, data pertaining to the measurement 
properties of the 2MWT and the interpretation of the two-minute walk distance 
(2MWD) are lacking (224). Section 2.3.1 reviews the literature which has reported 
data pertaining to the measurement properties of the 2MWT. Section 2.3.2 describes 
the cardiorespiratory responses and levels of symptoms during the 2MWT. Section 
2.3.3 reviews the studies that have reported the regression equations to estimate the 
2MWD in healthy adults. 
2.3.1 Measurement properties of the 2MWT 
The measurement properties of an assessment tool are often reported using criteria 
such as reliability, validity and responsiveness. The following sections review the 
literature pertaining to the measurement of reliability, validity and responsiveness of 
the 2MWT in people with COPD. Studies in other populations are reviewed when 
there are no data pertaining to the measurement of reliability, validity and 
responsiveness of the 2MWT in people with COPD.  
2.3.1.1 Reliability and the effect of test repetition 
Estimates of reliability are most often evaluated in terms of inter- and intra-rater 
reliability (225). Inter-rater reliability relates to the variation in measurements when 
two or more tests are performed on the same group of individuals but by different 
investigators. Intra-rater reliability refers to the variation in measurements when two 
or more tests are performed on the same group of individuals by the same 
investigator. In other words, inter-rater reliability measures the effect that changing 
the investigator has on the test outcome, while intra-rater reliability (i.e. also known 
as repeatability) measures the reliability of the test, in this instance the 2MWT, when 
all other variables (e.g. participants, environment and investigator) are constant. To 
date, four studies have evaluated the reliability of the 2MWD in people with COPD 
(1, 2, 7, 8). Of these four studies, all have reported the reliability of the 2MWDs 
performed by the same investigator (i.e. intra-rater reliability or repeatability). Two 
reported a small but significant increase in the 2MWD with test repetition (2, 7), one 
reported a small difference, which is likely to have been significant (1) and one 
found no change in the 2MWDs on repeat tests (8) (Table 2.2). Disparities in the 
results may have been due to the differences in the 2MWT protocol used between the 
studies. For example, in the only study that did not demonstrate a significant 
improvement in the 2MWD with test repetition, the participants were given a 




practice walk a day prior to the actual testing day (8). Therefore, the effect of test 
repetition on the 2MWD in this study could have been minimised as the participants 
were familiar with the test. Although this discrepancy in results may be explained by 
the inclusion or otherwise of a practice walk, it is also important to note that these 
four studies were undertaken prior to the publication of standards for performing the 
filed-based walk test (226), and the protocol they used were either not described (1), 
provided no encouragement (8), had the investigator walking in front of the patient 
during the test (7) or included a mixed sample of patients with COPD and chronic 
heart failure (2). Therefore, the effect of test repetition on the 2MWD in people with 
COPD performed using a protocol based on the standards for performing field-based 
walk test is unknown.  
Although indices such as ICC, coefficient of variation (CV) and differences in mean 
2MWDs analysed using either a paired t-test or analysis of variance are used to 
report aspects of reliability (Table 2.2), these measures only provide information 
about group data, not about individual variability. In contrast, indices of reliability 
such as the standard error of measurement (SEM) and coefficient of repeatability 
(COR) can be applied to provide an estimate of a range of values within which an 
individual’s true score is likely to lie (227). That is, a difference in the 2MWDs that 
is greater than the measurement error reported using these indices can be interpreted 
as a change that is beyond the threshold of error inherent in the test and may 
represent a true change in this outcome. However, neither the SEM nor the COR for 
the 2MWD have been reported in people with COPD.
















Table 2.2: Reliability measures for the 2MWD in people with COPD 
Author/ 
year 
Participants Test protocols Inter-rater 
reliability 
Test-retest reliability 
p-values ICC CV 
Butland  
et al. 1982 (1) 
n = 13 
Age = 51 ± 14 yr 
FEV1 = 0.98 ± 0.25L 
FEV1% = NR 
Practice test: No 
Test-retest intervals: ≥ 1hr 
 
NT Within-day measures 
W1 vs. W2 ↑4m (3%); p value = NR 
W2 vs. W3 ↑5m (4%); p value = NR 






et al. 1984 (2) 
n = 43 
Age = 65 ± 8yr 
FEV1 = 0.97 ± 0.25L 
FEV1% = NR 
Practice test: No 
Test-retest intervals: 2 weeks 
 
NT Between-day measures  
p < 0.0001 on repeated 2MWDs 
NT 5.4% 
Eiser  
et al. 2003 (7) 
n = 57 
Age = 69 ± 8yr 
FEV1 = 0.92 ± 0.38L 
FEV1% = 35±12% 
 
Practice test: No 
Test-retest intervals: 30 min 




NT Within-day measures 
W1 vs. W2 ↑3m (2%); p < 0.05 
W2 vs. W3 ↑2m (1%); p > 0.05 
 
Between-day measures 
D1 vs. D2 ↑4m (3%); p < 0.05 




et al. 2006 (8) 
n = 45 
Age = 72 ± 8yr 
FEV1 = 0.88 ± 0.27L 
FEV1% = 42 ± 13% 
 
Practice test: Yes 
Test-retest intervals: 20 min 
 
NT Within-day measures 
W1 vs. W2 ↑0.3m (0.2%); p > 0.05 
W2 vs. W3 ↑0.5m (0.4%); p > 0.05 
 
> 0.99 NT 
Data are presented as mean ± standard deviation. Abbreviations: 2MWD, two-minute walk distance; CV, coefficient of variation; D1, day 1; D2, day 2; FEV1, forced 
expiratory volume in one second; hr, hours; ICC, intraclass correlation coefficient; m, metres; min, minutes; NR, not reported; NT, not tested; SD, standard deviation; W1, 
walk 1; W2, walk 2; yr, year. 
 





Validity is the extent to which a test measures what it is intended to measure (225). 
In relation to the 2MWT, validity measures the degree to which the distance walked 
during the test is a measurement of functional exercise capacity. Although the 
2MWT, by virtue of being a walking-based test of exercise tolerance, has inherent 
face and content validity, this alone is not adequate proof of its validity, as both face 
and content validity rely on subjective opinions (225). With regard to criterion-
related validity, earlier work has demonstrated a moderate association between the 
2MWD and measures of VO2 peak (r = 0.45; p = 0.002) obtained during a laboratory-
based cardiopulmonary exercise test (i.e. the gold standard in measuring exercise 
capacity) (8). Further, the 2MWD has been shown to be strongly associated with the 
distance walked during the 6MWT (r = 0.89 - 0.94) (1, 8) and the 12MWT (r = 0.86) 
(1). Data pertaining to the construct validity of the 2MWT have been reported in 
populations other than COPD (228, 229). Rossier et al. (229) demonstrated that the 
2MWD in patients with neurological disabilities was significantly lower in those who 
used a walking aid compared to those who walked independently (38 ± 21m vs. 84 ± 
30m; p < 0.001). They also reported a lower 2MWD in those who presented with 
sensory impairment than those who did not present with sensory impairment (49 ± 
28m vs. 68 ± 36m; p = 0.02). This capacity of the 2MWD to discriminate between 
patients with or without impairments in mobility supports its validity.  
2.3.1.3 Responsiveness 
Responsiveness is a measure of the capacity of a test to detect change over time 
(225). In people with COPD, the 2MWD has been shown to be responsive to changes 
following bronchodilator therapy and a PRP (7, 8). Specifically, the 2MWD 
increased by 9 ± 1m (p < 0.001) following bronchodilator therapy and 17 ± 14m (p < 
0.01) following a PRP (7, 8). Leung et al. (8) also reported moderate effect sizes for 
the change in both the 2MWD and the 6MWD following a PRP (i.e. f2 = 0.61 and 
0.53, respectively). However, these earlier studies were both undertaken in people 
with COPD who were clinically stable and therefore the responsiveness of the 
2MWD to change following interventions (e.g. exercise training) during an 
AECOPD is unknown. Further, although the changes in the 2MWD after 
bronchodilator therapy and PRP in these two studies were significant, it is not known 
if they were clinically important. This is because data pertaining to the MCID, 




defined as the smallest difference in the 2MWD that is noticeable and considered 
important for people with COPD, has not been established.  
2.3.2 Cardiorespiratory responses and levels of symptoms during the 2MWT  
Although the 2MWT is likely to be a less burdensome measure of exercise capacity 
when compared to the 6MWT and the 12MWT (1, 7, 8), there are few studies 
comparing responses elicited during these tests. To date, one study has compared the 
levels of symptoms during the 2MWT with those during the 6MWT (8). In this 
study, Leung et al. (8) reported a significantly higher rating of perceived exertion 
(RPE) on completion of the 6MWT compared to the 2MWT in people with moderate 
to severe COPD (3.0 ± 2.0 vs. 3.3 ± 0.3; p < 0.05). However, it is important to note 
that performance was encouraged during the 6MWT but not during the 2MWT, and 
this may have contributed to the higher RPE elicited at the end of the 6MWT. No 
studies have compared the cardiorespiratory responses elicited during the 2MWT and 
the 6MWT in people with COPD or other clinical populations. Such data are 
important, especially in people characterised by profound dyspnoea, as they will 
assist in determining whether or not the 2MWT is better tolerated than the 6MWT. 
2.3.3 Regression equations to estimate the 2MWD in a healthy adult 
population 
To date, there are two published regression equations which were developed to 
estimate the 2MWD in healthy adult populations; one was derived from a sample of 
Brazilian adults (17) and the other one was derived from a sample of American 
adults (18). Equations such as these offer clinicians and researchers the opportunity 
to express the 2MWD measured in patient populations as a percentage of the value 
estimated in healthy individuals. This section will compare these equations and 
summarise the factors which are most likely to contribute to the 2MWD in a healthy 
adult population. 
2.3.3.1 Studies that have established regression equations to estimate the 2MWD  
Selman et al. (17) derived an equation to estimate the 2MWD from a convenience 
sample of 390 healthy Brazilian adults. The 2MWT was performed in a 30m corridor 
and all participants completed two 2MWTs with a 30-minute rest interval between 
tests. The participants were instructed to walk as fast as possible and a standardised 
phrase of encouragement was provided only once (i.e. at one minute) during the test. 




The better of the two 2MWDs was used in their analysis. The regression equation 
derived in this study is presented in Table 2.3. Although the 2MWD was 
significantly different between males and females and associated with age (r = -
0.50), weight (r = 0.23) and height (r = 0.40) (all p < 0.001), only age and gender 
were retained in the equation. Together, these variables explained 51% of the 
variance in the 2MWD in this sample. Selman et al. (17) demonstrated that men 
walked 12% further than women. The finding that men walked further than women 
during the 2MWT is most likely explained by gender related differences in aerobic 
capacity, muscle mass and, of particular importance for walking-based tests, height 
and stride length. That is, when compared to women, men are generally taller, and 
taller individuals walk with a longer stride length when compared with shorter 
individuals. The finding that the 2MWD decreased with advancing age may be 
explained by the physiological changes that accompany ageing such as the decline in 
muscle mass (230, 231). 
In the other study, Bohannon et al. (18) derived two gender-based equations to 
estimate the 2MWD from a sample of 1,137 American adults. The 2MWT was 
performed over a 15m walking course. Similar to the study by Selman et al. (17), the 
participants were instructed to walk as fast as possible and a standardised phrase of 
encouragement was provided only once (i.e. at 1 minute) during the test. The 
regression equation derived in this study is shown in Table 2.3. Although Bohannon 
et al. (18) demonstrated that the 2MWD was associated with age (r = -0.41), body 
mass index (BMI, r = -0.32), height (r = 0.29) and weight (r = -0.16) (all p < 0.001), 
only BMI and age were retained in the equation for each sample. These equations 
explained 56% and 57% of the variance in the 2MWD in males and females, 
respectively. Similar to the study by Selman et al. (17), this study found that age 
offered the best explanation of the 2MWD in both men and women. However, 
Bohannon et al. (18) found that BMI also explained a significant proportion of 
variance in the 2MWD in their sample. The importance of BMI in the regression 
equation derived in the American study is most likely explained by the higher BMI 
(mean ± SD, 29 ± 7kg/m2) and wider range of BMIs (17 – 58kg/m2) in their study 
participants when compared to the BMIs in the Brazilian study (median [inter-
quartile range], 25kg/m2 [23 - 28kg/m2]).
















    
Table 2.3: Regression equations to estimate the 2MWD 
 
*male = 1, female = 0 
Abbreviations: 2MWD, two-minute walk distance; BMI, body mass index; m, metres; yr, year. 
 
Author  Regression equations R2  




Bohannon et al. (18) ♂: 2MWD, m = 279.096 - (0.998 × age, yr) - (1.426 × BMI) 
♀: 2MWD, m = 257.177 - (0.723 × age, yr) - (1.688 × BMI) 
0.56 
0.57 













2.3.3.2 Factors likely to influence the 2MWD 
2.3.3.2.1 Participant characteristics and effort during the test 
Although earlier work has reported that age, gender and BMI are important factors in 
determining the 2MWD in healthy individuals (17, 18), studies that have established 
regression equations for the 6MWD have included other variables such as height and 
leg length (21), weight (21, 39), daily PA (30) and peak heart rate (HR) (19-21). The 
following section describes factors related to participant characteristics other than 
age, gender and BMI and markers of participant effort (e.g. peak HR) that are likely 
to influence the 2MWD.  
Both of the studies that developed regression equations to estimate the 2MWD 
demonstrated that height has a weak to moderate association with the 2MWD (17, 
18). This is consistent with most of the studies that have established regression 
equations to estimate the 6MWD (21, 28, 33-35). Similar to the explanation 
regarding why men usually walked a greater distance during walking-based tests 
when compared to women, the influence of height and leg length on walking 
distance can also be explained by a taller height or longer leg length being associated 
with a longer stride length and thus resulting in a longer distance walked (32). 
Weight has been shown to have a weak association with the 2MWD (r = -0.16 to 
0.23) (17, 18) as well as the 6MWD (r = 0.21 to 0.38) (28, 36, 39). This might be 
related, at least in part, to the narrow range in weight among the participants in the 
studies in this area. Dependent variables that have a narrow range in values are less 
likely to be retained in a regression equation. 
Although it is possible that the distance achieved during the 2MWT is influenced by 
a participant’s daily PA, most of the studies that have evaluated the influence of daily 
PA on the 6MWD have demonstrated no significant association between these two 
variables (20, 22, 23, 33). Being a self-paced walk test, the participant’s mood and 
motivation may also influence the 2MWD. As it is difficult to ascertain whether a 
participant is performing at their peak during a walking test, it has been suggested 
that peak HR achieved during the test be used as a surrogate measure of the 
participant’s effort during the test (25). In view of this, several studies that have 
established a regression equation for the 6MWD have also reported the peak HR 
measured during the test, expressed as a percentage of the predicted maximum HR 













(i.e. [peak HR / 220-age] x 100) (20, 22-26, 31). In some of these studies, the 
percentage of the predicted maximum HR achieved on test completion was also 
identified as a predictor of the 6MWD and explained an additional 13% to 21% of 
the variance in the 6MWD (19, 20, 25). As both of the previously published 
regression equations to estimate the 2MWD did not include this variable in the 
analysis, it is unknown whether the addition of peak HR would increase the total 
variance explained by the regression equations. 
2.3.3.2.2 Ethnicity 
In addition to differences in the participant characteristics and markers of participant 
effort, earlier work that has established regression equations to estimate the 6MWD 
has demonstrated differences in the 6MWD between samples of different ethnicities. 
Specifically, in two studies (21, 39) where the 6MWT was performed using an 
identical protocol and by the same team of investigators in an Australian sample and 
a Singaporean sample, the equations not only retained different predictors for the 
6MWD but also different coefficients for the same predictors (Table 2.4). This 
suggests that factors other than the test protocol may influence walking performance. 
When the regression equation derived from a sample of Singaporean adults (21) was 
compared with the regression equation derived from a sample of Australian adults 
(39), the influence of weight on the 6MWD was greater in Singaporeans than 
Australians. That is, for every 1kg increase in weight, the 6MWD would decrease by 
3.51m using the equation derived from Singaporean adults and decrease by only 
1.15m using the equation derived from Australian adults. Differences in the influence 
body weight has on the 6MWD in these equations may be explained by differences 
in body composition between the samples. That is, differences in body build (trunk-
to-leg-length ratio and slenderness) between Asians and Caucasians result in Asians 
having a lower percentage of lean body mass (i.e. higher percentage of fat mass) for 
a given BMI when compared to Caucasians (232). As a result, an increase in weight 
or BMI in Asian is more likely to reflect an increase in body fat and therefore 
compromised walking distance. This suggests that the two previously published 
regression equations to estimate the 2MWD will be of most use for Brazilian (17) 
and American (18) people, but may be less accurate for people from other countries. 
















Table 2.4: Regression equations to estimate the 6MWD in Chinese Singaporeans and Caucasian Australians 
Author  Ethnicity Regression equations R2  
Poh et al. (21) Chinese Singaporean 6MWD, m = (5.50 × % predicted HRmax) + (6.94 × height, cm) - 
(4.49 × age, yr) - (3.51 × weight, kg) - 473.27 
0.78 
 
Camarri et al. (39)  Caucasian Australian  6MWD, m = 216.90 + (4.12 × height, cm) - (1.75 × age, yr) - 
(1.15 × weight, kg) - (34.04 × gender*) 
0.36 
 
*male = 1, female = 0 
Abbreviations: 2MWD, two-minute walk distance; BMI, body mass index; cm, centimetres; HRmax, heart rate maximum; 
kg, kilograms; m, metres; yr, year. 




2.3.3.2.3 Differences in the administration of the test 
It appears that the length of the walking track used to conduct the test may influence 
the 2MWD. For example, the 2MWD in the study by Bohannon et al. (18) was 
shorter (181 ± 33m) when compared to the study by Selman et al. (17) (median 
[interquartile range], 211 [191 – 234]) and the study by Bohannon used a walking 
track which was 15m less than that used by Selman et al. (17) (15.2m vs 30m). 
Performing the 2MWD over a shorter track length may compromise the distance 
achieved as it requires participants to slow down to turn and reverse direction more 
frequently (24, 33, 233). Although the current ERS/ATS technical standard for 
conducing field-based walking tests does not provide recommendations for the 
minimal track length for a 2MWT, it states that the 6MWT should be performed on a 
track ≥ 30m (226). In addition to track length, the shorter 2MWD in the study by 
Bohannon et al. (18) when compared to the 2MWD in the study by Selman et al. (17) 
may also be attributable to the fact that the participants in the study by Selman et al. 
(17) had the opportunity to improve their 2MWD as they undertook two tests and the 
best test result was used in the regression analysis. Selman et al. (17) reported that 
majority of the participants (n = 295 [76%]) in their study walked a greater distance 
in the second 2MWT.  
Other components of test protocol that may influence performance during the 2MWT 
include the shape of the walking track (234, 235) and the use of test instructions 
(236). Although data are lacking for the 2MWD, earlier work has demonstrated that 
modifying track layout from a straight to a circular/oval track increased the 6MWD 
by as much as 28m (234, 235). Further, participants have been shown to walk 53m 
further on the 6MWT with the instruction to walk ‘as fast as possible’ compared to 
other instructions such as to walk ‘at your normal pace’ (236). Although factors such 
as track length and layout, accounting for improvements that result from test 
familiarisation and differences in instructions are not variables included in regression 
equations, the impact these factors have on the 6MWD suggests that these factors 
need to be standardised in future studies that aim to develop a regression equation to 
estimate the 2MWD in healthy adults.  





In people who experience severe dyspnoea on exertion, such as those with severe 
stable COPD or those who are hospitalised for an AECOPD, a short test, such as the 
2MWT, may be an appropriate alternative to the 6MWT to measure functional 
exercise capacity. However, data pertaining to the measurement properties of the 
2MWT are scarce and no studies to date have compared the cardiorespiratory 
responses elicited during the 2MWT and the 6MWT in this population. Data 
pertaining to the interpretation of the 2MWD are also limited. Regression equations 
to estimate the 2MWD in populations other than Brazilian and American are not 
available. In order for the uptake of the 2MWT to increase in clinical practice, more 
data are needed on the measurement properties of the 2MWD. Further regression 
equations derived in local populations would assist in the interpretation of the 
2MWD. These data would also promote the use of the 2MWT as a measurement of 
exercise capacity to evaluate the effect of interventions particularly in population for 
whom the 6MWT may be considered too burdensome. 
2.4 Part 4 
In people with stable COPD, there is strong evidence that a PRP which includes 
exercise training leads to an improvement in multiple outcomes including dyspnoea 
and fatigue (60), feelings of anxiety and depression (61), exercise capacity (60), and 
HRQoL (60, 61). There is also some evidence demonstrating the benefits of exercise 
training in this population on outcomes such as rate of exacerbation (237) and 
healthcare utilisation (238). However, data to support the benefits of PRPs or 
exercise training during a period of hospitalisation for an AECOPD are limited. 
Although a Cochrane review has reported that exercise training initiated during the 
period of hospitalisation or immediately following discharge for an AECOPD is safe 
and effective at improving exercise capacity and HRQoL (239), only one RCT in this 
review included an exercise program which commenced within two to three days of 
hospitalisation for an AECOPD (240). However, this study extended the in-patient 
exercise program to include an eight weeks after discharge out-patient rehabilitation 
program and only evaluated the effect of the exercise training on completion of the 
out-patient program (240). Therefore, data included in the Cochrane review do not 
provide information regarding the safety or effectiveness of an exercise program 
within the period of hospitalisation for an AECOPD. Since the time of the Cochrane 




review, another eight RCTs evaluating the effects of exercise training in people 
hospitalised for an AECOPD have been published with mixed results. This part of 
the thesis reviews studies which have reported the effects of exercise training in 
people hospitalised for an AECOPD (Figure 2.1). Specifically, section 2.4.1 reviews 
the studies that investigated the effect of exercise training initiated in people 
admitted to a hospital ward (i.e. not an intensive care unit) for an AECOPD. Section 
2.4.2 reviews the studies that investigated the effect of exercise training in people 
who had been recently discharged from hospital for an AECOPD. Both sections 
focus on the effect that exercise training has on outcomes of exercise capacity, QMF 
and PA.   
 
  

















Figure 2.1: Overview of the studies reviewed in part 4 of the literature review.  
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2.4.1 Exercise training initiated during the period of hospitalisation  
To date, nine studies, published as full papers, have evaluated the effects of exercise 
training initiated during the period of hospitalisation for an AECOPD (65-67, 70-72, 
240-242). These studies have applied an exercise training intervention in one group 
and usual care in the control group (CG). The sample sizes ranged from 26 to 389 
and the participants had moderate to severe COPD. Of these nine studies, six (67%) 
initiated exercise training early (i.e. within two to three days of hospital admission) 
(70-72, 240-242) (Table 2.5 and Table 2.6) and three (33%) initiated exercise 
training after a period of stabilisation in clinical status (i.e. between 6 and 8 days 
after hospital admission) (65-67) (Table 2.7). Although all nine studies initiated the 
exercise program during the period of hospitalisation, five (56%) completed the 
training program prior to in-patient hospital discharge (65, 70-72, 242) and four 
(44%) extended the in-patient exercise program with an after discharge program (66, 
67, 240, 241). The training protocols applied in these RCTs varied considerably with 
two (22%) prescribing exclusively resistance training (71, 72), two (22%) 
prescribing exclusively aerobic training (65, 67), four (44%) prescribing a 
combination of aerobic and resistance training (66, 70, 240, 242) and one (11%) 
prescribing neuromuscular electrical stimulation in addition to a combination of both 
aerobic and resistance training (241). The mean number of training sessions 
completed during the hospitalisation period ranged from three to 10 sessions (65-67, 
70-72, 241).  
 
Of these nine studies, four (44%) reported a robust randomisation process (70, 71, 
240, 241), five (56%) reported concealment of the randomisation sequence (70-72, 
240, 241) and four (44%) reported blinding of the outcome assessors (70, 71, 240, 
241). Information pertaining to the concealment of the randomisation sequence and 
blinding of the outcome assessor was not provided in three (65, 67, 242) and four 
(65-67, 242) studies, respectively. The loss to follow-up ranged between 6% and 
37% in studies where exercise training was completed within the hospitalisation 
period (70-72, 242), and 13% (240) and 20% (241) when the in-patient exercise 
program was extended past hospital discharge.  
  
















Table 2.5: Summary of studies where exercise training was initiated within two to three days of hospital admission and completed within the 
period of hospitalisation 
Author/ year Intervention Significant between-group 
difference in favour of EG CG EG 
Troosters et 
al. 2010 (72) 
n = 19, FEV1 = 50 ± 18%, age = 69 ± 7yr 
Chest physiotherapy for airway clearance 
and breathing exercises + no exercise 
program provided during admission or 
after discharge 
n = 17, FEV1 = 40 ± 12%, age = 67 ± 8yr 
Usual care + quadriceps strengthening on knee extension chair at 70% of 
1RM for 3 sets of 8 repetitions 
Duration: 1 session/day for 7 days 
 
Re-assessment at discharge 
↑QMF 
Tang et al. 
2012 (70)  
n = 11, FEV1 = 47 ± 20%, age = 78 ± 9yr 
Chest physiotherapy for airway 
clearance, mobility assessment and 
functional training for safe discharge 
 
n = 11, FEV1 = 45 ± 19%, age = 68 ± 
10yr 
Low intensity EG 
Usual care + 7.5min walking at 
40% of speed during 3MWT + hip 
abduction, lunges, simulated lifting 
and chest press at 40% of 1RM for 
20-25 repetitions 
Duration: 2 sessions/day throughout 
hospitalisation 
n = 10, FEV1 = 46 ± 18%, age = 74 ± 
10yr 
Moderate to high intensity EG 
Usual care + 7.5min walking at 
70% of speed during 3MWT + hip 
abduction, lunges, simulated lifting 
and chest press at 70% of 1RM for 
8-10 repetitions 
Duration: 2 sessions/day throughout 
hospitalisation 
Re-assessment at discharge 
No significant between-
group differences reported in 
any outcomes 
Borges et al. 
2014 (71) 
n = 14, FEV1 = 39 ± 16%, age = 68 ± 9yr 
Chest physiotherapy for airway 
clearance, NIV if needed, and verbal 
instruction to carry on with usual PA + 
no exercise program provided during 
admission or after discharge  
n = 15, FEV1 = 42 ± 14%, age = 64 ± 13yr 
Usual care + WBET 80% of 1RM for sh flexion and abduction, elb flexion, 
hip flexion kn flexion and extension for 2 sets of 8 repetitions 
Duration: 1 session/day throughout hospitalisation 
Re-assessment at discharge 
↑6MWD  
↑Sh abductors muscle force  
↑Elb flexors muscle force 
↑Kn flexors muscle force 
↑Hip flexors muscle force 
He et al.  
2015 (242) 
n = 28, FEV1 = 39 ± 5%, age = 74 ± 2yr 
Not described 
n = 66, FEV1 = 38 ± 3%, age = 69 ± 2yr 
Treadmill walking at 60% of the peak work rate during treadmill 6MWT for 
5-10min increased to 20min + bilateral sh abduction and flexion using light 
weight for 2min + strength training using free weights/own body weight, 
begin with 1 set of 10 repetition increased to 3 sets of 10 repetitions 
Duration: 2 sessions/day throughout hospitalisation 
Re-assessment at discharge 
No analysis for between-
group differences performed 
Data are presented as mean ± standard deviation. n = number included in final analysis. Abbreviations: 1RM, one-repetition maximum; 3MWT, three-minute walk test; 
6MWD, six-minute walk distance; 6MWT, six-minute walk test; CG, control group; EG, exercise group; elb, elbow; FEV1, forced expiratory volume in one second; kn, knee; 
min, minutes; NIV, non-invasive ventilation; PA, physical activity; QMF, quadriceps muscle force; sh, shoulder; WBET, whole body-body exercise training; yr, years.
  
















Table 2.6: Summary of studies where exercise training was initiated within two to three days of hospital admission and extended to an after 
discharge program 
Author Intervention Significant between-group 
difference in favour of EG CG EG 
Eaton et al. 
2009 (240) 
In-patient care 
n = 50, FEV1 = 35 ± 16%, age = 70 ± 9yr 
Treatment in accordance with the ATS/ERS 
guidelines (88) and advice on exercise and 
maintaining daily activities 
Follow-up at 3 months 
n = 45 
In-patient program  
n = 40, FEV1 = 36 ± 16%, age = 70 ± 10yr 
Usual care + supervised walking + UL and LL resistance exercise 
≥ 30 min/day (no further details are provided) 
Duration: 1 session/day throughout hospitalisation 
Out-patient hospital-based program 
n = 39  
1hr supervised training (no further details are provided) 
Duration: 2x/week for 8 weeks 
Re-assessment at 3 months after 
discharge 
↑CRQ fatigue domain  
↑SF-36 physical function 
↓HAD anxiety 
Greening et 
al. 2015 (241)  
In-patient care  
n = 193, FEV1 = 57 ± 24%, age = 71 ± 10yr 
Chest physiotherapy for airway clearance, 
mobility assessment, and advice on 
smoking cessation + no exercise program 
provided during admission or after 
discharge 
Follow-up at 6 weeks 
n = 162 
 
In-patient program  
n = 196, FEV1 = 52 ± 25%, age = 71 ± 9yr 
Usual care + walking at walking speed at 85% of VO2 peak during 
ESWT + resistance training (biceps curls, triceps curls, kn 
extension, sit to stand, and step ups) + NMES on both quadriceps 
for 30 min/day 
Duration: 1 session/day throughout hospitalisation 
Home-based program (unsupervised) 
n = 148 
Progressive walking + NMES 
Duration: 1 session/day for 6 weeks 





Data are presented as mean ± standard deviation. n = number included in final analysis. Abbreviations: 1RM, one-repetition maximum; ATS/ERS, American Thoracic 
Society/European Respiratory Society; CG, control group; CRQ, Chronic Respiratory Questionnaire; EG, exercise group; elb, elbow; ESWT, endurance shuttle walk test; 
FEV1, forced expiratory volume in one second; HAD, hospital anxiety and depression; hr, hours; kn, knee; LL, lower limb; min, minutes; NMES, neuromuscular electrical 
stimulation; SF-36, 36-item Short Form survey; UL, upper limb; VO2peak, peak oxygen consumption; yr, years. 
 
  
















Table 2.7: Summary of studies where exercise training was initiated following a period of stabilisation in clinical status 
Author Intervention Significant between-group  






In-patient care  
n = 14, FEV1 = 38 ± 3%, age = 66 ± 12yr 
Standard physiotherapy (not further details 
are provided) + no exercise program 




n = 15, FEV1 = 34 ± 3%, age = 62 ± 9yr 
Supervised 5 self-paced walking training/day at ≥ 75% of the daily 6-
min treadmill walking test without any time limit 
Start: 6 to 8 days following hospital admission 
Duration: 10 consecutive days 
Re-assessment at day 5 and Day 10 
 ↑6MWD 
Changes throughout the training period 
↑% in minute ventilation during 6MWT 
Comparison at the same treadmill 6MWT 
work load as on Day 1  







n = 12, FEV1 = 38 ± 7%, age = 69 ± 7yr 
Standard physiotherapy (not further details 
are provided) + no exercise program 
provided during admission or after 
discharge 
After discharge 
No home visits but received monthly 
phone calls to perform regular exercise 
In-patient program 
n = 14, FEV1 = 35 ± 7%, age = 64 ± 8yr 
Supervised 5 self-paced walking training/day at ≥ 75% of the daily 6-
min treadmill walking test without any time limit 
Start: 4 to 7 days following hospital admission 
Duration: 10 consecutive days 
Home-based exercise program (unsupervised) 
15min walking at 125% of discharge treadmill 6MWD 3 times/day, 
visited every 2 weeks at home during the first 3 months, followed 
with monthly phone calls to perform regular exercise 
Duration: 18 months 













n = 15, FEV1 = 45 ± 18%, age = 64 ± 9yr 
No exercise program provided during 
admission or after discharge (no further 
details are provided) 
After discharge 
No intervention  
In-patient program 
n = 15, FEV1 = 46 ± 21%, age = 63 ± 7yr 
Supervised 20 min interval training for walking exercise at 75% of 
the workload achieved during the baseline CPET + UL and LL 
resistance exercises at 70 % of 1RM for 3 sets of 8 repetitions 
Start: Not described 
Duration: 3 to 4 days 
Out-patient hospital-based program (same as in-patient program) 
Duration: 3 sessions/week for 3 weeks 
Re-assessment at 3 weeks after discharge 
↑FEV1 % predicted 
↑6MWD 
↑exercise duration during CPET 
↑SF-36 in all domains except pain and 
general health  
Data are presented as mean ± standard deviation. n = number included in final analysis. Abbreviations: 1RM, one repetition maximum; 6MWD, six-minute walk distance; CG, 
control group; CPET, cardiopulmonary exercise testing; CRQ, Chronic Respiratory Questionnaire; EG, exercise group; FEV1, forced expiratory volume in one second; LL, 
lower limb; min, minutes; PaCO2, arterial blood gas pressure of carbon dioxide; SF-36, 35-item short form survey; TDI, transition dyspnoea index; UL, upper limb; yr, years.




2.4.1.1 Results of the studies that investigated the effects of exercise training 
initiated during the period of hospitalisation 
Regarding the results of studies that initiated exercise training during a period of 
hospitalisation for AECOPD, all nine studies explored the effect of exercise training 
on exercise capacity. Of these, five (56%) demonstrated a significant between-group 
difference in this outcome (65-67, 71, 241), of which four (80%) included walking 
training as the exercise modality (65-67, 241). This finding, at least in part, suggests 
that walking training is needed to improve exercise capacity in people hospitalised 
for an AECOPD. However, of these five studies, three (60%) initiated exercise 
training after four to eight days of hospital admission (65-67) and therefore the 
results of these studies are unlikely to be relevant for countries such as Australia and 
Malaysia, in which the hospital length of stay for an AECOPD is often less than one 
week (68, 69). Of the two studies which initiated exercise training within two to 
three days of hospitalisation for AECOPD and demonstrated a significant between-
group difference in a measure of exercise capacity, the study by Borges et al. (71) 
reported the use of very long resistance training sessions (i.e. 90 minutes sessions, 
performed daily), which are unlikely to be feasible in a busy clinical setting. In the 
other study (241), although exercise training was initiated within two days of hospital 
admission, on average only 2.7 ± 2.6 sessions of aerobic training and 2.5 ± 1.9 
sessions of resistance training were performed during the in-patient program. The 
majority of the training (i.e. a 6-week exercise program) was home-based following 
hospital discharge and most importantly, the effect of the in-patient program on 
exercise capacity was not evaluated. Therefore, to date, there are no studies that have 
reported the effect of a combined program of both aerobic and resistance training 
initiated within two to three days of hospitalisation for an AECOPD, on exercise 
capacity measured at the time of hospital discharge. 
 
Of the other four studies (70, 72, 240, 242), three (75%) (70, 72, 240) did not 
demonstrate significant between-group difference in exercise capacity and one (25%) 
(242) did not report whether there was a significant between-group difference in this 
outcome at the completion of the exercise program. The three studies that did not 
demonstrate significant between-group difference in exercise capacity were 
characterised by low levels of program participation (i.e. only 40% of the patients 




assigned to the rehabilitation group attended 75% or more of the out-patient exercise 
sessions) (240), small sample sizes (i.e. n = 10 vs. 11) (70) and the use of exercise 
that was very specific for the improvement in muscle strength but not  exercise 
capacity (i.e. one session of knee extension exercise each day, without any aerobic 
exercise) (72). 
 
Regarding the effects on QMF, of the four studies that reported data on this outcome 
(70-72, 241), only one (72) demonstrated a significant between-group difference in 
favour of the exercise group (EG). The study which demonstrated a significant 
between-group difference for QMF evaluated this outcome using an isokinetic 
dynamometer, reported data on 36 participants, with participants completing an 
average of 6 ± 1 sessions of training which involved three sets of eight repetitions of 
knee extension at 70% of 1RM. Although the data by Troosters et al. (72), suggests 
that specific resistance for the quadriceps muscle during a period of hospitalisation is 
safe and effective at increasing QMF, the training program in this study necessitated 
the use of a knee-extension chair (Gymna, Bilzen, Belgium). This equipment may 
not be readily available, especially in countries with limited healthcare resources, 
such as Malaysia. In contrast with this study, the lack of effect on QMF in the other 
three studies appears to be due to the use of a less sensitive outcome measure to 
evaluate muscle force (i.e. MMT) and a smaller sample size in one study (70), and 
the prescription of a much lower dose of training that was also not specific to the 
quadriceps muscle in the other two RCTs (71, 241). It is currently unknown whether 
or not resistance exercises performed using minimal or no equipment such as half 
squats, initiated early during a period of hospitalisation for an AECOPD, are 
effective at increasing QMF. 
 
Regarding the effects on PA, only one study reported data on the average time people 
hospitalised for an AECOPD spent sitting, lying, standing and walking (71). This 
study demonstrated that the participants in both EG and CG were mostly inactive and 
there were no significant between-group differences in the time they spent sitting, 
lying, standing and walking, not only during the period of hospitalisation but also a 
month following hospital discharge (71). One possible reason that this study did not 
demonstrate any significant changes in standing or walking relates to the type of 
exercises prescribed as part of their training program. That is, this study only 




included resistance training exercise. The principle of task specificity is known to 
influence training-related adaptations and suggests that in order to maximise any 
increase in standing and walking-based activities, the training program should 
incorporate standing and walking-based training (243). 
 
Regarding the effects on HRQoL, of the five studies that have reported data on this 
outcome (66, 67, 71, 240, 241), three (60%) demonstrated a significant between-
group difference in favour of the EG (66, 67, 240). These studies assessed HRQoL 
using the CRQ and/or the SF-36 between three weeks and 18 months following 
hospital discharge (66, 67, 240). In contrast, the two RCTs that did not demonstrate a 
significant between-group difference in HRQoL both measured this outcome using 
the SGRQ (71, 241). One evaluated the effect of exercise training on HRQoL at 
discharge (71) and the other collected measures at six weeks, three, six and 12 
months after randomisation (241). Although it is possible that the lack of effect on 
HRQoL in these two studies related to the use of a different outcome measure (i.e. 
the SGRQ), it is perhaps more likely related to the different effect these exercise 
programs had on exercise capacity. That is, of the three studies that reported 
significant between-group differences in HRQoL, most also demonstrated significant 
between-group difference in exercise capacity (66, 67). On the other hand, in those 
studies that did not report a significant between-group difference in HRQoL, 
significant between-group differences in exercise capacity were less consistent (71, 
241). Therefore, it is possible that improvements in HRQoL are more likely to be 
achieved by programs which are effective at optimising exercise capacity. 
 
Regarding the effects on  healthcare utilisation, of the four studies that reported data 
on this outcome (67, 72, 240, 241), only one (67) demonstrated a significant 
between-group difference in re-admission rate over an 18 months period in favour of 
the EG. This study initiated the exercise program during the period of hospitalisation, 
and then extended the program for 18 months following discharge. In the period 
following discharge, the participants were prescribed with an unsupervised home-
based exercise program that comprised 15 minutes walking three times per day for 
18 months. The participants were visited every two weeks during the first three 
months and afterwards received monthly phone calls to encourage them to perform 
regular exercise. This is in contrast to the other three studies which did not 




demonstrate any between-group difference in this outcome, where the exercise 
program and contact with the investigators were completed after four to eight weeks 
post-discharge but data on healthcare utilisation were collected for three to 12 
months (72, 240, 241).  
 
Regarding safety, one study (70) reported one serious adverse event in one (3%) of 
the 32 participants during the training program. Specifically, the participant in this 
study developed chest pain during the walking training and it was confirmed by 
electrocardiogram that the participant was experiencing atrial fibrillation. However, 
the chest pain resolved within one hour without any medical intervention and the 
participant resumed participation in the study without further incident. No serious 
adverse events were reported in other studies.  
 
Regarding adherence to the training program, for the training undertaken during the 
period of hospitalisation, adherence to the training sessions was reported to be 
between 85% and 95% (70, 71, 241). When the in-patient exercise program was 
extended to an after discharge program, it appears that the adherence to the exercise 
sessions was lower than that seen during the hospitalisation period. For example, 
Eaton et al. (240) reported that only 40% of those in the EG attended 75% or more of 
the out-patient exercise program. In another example, Greening et al. (241) found 
that daily adherence to the unsupervised home-based exercise program was reported 
by only 54% and 61% of the participants for aerobic and resistance training, 
respectively. 
 
2.4.2 Exercise training initiated shortly following discharge from hospital for 
an AECOPD 
To date, there are five studies that have evaluated the effects of exercise training 
initiated shortly following discharge from hospital for an AECOPD (244-248) (Table 
2.8). These studies have applied an exercise training intervention in one group and 
usual care in the CG. The sample sizes ranged from 26 to 60 and the participants had 
moderate to severe COPD and had been discharged from hospital for an AECOPD. 
Exercise training was commenced either immediately (248) or within one to three 
weeks following hospital discharge (244-247). Of these five studies, three (60%) 
conducted the training programs in an out-patient hospital setting (245-247), one 




(20%) as a community-based program (244) and one (20%) provided the training 
program at home (248). All studies reported that the exercise programs were 
supervised by physiotherapists, nurses or a doctor from a department of pulmonary 
medicine. In contrast with the studies that evaluated the benefits of exercise training 
within the hospitalisation period, where the training protocols varied greatly, all five 
studies in which exercise training was initiated following discharge included both 
aerobic and resistance exercises in their exercise program. The frequency of the 
training sessions was between two and three sessions per week and the duration of 
the training ranged from six to 12 weeks.  
 
Of these five studies, although group allocation appeared to be randomised, two 
studies reported concealment of the randomisation sequence (246, 248) and only one 
reported blinding of the outcome assessor (245). Information pertaining to the 
concealment of the randomisation sequence and blinding of the outcome assessor 
was not provided in three (244, 245, 247) and two (247, 248) studies, respectively. 
The loss to follow-up in these studies ranged between 15% and 19% (244-246, 248). 
 
2.4.2.1 Results of the studies that investigated the effects of exercise training 
initiated shortly following discharge from hospital for an AECOPD 
Regarding the results of studies that initiated exercise training shortly following 
discharge from hospital for an AECOPD, all five studies explored the effect of 
exercise training on exercise capacity. Of these, four (80%) demonstrated significant 
between-group difference in favour of the EG in this outcome (244, 246-248). The 
lack of training effect in the study by Ko et al. (245) could have been attributed to the 
fact that although the participants in the EG received an eight weeks hospital-based 
out-patient exercise program, participants in the CG were instructed to exercise 
regularly at home (245). Specifically, they were instructed to walk and to perform 
some stretching exercise on daily basis. Adherence with this advice among those in 
the CG may have improved their 6MWD. 
 
Regarding the effects on QMF, of the two studies that reported data on this outcome 
(246, 248), only one (246) demonstrated a significant between-group difference in 
favour of the EG. The study which demonstrated a significant between-group 
difference for QMF evaluated this outcome using a strain gauge and reported data on 




97 participants. An average of 16 sessions of training were completed which 
involved twice-weekly aerobic and resistance exercises for eight weeks (246). In 
contrast with this study, the lack of effect on QMF in the other study appears to be 
due to the smaller sample size (i.e. 13 in each group) and the prescription of a lower 
dose of exercise (i.e. 12 vs. 16 exercise sessions) (248). Although it is possible that 
differences in content of the training program between the two studies also 
contributed to the different effects on QMF, neither study described the exercise 
program in sufficient detail to allow such a comparison to be made. 
 
None of the five studies that have evaluated the effects of exercise training initiated 
shortly following discharge from hospital for an AECOPD measured the effect on 
PA. Therefore, the effect of exercise training initiated shortly following discharge 
from hospital for an AECOPD on PA is unknown.
  
















Table 2.8: Summary of studies where exercise training was initiated shortly following discharge from hospital for an AECOPD 
Author/ 
year 
Intervention Significant between-group  
difference in favour of EG CG EG 
Man et al. 
2004 (244) 
Usual care 
n = 21, FEV1 = 37 ± 15%, age = 71 ± 9yr 
  Not described 
Community-based program 
n = 21, FEV1 = 42 ± 19%, age = 70 ± 9yr 
Supervised 1 hour walking, cycling, strength training for the UL 
and LL, and 1 hour of educational activities 
Start: within 10 days of discharge  
Duration: 2 sessions/week for 8 weeks  
Home-based program  
(Commenced together with the community-based program) 
Unsupervised exercise for ≥ 20 min/day (no further details are 
provided) 
 
Re-assessment at 3 months after discharge 
↑ISWD 
↓SGRQ 
↑CRQ (all 4 domains)  
↑SF-36 (physical function) 
Murphy 
et al. 2005 
(248) 
Usual care 
n = 13, FEV1 = 42 ± 12%, age = 65 ± 11yr 
Standard medical treatment + no exercise 
program provided  
 
Participants who required PRP were offered 
out-patient PRP after the completion of the 
study  
Home-based program 
  n = 13, FEV1 = 38 ± 12%, age = 67 ± 10yr 
Supervised aerobic exercises (step up and down a stair, sit to 
stand) and light resistance exercises using Thera-Band for 30-40 
min 
Start: immediately following hospital discharge 
Duration: 2 sessions/week for 6 weeks  
 




↓SGRQ (total score and activity)  
↑CRQ (dyspnoea and emotion)  
Seymour 
et al. 2010 
(246) 
Usual care 
n = 30, FEV1 = 52 ± 22%, age = 65 ± 10yr 
Participants were provided with general 
information about COPD 
 
Out-patient hospital-based program 
n = 67, FEV1 = 52 ± 20%, age = 67 ± 10yr 
Supervised limb strengthening and aerobic exercises 
Start: within 7 days of discharge 
Duration: 2 sessions/week for 8 weeks 





↓SGRQ (total score and activity)  
↑CRQ (dyspnoea and emotion)  
   continues next page 
  

















Author/ year Intervention Significant between-group  
difference in favour of EG CG EG 
Ko et al. 2011 
(245) 
Usual care 
n = 26, FEV1 = 41 ± 18%, age = 74 ± 6yr  
Participants were given simple 
instructions to do regular exercise at home 
that include walking and stretching 
exercises 
Out-patient hospital-based program 
n = 25, FEV1 = 46 ± 20%, age = 73 ± 8yr 
Supervised treadmill, arm cycling, arm and leg weight training 
Start: within 3 weeks after hospital discharge 
Duration: 2 hr/session, 3 session/week for 8 weeks 
Home-based program 
Commenced together with the hospital-based program 
Duration: 20 min/day 
 Re-assessment at 3, 6 and  12 months 
after discharge 
↓SGRQ (total score and impacts)  
Deepak 
et al. 2014 
(247) 
Usual care 
n = 15, FEV1 = 47 ± 15%, age = 59 ± 7yr 
Not described  
Out-patient hospital-based program 
n = 15, FEV1 = 53 ± 18%, age = 58 ± 7yr 
Supervised limb strengthening and aerobic exercises 
Start: within 2 weeks of discharge 
Duration: 2 hr/session for 12 weeks (number of sessions per 
week was not described) 
 Re-assessment at 3 months after discharge 
↑6MWD 
↓SGRQ total score 
Data are presented as mean ± standard deviation. n = number included in final analysis. Abbreviations: 6MWD, six-minute walk distance; CG, control group; COPD, chronic 
obstructive pulmonary disease; CRQ, Chronic Respiratory Questionnaire; EG, exercise group; FEV1, forced expiratory volume in one second; hr, hours; LL, lower limb; PRP, 
pulmonary rehabilitation program; QMF, quadriceps muscle force; SF-36, 36-item Short Form survey; SGRQ, St George’s Respiratory Questionnaire; ISWD, incremental 
shuttle walk distance; UL, upper limb; yr, years.




Regarding the effects on HRQoL, all five studies demonstrated significant between-
group differences in favour of the EG, measured using the CRQ, SGRQ or the SF-36. 
With regard to the effect on healthcare utilisation, of the three studies that reported 
data on this outcome (245, 246, 248), two (67%) demonstrated a significant between-
group difference in favour of the EG in the number of hospital re-admissions 
measured within three months following hospital discharge (246, 248). In these two 
studies, data on hospital re-admission rate were collected within the period where 
exercise training was provided (i.e. over a 3 months period) (246, 248). This is in 
contrast to the only study that did not demonstrate a significant between-group 
difference in this outcome, where exercise training was provided for eight weeks but 
data on re-admission rate were collected over a period of one year (245). This 
suggests that the effect of exercise training on re-admission rate may be greatest 
during the period that the program is provided. 
None of the five studies that have investigated the effect of exercise training initiated 
shortly following discharge from hospital for an AECOPD evaluated adverse events 
or reported data pertaining to safety of the exercise training. Regarding adherence to 
the training program, using a standard cut-off of 50% classes attended, adherence to 
the training sessions were reported to be between 73% and 77% (244-246).  
2.4.3 Summary 
To date, there have been 14 studies that have explored the effect of exercise training 
initiated during or shortly following hospital discharge for an AECOPD. Of these, 
nine (64%) have initiated exercise training during the hospital admission and five 
(36%) have initiated exercise training shortly following discharge. Although 10 
(71%) studies reported randomising participants to groups and six (43%) reported 
concealment of the randomisation sequence, studies in this area generally did not 
report using a blinded outcome assessor and also had large losses to follow-up. These 
considerations increase the risk of bias in the study results. Regarding the results of 
those studies that initiated exercise training shortly following hospital discharge, it 
appears that a combination of aerobic and resistance training is effective at 
improving exercise capacity and HRQoL. Of those studies that initiated exercise 
training within the period of hospitalisation, the results of those studies where 
exercise training was commenced late (i.e. between 4 and 8 days after hospital 
admission) may not be relevant in the Australian and Malaysian context where 




hospital length of stay for an AECOPD is often less than one week. Regarding the 
results of those studies that initiated the exercise program early (i.e. within 2 to 3 
days of hospitalisation), it appears that walking training is needed to improve 
exercise capacity. However, to date no study which has evaluated the effects of an 
exercise program, initiated within two to three days of hospitalisation for an 
AECOPD and, comprising aerobic or a combination of aerobic and resistance 
exercise, has been powered to detect between-group differences in outcomes such as 
exercise capacity and QMF.




CHAPTER 3  
2MWT: MEASUREMENT PROPERTIES AND 
COMPARISON OF CARDIORESPIRATORY RESPONSES 
WITH THE 6MWT IN PEOPLE WITH MODERATE TO 
SEVERE COPD 
 
This chapter presents the study that examined some of the measurement properties of 
the two-minute walk test (2MWT) and compared the cardiorespiratory responses and 
levels of symptoms during the 2MWT and six-minute walk test (6MWT) in people 
with moderate to severe chronic obstructive pulmonary disease (COPD). The 
research questions answered in this chapter are:  
i. What is the magnitude of change in the two-minute walk distance (2MWD) 
with test repetition? 
ii. What is the coefficient of repeatability (COR) for the 2MWD measured over 
two days? 
iii. Does the 2MWT provide a valid of assessment of functional exercise 
capacity? 
iv. Is the distance walked during the 2MWT different to one third of the six-
minute walk distance (6MWD)?  
v. Does the 2MWT elicit different cardiorespiratory responses and levels of 
symptoms when compared with the 6MWT? 
 
The details of the study design are provided, including a description of the study 
inclusion and exclusion criteria, recruitment strategies and assessment protocol. 
Details of the measurements and statistical analyses are also described. The results 
are presented and discussed.




3.1 Study design  
A single group cross-sectional study was undertaken between October 2012 and May 
2013. Data collection for each participant was completed during two testing sessions, 
each of two hours duration that were separated by a minimum of 48 hours and a 
maximum of 14 days. An overview of the study design is provided in Figure 3.1. 
3.1.1 Approval from Human Research Ethics Committees 
Approval to conduct the study was granted by the Human Research Ethics 
Committees (HRECs) of Sir Charles Gairdner Hospital (SCGH) (approval number 
2012-054) and Curtin University (approval number HR 76/2012). Written, informed 
consent was obtained from all participants prior to data collection.





Figure 3.1: Overview of the study design. 
* Heart rate, SpO2 and dyspnoea level were recorded prior to each test. 
Abbreviations: 2MWT, two-minute walk test; 6MWT, six-minute walk test; COPD, 
chronic obstructive pulmonary disease; min, minutes; mMRC, modified Medical 
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3.1.2 Participants  
3.1.2.1 Inclusion criteria 
Participants were eligible for inclusion in this study if they had a diagnosis of COPD 
(249) and were clinically stable, defined as an absence of any change in respiratory 
symptoms in the previous four weeks that required a change in medication (53), and 
had at least moderate functional impairment (i.e. 6MWD of ≤ 450m) mainly due to 
profound dyspnoea. The threshold of ≤ 450m to define moderate functional 
impairment was based on earlier work by Starobin et al. (250) who demonstrated that 
a 6MWD of ≤ 450m in people with COPD corresponded to a peak rate of oxygen 
consumption (VO2 peak) of 15 to 20ml/kg/min, measured during a cardiopulmonary 
exercise test, which indicated moderate functional impairment. 
People with moderate to severe COPD with at least moderate functional impairment 
were specifically recruited into this study as they were likely to have similar 
characteristics as those experiencing an acute exacerbation of COPD (AECOPD), 
such as profound dyspnoea and oxygen desaturation on exertion and marked 
impairment in exercise capacity. This was necessary given that the purpose of this 
study was to propose the use of the 2MWT for the assessment of functional exercise 
capacity in the acute setting, that is, when patients are hospitalised with an 
AECOPD. Although it would have been ideal to recruit patients hospitalised with an 
AECOPD, this was not considered feasible as these patients often change rapidly in 
response to treatment (251), which would confound the estimate of the repeatability 
of the 2MWD over two days. Further, it is unlikely that those hospitalised with an 
AECOPD would be able to complete the study protocol, which comprised five 
walking tests over two days.  
3.1.2.2 Exclusion criteria 
Exclusion criteria comprised: (i) presence of condition, other than COPD, which was 
the primary reason for a limitation in exercise capacity (e.g. neurological disease, 
severe symptomatic musculoskeletal pain, impaired cognitive function or 
claudication pain), (ii) a known contraindication to exercise (Appendix 2) (167), (iii) 
prescribed with beta-blockers (i.e. medications known to affect heart rate response to 
exercise), and (iv) inability to understand English. 





Patients attending out-patient pulmonary rehabilitation programs (PRPs) conducted 
under the jurisdiction of the SCGH’s HREC were screened through the PRP’s 
records. This program does not accept people with severe, limiting cardiac disease. 
Those who met the selection criteria for the study were asked if they were interested 
in being told about the study by the physiotherapists responsible for running the PRP. 
Those who expressed an interest were provided with a verbal explanation about the 
study and were approached to participate in this study by the investigator (PhD 
candidate).   
3.1.4 Assessment protocol 
All participants performed three 2MWTs on day one, and one 2MWT and one 
6MWT on day two. The order of the tests on day two was randomly assigned using a 
computer-generated and concealed randomisation sequence. Participants were given 
a minimum of 20 minutes rest between consecutive walking tests (75). The rest 
period was extended when necessary until the HR, percutaneous oxygen saturation 
(SpO2) and dyspnoea (Borg category ratio scale) had returned close to the baseline 
measurements. This was defined as within five beats per minute (bpm), 1% and 1 
point of baseline (i.e. pre-test) values for differences in HR, SpO2 and dyspnoea, 
respectively (6). All participants were tested at a similar time of the day on both 
study days. They were also instructed to continue their usual medications on the day 
of testing.  
3.2 Measurements 
3.2.1 Walk tests 
The 2MWT and the 6MWT were carried out in accordance with a protocol adapted 
from the European Respiratory Society (ERS)/American Thoracic Society (ATS) 
Technical Standards for the 6MWT (226) with the following modifications: (i) the 
inclusion of standardised encouragement every 15s instead of 30s to recommence 
walking if the participant rested during  any of the tests, (ii) standardised 
encouragement every 30s instead of every minute during the 2MWT and (iii) the 
instruction ‘to walk as fast as you can’ instead of ‘to walk as far as possible’ (see 
subheading 2.3.3.2.3).  
 




All participants were familiar with the 6MWT but not with the 2MWT prior to 
participating in this study. Absolute contraindications to performing the exercise tests 
were taken from published guidelines for cardiopulmonary exercise testing 
(Appendix 2) (167). Additional relative contraindications comprised: (i) pre-exercise 
HR of > 125bpm and (ii) resting SpO2 of < 90%. Those who were using oxygen 
therapy performed the tests whilst breathing oxygen supplied at their prescribed flow 
rate for exercise with the oxygen cylinder transported by the participant using a 
wheeled walker or a trolley.  
 
Both tests were performed over a 30m straight course within a level enclosed 
corridor and were supervised by the same investigator. Chairs were placed at both 
ends and at the mid-way point to allow seated rests if required. Standardised 
instructions were read aloud to the participants before each test. They were informed 
that they could slow down or rest if necessary. Participants were also told to stop 
walking and inform the investigator if they experienced any chest pain or dizziness. 
Participants who demonstrated profound oxygen desaturation, defined as SpO2 < 
80% were instructed to stop walking immediately and to recommence walking if 
SpO2 recovered to ≥ 80% (226).  
 
Heart rate (Polar a1, Polar Electro Oy, Kempele, Finland) and SpO2 (Masimo Rad-
5v, Masimo Corporation, California, USA) were measured throughout both tests with 
the values were recorded before the test, at the end of each minute during the 6MWT 
and every 30s during the 2MWT, and at test completion. Peak HR was expressed as 
percentage of predicted HR maximum using the formula, 210 − (0.65 × age) (252). 
This formula was used because it is the formula recommended by the American 
College of Sports Medicine (253) and in contrast to the most commonly used 
formula to estimate the peak HR (i.e. 220 − age) (254), this formula is less likely to 
underestimate the peak HR in older adults. The investigator walked behind the 
participant and care was taken to avoid the walking speed of the investigator 
influencing that of the participant. Upon test completion, participants remained in the 
testing area and SpO2 was monitored until it returned to ≥ 90%. In participants who 
chose to rest, or in whom a rest was imposed because of profound oxygen 
desaturation (SpO2 < 80%) (226), the nadir SpO2 was recorded together with rest 
duration. The reason for resting was also documented in those who chose to rest. 




Dyspnoea was assessed using the Borg category ratio scale (147) at rest, upon test 
completion, and at the start of any rests taken during the test. The Borg category ratio 
scale was also used to record leg fatigue at the end of the test (147). The primary 
outcome measure in both tests was the distance walked.  
3.2.2 Descriptive measures 
3.2.2.1 Participant details 
Details were recorded pertaining to age, gender and ambulatory oxygen use. Weight 
and height were measured and used to calculate body mass index (BMI [kg/m2]). 
3.2.2.2 Functional limitation 
Functional limitation resulting from dyspnoea was assessed using the modified 
Medical Research Council (mMRC) dyspnoea scale (151, 152). This scale comprises 
five statements each of which is assigned a grade that ranges from zero “I only get 
breathless with strenuous exercise” to four “I am too breathless to leave the house or 
I am breathless when dressing”. The participant selects the statement which best 
describes their level of limitation in daily activities due to breathlessness. The 
mMRC scale has been shown to be a valid method of categorising people with 
COPD in terms of their level of functional disability (255).  
3.2.2.3 Spirometry  
Spirometry was performed according to standard procedures (256) using a portable 
Spirometer (EasyOne NDD Medical Technologies, Massachusetts, USA). Testing 
was conducted by the investigator who was trained and certified to standards which 
aligned with the ATS/ERS standards (256). Participants were required to perform a 
minimum of three acceptable forced vital capacity (FVC) manoeuvres (256). The 
largest forced expiratory volume in one second (FEV1) and FVC from any of the 
three manoeuvres that met the acceptability and repeatability criteria were selected as 
the test results. Both FEV1 and FVC were expressed as a percentage of the predicted 
normal values (257).  
3.2.2.4 BMI, degree of airflow Obstruction, Dyspnoea and Exercise capacity 
(BODE) index 
The BODE index, a multi-dimensional score that comprises measures of BMI, FEV1, 
mMRC dyspnea grade and the 6MWD, was calculated to provide a global 




description of disease severity that was not only based on the assessment of airflow 
limitation but also considered the systemic manifestations of COPD (152).  
3.3 Statistical analyses  
3.3.1 Sample size calculations  
Earlier work using the same 6MWT protocol as used in this study, and upon which 
the 2MWT protocol has been based, demonstrated an increase of 37 ± 37m (mean ± 
standard deviation [SD]) between repeat 6MWDs in people with moderate to severe 
COPD (6). As the duration of the 2MWT is one third of the 6MWT, it is most likely 
that the difference between repeat 2MWDs would be approximately one third of the 
difference in the repeat 6MWD (i.e. 12 ± 12m). However, as this study was designed 
to recruit individuals with at least moderate functional limitation (to be more 
representative of those individuals experiencing an AECOPD), it was anticipated that 
the difference between repeat 2MWDs would be slightly less than 12m. Therefore, 
prospective sample size calculations were undertaken to ensure adequate power (α = 
0.05, 1 - β = 0.8) to detect a difference between repeat 2MWDs of 9 ± 12m. A 
sample size of 16 participants was required to detect this difference. Assuming a 
20% withdrawal rate, the recruitment target for this study was 20 participants. 
3.3.2 Statistical analyses 
All analyses were performed using the Statistical Package for Social Sciences (SPSS 
version 19.0; Chicago, IL, USA) with a probability (p) value < 0.05 used to indicate 
statistical significance. The distribution of data was examined by graphical 
(frequency histograms and box plots) and statistical methods (Shapiro-Wilk test). 
To explore the effect of test repetition on the 2MWDs, the three 2MWDs measured 
on day one were analysed using a repeated measures analysis of variance (RM-
ANOVA). Post-hoc analysis using the Bonferroni method was conducted to compare 
the differences between the repeat 2MWDs. To explore the validity of the 2MWT as 
a measure of functional exercise capacity in people with COPD, the relationship 
between the 2MWD and the 6MWD was analysed using Pearson’s correlation 
coefficient. The strength of the correlation was interpreted based on the grading 
scheme used by Cohen (258). 




To determine the coefficient of repeatability of the 2MWDs measured over two 
different days, the methods described by Bland and Altman were used (259). 
Specifically, bias was defined as the mean difference between the best of the three 
2MWDs measured on day one and the 2MWD measured on day two. The COR was 
calculated as 1.96 × √2 × within-subject SD of the two 2MWDs (259). The within-
subject SD was estimated from the square root of the residual mean square, obtained 
from the RM-ANOVA. The bias and COR were also calculated separately for those 
who performed the 6MWT first vs. those who performed the 2MWT first to establish 
if the order of the test had an influence on COR.  
Data collected on day two were used for further analyses. To evaluate whether the 
distance walked during the 2MWT was interchangeable with one third of the 
distance walked during the 6MWT, a paired sample t-test was used to compare these 
distances. The proportion of participants who rested during the 2MWT was 
compared with those who rested during the 6MWT using Pearson’s Chi-square test. 
With regard to a comparison of the responses during the 2MWT with the 6MWT, 
paired sample t-tests were used to compare the peak HR, nadir SpO2, peak dyspnoea 
and the end-test leg fatigue scores during the 2MWT with those during the 6MWT. 
All data are expressed as mean ± SD or 95% confidence interval (CI) unless 
otherwise stated. 
3.4 Results  
Of the 20 individuals who consented to participate, two (10%) did not attend the 
second day of the testing session; one (5%) required hospital admission due to an 
AECOPD and one (5%) was unable to attend the follow-up assessment within the 
study period. The characteristics of the 20 participants are presented in Table 3.1.  
3.4.1 Effect of test repetition 
The means (± SD) of the 2MWDs during the three 2MWTs on day one were 135 ± 
27m, 141 ± 23m, and 145 ± 24m, respectively and the mean ± SD of the best 2MWD 
was 146 ± 24m. The distance walked in the 2MWD improved significantly with test 
repetition (p < 0.001). The 2MWD increased by a mean of 6m; 95% CI, 2m to 9m 
between walk 1 and walk 2, and by a mean of 4m; 95% CI, 2m to 6m between walk 
2 and walk 3 (Figure 3.2). When expressed as a percentage of difference from 
baseline, the 2MWD increased by a mean of 4%; 95% CI, 1% to 7% between walk 1 




and walk 2 and a mean of 3%; 95% CI, 1% to 4% between walk 2 and walk 3. Two 
participants (10%) walked the same distance on all three 2MWTs. A total of two 
(10%), five (25%) and 13 (65%) participants achieved their best 2MWD on the first, 
second and third test, respectively.  
3.4.2 Repeatability of the 2MWD 
The bias and COR for the 2MWD measured over two days were 1m and 14m, 
respectively (Figure 3.3a). These values were -1m and 11m in participants who were 
randomly assigned to perform the 2MWT first, and 2m and 16m in participants who 
performed the 6MWT prior to the 2MWT (Figure 3.3b and 3.3c). 
3.4.3 Validity of the 2MWT 
There was a strong positive linear association between the 2MWD and the 6MWD (r 
= 0.66; p = 0.003).  
3.4.4 2MWD vs. one third of the 6MWD 
Using data collected on day two, the distance walked during the 2MWT and one 
third of the distance walked during the 6MWT were 147 ± 24m and 115 ± 29m, 
respectively. Therefore, the participants walked a mean of 31 ± 22m (27%) further 
during the 2MWT than one third of the distance walked during the 6MWT (p < 
0.001).  
3.4.5 Cardiorespiratory responses and levels of dyspnoea and leg fatigue 
during the 2MWT and 6MWT 
The mean 2MWD and the 6MWD on day two were 147 ± 24m and 346 ± 88m, 
respectively. Thirteen (72%) participants rested during the 6MWT, whereas only two 
(11%) participants rested during the 2MWT (p < 0.001). The rest duration ranged 
from 3s to 167s during the 6MWT and 7s to 13s during the 2MWT. 
Cardiorespiratory responses and levels of symptoms during the tests are shown in 
Table 3.2. The peak HR was greater for the 6MWT than for the 2MWT (mean 
difference; 95% CI, 6; 4 to 9 bpm), while the nadir SpO2 was lower during the 
6MWT than during the 2MWT (-4; -6 to -2 %). Peak dyspnoea was greater during 
the 6MWT than during the 2MWT (mean difference; 95% CI, 0.9; 0.4 to 1.4) but 
there was no difference in end-test leg fatigue (0.3; -0.2 to 0.9) between the two tests.  




The pattern of response in HR and SpO2 during the 2MWT and the 6MWT is 
illustrated in Figure 3.4. Heart rate increased rapidly throughout the 2MWT and 
during the first two to three minutes of the 6MWT after which it tended to plateau. 
Oxygen saturation decreased throughout the 2MWT. During the 6MWT, SpO2 
decreased rapidly during the first two to three minutes and then continued to decrease 
at a slower rate until the end of the test. For the 2MWT, the nadir SpO2 occurred at 
the end of the test in all participants. In contrast, during the 6MWT, the nadir SpO2 
occurred during the test in six participants (33%), all of whom rested at least once. 





Table 3.1: Characteristics of the participants (n = 20) 
   Mean ± SD 
Age, yr  72.5 ± 8.3 
Height, m    1.66 ± 0.08 
Weight, kg    67.1 ± 19.8 
Body mass index, kg/m2  24.2 ± 6.8 
FEV1, L   0.73 ± 0.33 
FEV
1
 %pred   28 ± 13 
FVC, L   1.72 ± 0.65 
FVC %pred   51 ± 15 
FEV1/FVC   0.42 ± 0.07 
BODE index   5 ± 2 
  n (%) 
Gender Male 9 (45) 
 Female 11 (55) 
GOLD Grade Grade I 0 
 Grade II 2 (10) 
 Grade III 6 (30) 
 Grade IV 12 (60) 
mMRC Grade 0 0 
 Grade 1 1 (5) 
 Grade 2 9 (45) 
 Grade 3 9 (45) 
 Grade 4 1 (5) 
Wheeled walker  16 (80) 
LTOT  16 (80) 
Data are presented as mean ± standard deviation (SD) or n, number of 
participants and (%), percentage. Abbreviations: BODE, Body mass index, 
Airflow Obstruction, Dyspnoea and Exercise capacity; FEV1, forced expiratory 
volume in one second; FEV1 %pred, percentage of predicted FEV1 (257); FVC, 
forced vital capacity; FVC %pred, percentage of predicted FVC; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease; kg, kilograms; L, litres; LTOT, 
long-term oxygen therapy; m, metres; mMRC, modified Medical Research 
Council; yr, years.






Figure 3.2: The 2MWDs during the three consecutive 2MWTs on day one (n = 20). 
Data are presented as mean ± standard error (SE). 
*p < 0.05 and **p < 0.005. Abbreviations: 2MWD, two-minute walk distance; 
2MWT, two-minute walk test.






Figure 3.3a: Bland and Altman plot showing the coefficient of repeatability for the 
2MWD measured on two different days for all participants (n = 18).  
The solid line corresponds to the mean difference (i.e. bias) between the two 
2MWDs. The dashed lines indicate the upper and lower limits of the coefficients of 
repeatability. Abbreviation: 2MWD, two-minute walk distance.
a) 















































Figure 3.3b: Bland and Altman plot showing the coefficient 
of repeatability for the 2MWD measured on two different 
days for participants who were randomly assigned to perform 
the 2MWT first (n = 8) on the second day of testing. 
Abbreviations: 2MWD, two-minute walk distance; 2MWT, 
two-minute walk test. 
Figure 3.3c: Bland and Altman plot showing the coefficient 
of repeatability for the 2MWD measured on two different 
days for participants who were randomly assigned to perform 
the 6MWT first (n = 10) on the second day of testing. 
Abbreviations: 2MWD, two-minute walk distance; 6MWT, 
six-minute walk test.  




Table 3.2: Cardiorespiratory responses and levels of dyspnoea and leg fatigue during 
the 2MWT and the 6MWT (n = 18) 
  2MWT 6MWT 
Distance (m)  147 ± 24 346 ± 88 
6MWD %pred  -   57 ± 14 
Number of rests, n (%) 1 2 (10) 8 (40) 
2 0 4 (20) 
3 0 1 (5) 
Reason for rest, n (%) Dyspnoea 2 (10) 10 (50) 
SpO2 < 80% 0 2 (10) 
Leg fatigue 0 1 (5) 
Pre-test HR (bpm)   87 ± 13     86 ± 14 
 SpO2 (%) 96 ± 2         96 ± 2 
 Dyspnoea   1.1 ± 1.0        1.2 ± 1.0 
During/End-test Peak HR (bpm) 107 ± 13       112 ± 15** 
 Peak HR (%pred HRmax) 67 ± 7         69 ± 9 
 Nadir SpO2 (%) 86 ± 6         82 ± 7** 
 Nadir SpO2 < 85%, n (%) 9 (45)    11 (55) 
 Peak dyspnoea   4.1 ± 2.0       5.0 ± 1.8* 
 Leg fatigue   2.1 ± 1.9     2.4 ± 2.3 
Data are presented as mean ± standard deviation or n, number of participants and 
(%), percentage. *p < 0.01 and **p < 0.001 compared with 2MWT. Abbreviations: 
2MWT, two-minute walk test; 6MWT, six-minute walk test; 6MWD, six-minute 
walk distance; 6MWD %pred, percentage of predicted 6MWD (20); %pred 
HRmax, peak HR as % of HRmax (210 – [0.65 × age]) (252); bpm, beats per 
minute; HR, heart rate; m, metres; SpO2, percutaneous oxygen saturation.





Figure 3.4: Pattern of response in a) HR, b) SpO2 for each test.  
Six-minute walk test,    ; two-minute walk test,    . Data are presented as mean ± 
standard deviation. Abbreviations: bpm, beats per minute; HR, heart rate; min, 












The main findings of this study are, in people with moderate to severe COPD: (i) the 
2MWD increased by a small but significant amount with test repetition; (ii) there was 
a strong correlation between the 2MWD and the 6MWD suggesting that the 2MWT 
is a valid assessment of functional exercise capacity; (iii) the coefficient of 
repeatability for the 2MWD repeated over two days was 14m; (iv) participants 
walked significantly further during the 2MWT compared to one third of the distance 
walked during the 6MWT and, (v) when compared to the responses during the 
2MWT, the 6MWT elicited higher peak HR, greater dyspnoea, lower nadir SpO2, but 
no difference in end-test leg fatigue.  
3.5.1 Effect of test repetition  
The presence of a learning effect in walking tests such as the twelve-minute walk test 
(260, 261), 6MWT (6, 262-264) and incremental shuttle walk test (ISWT) (265, 266) 
has been well documented. The ERS/ATS Technical Standard for field-based 
walking test recommends that two tests should be performed when the 6MWT or the 
ISWT is used to assess change following an intervention or over time (226). It has 
been suggested that the mechanisms for the increase in walking distance with test 
repetition include improvement in the ability of the participant to pace themselves 
during the repeated tests, increased familiarity with the walking course, increased 
motivation, and, in those with dyspnoea on exertion such as in individuals with 
COPD, test repetition also improved their habituation to the sensation of dyspnoea 
(6, 235).  
The present study found that there was a small but significant increase in the 2MWD 
with test repetition. Although the 2MWD may have increased further on additional 
tests, Butland et al. (1) found that when a fourth test was performed in a single 
session, the 2MWD increased by only a mean of 1m. Earlier work that has 
investigated the effect of test repetition on the 2MWD has reported inconsistent 
findings (1, 2, 7, 8). Three studies reported a small but significant increase in the 
2MWD with test repetition in people with COPD who were naïve to the 2MWT (1, 
2, 7), whereas one study found no change in the 2MWD on repeat tests in those with 
prior experience of the test (8). The finding of the study by Leung et al. (8), where no 
significant increase in the 2MWD with test repetition was found, may be explained 
by the inclusion of a practice walk that was undertaken the day before the actual 




testing session. Moreover, encouragement was not provided during the test which 
may have reduced the magnitude of any improvement with test repetition (2). Of 
note, although the data in the present study demonstrated a significant increase in 
2MWD with test repetition, the magnitude of this effect appears to be smaller than 
the effect of test repetition on the 6MWD in people with COPD. Specifically, in one 
previous study where the 6MWT was performed using an identical protocol as that 
used in the present study and carried out by the same team of investigators (6), the 
6MWD was found to increase by a mean of 37m; 95% CI, 33m to 41m between walk 
1 and walk 2. When expressed as a percentage of difference from baseline, the 
previous study reported that the 6MWD increased by a mean of 11%; 95% CI, 9% to 
12% between walk 1 and walk 2. Therefore, although repeating the 2MWT appears 
to produce a small increase in the 2MWD, a practice walk for the 2MWT is less 
important than for the 6MWT and may not be necessary in people who may not be 
able to complete two 2MWTs within a day. 
3.5.2 Repeatability of the 2MWD  
The COR for the 2MWD measured over two days in people with moderate to severe 
COPD was 14m. This suggests that, for an individual patient, a change in the 2MWD 
of 14m or greater is needed in order to be 95% confident that the difference in the 
2MWDs is not due to the natural variability inherent in this test. Factors such as day-
to-day variability in respiratory symptoms and severity of airflow obstruction may 
explain the variation in the 2MWD performed over different days. For example, 
Espinosa et al. (267) evaluated the variability of the respiratory symptoms in 472 
individuals with severe COPD and found that symptoms such as chest tightness and 
dyspnoea were reported to vary on a daily basis by at least 27% of the individuals. 
The percentage of individuals who reported variability of these two symptoms over a 
longer period (i.e. a week) increased to 40% for dyspnoea and 52% for chest 
tightness. In another example among people with COPD, Kessler et al. (268) found 
that 45% of 2,258 symptomatic patients perceived variability in at least one symptom 
over the course of a day and the percentage increased to 54% in those who reported 
variability in at least one symptom over the course of a week. The participants also 
reported that their symptoms were worse in the morning compared to the rest of the 
day (268). However, it is important to note that in the present study all participants 
were tested at a similar time of the day and therefore the influence of diurnal 




variation in symptoms on walking performance is not likely to be the reason for the 
variability seen in the 2MWDs. If the two tests were performed at different times of 
the day, the random error in the present study is likely to have been greater and the 
COR would be larger than 14m. 
The order in which the tests were performed on the second day of testing made little 
difference to the COR. That is, in those who performed the 6MWT first on the 
second day of testing, the COR for the 2MWD was ± 16m. This was 5m greater than 
the COR for the 2MWD in those who performed the 2MWT first on the second day 
of testing (i.e. ± 11m). These data suggest that, in a hospital setting where patients 
are unlikely to do any activity prior to doing a 2MWT, the COR for the 2MWD may 
be as low as 11m. However, in an out-patient setting (e.g. out-patient PRP), where 
patients are likely to have to walk from the car park to the location of the program, 
the COR for the 2MWD may be somewhat greater (i.e. ±16m). 
The COR for the 2MWD in the present study was smaller than that reported in other 
populations such as in people with poliomyelitis (COR = 22m) (10), and samples of 
healthy Brazilian (COR = 24m) (17) and American (COR = 43m) adults (18). The 
reasons for a smaller COR for the 2MWD in the present study are likely to reflect 
disparities in the administration of the 2MWT between these studies. For example, 
the COR for the 2MWD in the present study was calculated between the best of three 
2MWDs on one day and the fourth 2MWD on another day, whereas, the three other 
studies calculated the COR for the 2MWD between the first and the second 2MWD 
conducted either on the same day (17) or on separate days (10, 18). That is, in these 
earlier studies, the COR may have been inflated by the effect of test repetition. 
Importantly, the COR for the 2MWD in the present study (i.e. 14m) was smaller than 
that previously reported for the 6MWD (51m (234) and 63m (269)) in people with 
moderate to severe COPD. This means that, in people with moderate to severe 
COPD, clinicians can be confident of a true change with much smaller changes in the 
2MWD than the 6MWD.  
3.5.3 Validity of the 2MWD 
The strong positive linear relationship between the 2MWD and the 6MWD 
corroborates findings from two previous studies in people with COPD (1, 8). This 
finding supports the validity of the 2MWD as a measure of exercise capacity in 




people with moderate to severe COPD. Although, comparison of the 2MWD with the 
‘gold standard’ measures of exercise capacity (e.g. VO2 peak) would have 
strengthened the conclusion that the 2MWD is a valid measure of exercise capacity, 
collection of such data was not feasible among participants in the present study 
because of the high proportion of participants who were on ambulatory oxygen. 
3.5.4 2MWD vs. one third of the 6MWD 
The finding that the mean distance walked during the 2MWT was 31 ± 22m (27%) 
further than one third of the distance walked during the 6MWT suggests that these 
two measures are not interchangeable with each other. This finding is important for 
clinicians who evaluate the effect of an intervention, such as an exercise training 
program, using the 6MWT. Specifically, in the event that a participant develops an 
AECOPD during an exercise training program, the clinician may prefer to perform 
the 2MWT on completion of the program, as this test is less burdensome on the 
participant than a 6MWT. In this instance, comparing one third of the distance 
walked during a 6MWT at baseline with the 2MWD measured post-intervention will 
lead to an over-estimation of the effect of the intervention on this outcome.  
3.5.5 Cardiorespiratory responses and levels of dyspnoea and leg fatigue 
during the 2MWT and 6MWT  
This is the first study to compare cardiorespiratory responses during the 6MWT with 
the 2MWT. In addition to being more time consuming, the 6MWT imposed a greater 
cardiorespiratory burden on people with moderate to severe COPD as indicated by a 
greater change in HR and SpO2 compared to the 2MWT.  
With regard to the levels of symptoms during the 2MWT and the 6MWT, there was a 
difference in peak dyspnoea, but not in the end-test leg fatigue between the two tests. 
The proportion of participants who rested during the 6MWT due to intolerable 
dyspnoea was also higher than during the 2MWT. Earlier work has demonstrated that 
during the 6MWT, dyspnoea increases in a linear fashion, and therefore, it is likely 
that the greater dyspnoea reported on completion of the 6MWT compared with the 
2MWT is largely due to the longer duration of the 6MWT (5, 270).  
The low scores for leg fatigue at the end of the 2MWT (2.1 ± 1.9) and 6MWT (2.4 ± 
2.3) in the present study are consistent with other studies that also reported low levels 
of end-test leg fatigue during the 6MWT (6, 158, 234, 265). Earlier work has 




demonstrated that, in people with COPD, the symptom, which limits performance 
during exercise, differs between exercise modalities. Specifically, dyspnoea has been 
identified as the most common symptom limiting performance during walking-based 
exercise, while leg fatigue has been identified as the most common symptom limiting 
performance during cycling-based exercise (157, 158). One possible explanation is 
that compared to cycling, walking involves a greater number of muscles, especially 
postural muscles. Therefore, for the same level of oxygen consumption (VO2), 
compared to cycling, during walking all of these muscles are working  at a lower 
fraction of their oxidative capacity (271). In contrast, cycling exercise is performed 
by a smaller muscle mass (i.e. largely the quadriceps muscle), and due to this, the 
oxidative capacity of the quadriceps muscle is often overwhelmed and there is early 
reliance on anaerobic energy systems and accumulation of lactic acid in the blood, 
leading to the sensation of dyspnoea (271). 
In contrast to the responses seen during the 6MWT, where both HR and SpO2 began 
to plateau after the first two to three minutes of the test, both HR and SpO2 changed 
rapidly and did not plateau during the 2MWT. This shows that the 2MWT was of 
inadequate duration to allow a steady state to be reached. Importantly, it suggests that 
the responses measured during the 2MWT were somewhat sub-maximal and 
therefore the 2MWT is less burdensome for the participant than the 6MWT.  
3.5.6 Strengths and limitations  
There are three main strengths of the present study. First, this study reports data 
pertaining to the measurement properties of the 2MWT that was carried out using a 
protocol based on the ERS/ATS technical standard for performing field-based walk 
test. Second, all tests were performed by the same investigator and the investigator 
ensure that all participants were tested at a similar time of the day. Third, for most 
outcome measures collected in this study there was minimal loss to follow up.  
The present study also had some limitations. Although being the first study to 
compare exercise responses between the 2MWT and the 6MWT, the sample size in 
the present study (n = 18) was relatively modest. A larger sample size would have 
improved the precision of the estimate of the differences in cardiorespiratory 
responses and levels of symptoms between the 2MWT and the 6MWT as well as 
between repeat 2MWDs. A larger sample size would also allowed for subgroup 




analyses such as differences in cardiorespiratory responses and levels of symptoms to 
the 2MWT and the 6MWT with participants grouped according to GOLD grades or 
between those requiring and not requiring supplemental oxygen. Nonetheless, this 
sample size was similar to that of previous studies that compared exercise responses 
during the 6MWT and the incremental exercise test such as incremental shuttle walk 
test and cycle ergometer test in people with moderate to severe COPD (n = 20) (5, 
272). Comparison of more detailed cardiorespiratory responses (e.g. VO2 peak, 
ventilation) to the 2MWT and 6MWT would have strengthened the conclusion that 
the 6MWT elicited a greater burden on the cardiorespiratory system as compared to 
the 2MWT. However, collection of such data was not feasible in these participants 
because of the high proportion of the participants in the present study who were on 
ambulatory oxygen.  
3.6 Conclusions 
This study has demonstrated that the 2MWT has a very small learning effect which 
appears to be smaller than the learning effect for the 6MWD reported in previous 
studies. Therefore, a practice walk for the 2MWT is less important than for the 
6MWT and may not be necessary in people with COPD. This study also 
demonstrated that the 2MWD is repeatable. The COR for the 2MWD was smaller 
than that previously reported for the 6MWD, and therefore clinicians can be 
confident of a true change in the 2MWD with much smaller changes in the test 
result. This study also provides preliminary evidence to support the 2MWT as a valid 
measure of functional exercise capacity in people with moderate to severe COPD. 
The finding that participants walked a greater distance during the 2MWT compared 
to one third of the distance walked during the 6MWT suggests that these two 
measures are not interchangeable. The 2MWT appears to be better tolerated than the 
6MWT in people with moderate to severe COPD. That is, when compared with the 
6MWT, the 2MWT elicited a significantly lower peak HR, less oxygen desaturation 
and less dyspnoea. The proportion of participants who rested due to intolerable 
dyspnoea was also lower during the 2MWT when compared to the 6MWT. 
Therefore, in the context of patients who experience severe dyspnoea on exertion, 
such as in some of those with moderate to severe stable COPD or in those who are 
hospitalised for an AECOPD, the 2MWT may provide a more appropriate objective 
measure of functional exercise capacity than the 6MWT. As the 6MWT has several 




applications in PRP (e.g. to evaluate change following PRP, prescribe a walking 
program, identify the presence of exercise induced desaturation) but does not appear 
to be routinely used in the acute setting, further studies are needed to evaluate other 
clinical applications of the 2MWT in this group of patients.  
The present study provides preliminary evidence pertaining to the potential use of the 
2MWT to detect exercise induced desaturation. The 2MWT seems to have a similar 
capacity to the 6MWT to detect clinically important oxygen desaturation given the 
fact that a similar proportion of patients in both tests desaturated more than 4% from 
baseline measures (273). However, the 6MWT may be a more relevant test for 
assessing the response to supplemental oxygen as the longer test duration is likely to 
be more representative of walking in daily life. The potential use of the 2MWT in 
prescribing the intensity of a walking training program and to evaluate change in 
exercise capacity following exercise training program in people hospitalised with an 
AECOPD are examined in Chapter 5. The finding that the 2MWT represents only a 
sub-maximal exercise test while the 6MWT represents a maximal or near maximal 
exercise test in people with moderate to severe COPD, the method of exercise 
prescription based on performance during the 2MWT was used not in the same way 
as a walking training program can be prescribed using the 6MWD. 




CHAPTER 4  
REGRESSION EQUATIONS TO ESTIMATE THE 2MWD 
IN MALAYSIAN ADULTS AGED 40 TO 75 YEARS 
 
This chapter presents the study that developed regression equations to estimate the 
two-minute walk distance (2MWD) in a sample of Malaysians adults. The research 
questions answered in this chapter are:  
i. Can age, gender, height, weight and change in heart rate (∆HR [i.e. peak HR 
- resting HR]) measured during the two-minute walk test (2MWT) explain 
at least 50% of the variance in the 2MWD? 
ii. Is the 2MWD measured in Malaysian adults similar to the 2MWDs 
estimated using the equations derived from Brazilian and American 
samples? 
 
The details of the study design are provided, including a description of the study 
inclusion and exclusion criteria, recruitment strategies and assessment protocol. 
Details of the measurements and statistical analyses are also described. The results 
are presented and discussed. 




4.1 Study design 
A prospective, cross-sectional study was undertaken between February 2013 and 
January 2014. Study participants were volunteers who responded to flyers distributed 
in four villages located within a 5km radius of each other in the Batu sub-district, 
Gombak, Malaysia. Data collection for each participant was completed during a 
single 3-hour session at any of the four villages, depending on the preference of the 
participant. An overview of the study design is provided in Figure 4.1. 
4.1.1 Approval from Human Research Ethics Committees 
Approval to conduct the study was granted by the Human Research Ethics 
Committees of Curtin University (approval number HR127/2012), and Universiti 
Teknologi MARA (approval number 600-FSK [PT.5/2]). Written, informed consent 
was obtained from all participants prior to data collection.





Figure 4.1: Overview of the study design. 
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4.1.2.1  Inclusion criteria 
To be eligible to participate, volunteers had to be aged between 40 and 75 years and 
have no major health issues (defined as no history of cardiopulmonary disease, lung 
or heart surgery, stroke, and not taking any of the following medications: anti-
arrhythmics, short- or long-acting bronchodilators, inhaled corticosteroids, 
mucolytics or antibiotics) (274). However, those who were prescribed medications 
for common conditions such as hypertension, hypercholesterolemia and diabetes 
mellitus were eligible to participate in this study as these medications are widely 
used among older adults, and the underlying conditions are unlikely to compromise 
the 2MWD. The age range of 40 to 75 years was selected as it is representative of 
people with COPD who have been referred to a pulmonary rehabilitation program 
(PRP) in Malaysia (275). The upper age limit of 75 years was used in this study due 
to the life expectancy in Malaysia being reported as 75 years in 2014 (276). 
4.1.2.2  Exclusion criteria 
Exclusion criteria comprised: (i) evidence of airflow obstruction (forced expiratory 
volume in one second [FEV1] to forced vital capacity [FVC] < 0.70) (249), (ii) 
resting blood pressure (BP) > 165/95mmHg (277), (iii) resting HR > 100 beats per 
minute (bpm), (iv) upper respiratory tract infection within the past four weeks, (v) 
smoking history > 10 pack-years or currently smoking (as elevated levels of 
carboxyhaemoglobin has been shown to reduce exercise capacity (278)), (vi) body 
mass index (BMI) > 40 kg/m2, (vii) use of a gait aid, (viii) presence of significant 
musculoskeletal or neurological disease likely to compromise the participant’s ability 
to perform the walking test and (ix) inability to understand either English or Malay. 
4.1.3 Recruitment and advice prior to day of testing 
Flyers (see Appendix 3) were distributed to the local community by the investigator 
(PhD candidate). At the time when the flyers were distributed, the investigator 
ascertained the potential interest of the volunteers. Those who expressed an interest 
in participating in this study were contacted via telephone to schedule an 
appointment. Participants were instructed to continue their usual medications on the 
day of testing. They were also asked to avoid alcohol and the consumption of a 




heavy meal for at least two hours prior to the testing session, and strenuous physical 
exercise in the previous 24 hours. 
4.1.4 Assessment protocol 
On the testing day, all participants underwent an interview using a standardised 
health screening form (see Appendix 4) and spirometry testing to confirm that they 
met the study criteria. Following the interview, all participants performed two 
2MWTs that were separated by a rest period of at least 20 minutes (20, 22, 24). This 
rest period was extended when necessary if HR had not returned to within 10bpm of 
the resting value measured prior to the first test (20). The same investigator 
supervised both 2MWTs. Two 2MWTs were performed in this study to account for 
any improvement resulting from familiarisation with the test protocol (i.e. a learning 
effect) and the best 2MWD was recorded as the test result. 
4.2 Measurements 
4.2.1 Primary outcome measure  
4.2.1.1 2MWD 
The 2MWT was carried out in accordance with the protocol for the six-minute walk 
test (6MWT) described by the ERS/ATS Technical Standards (226). The protocol 
was modified to include: (i) standardised encouragement every 30s instead of every 
minute, (ii) standardised encouragement every 15s instead of 30s to recommence 
walking if the participant rested during the test (Appendix 5a [English version], 5b 
[Malay version]) and (iii) the instruction ‘to walk as fast as you can’ instead of ‘to 
walk as far as possible’ (see subheading 2.3.3.2.3).  
An outdoor 30m straight course was used in this study. This was due to the difficulty 
in finding an indoor track of 30m length in all four villages. It has been shown in a 
previous study that there was no significant effect of setting (indoor vs. outdoor) on 
distance walked, rest duration or dyspnoea during the 6MWT in people with COPD 
(279), for whom variation in weather has been shown to provoke respiratory 
symptoms (280). Of note, all four testing locations were shaded, and the temperature 
in Kuala Lumpur is fairly steady throughout the year (i.e. ranges from 28°C to 32°C) 
(281). 




Participants were requested to sit for at least 10 minutes before the test started. 
During this resting time, measurements were made of HR and BP (Omron M10-IT, 
Omron Healthcare Europe, Hoofddorp, The Netherlands). Standardised instructions 
were read aloud to the participants prior to each test. They were informed that they 
could slow down or rest if necessary. Participants were also told to stop walking and 
inform the investigator if they experienced any chest pain or dizziness. 
4.2.2 Secondary outcome measures 
4.2.2.1 HR and symptoms 
Heart rate was recorded using a HR monitor (Polar a1, Polar Electro Oy, Kempele, 
Finland) before the test, every 30s throughout the test and at test completion. 
Dyspnoea and leg fatigue were assessed at the end of the test using the modified 
Borg 0-10 scale (147).  
4.2.3 Descriptive measures 
4.2.3.1 Participant details 
Details were recorded pertaining to age and gender. Body weight (kg) and height (m) 
were measured and used to calculate BMI (kg/m2).  
4.2.3.2 Spirometry 
Spirometry was performed in accordance with a standard protocol (256) using a 
portable spirometer (KoKo Legend II nSpire Health Inc., USA). Testing was done by 
the investigator who was trained and certified to standards aligned with the 
ATS/ERS standards (256). Participants were required to perform a minimum of three 
acceptable FVC manoeuvres (256). The largest FEV1 and FVC from any of the three 
manoeuvres that met the acceptability and repeatability criteria were selected as the 
test results. Both FEV1 and FVC were expressed as a percentage of the predicted 
normal values (282). 
4.3 Statistical analyses 
4.3.1 Sample size calculations 
As data on regression equations developed to estimate the 2MWD are limited, 
sample size calculations were performed using data that were collected to develop a 
regression equation to estimate the six-minute walk distance (6MWD) (24). In this 




earlier study, a sample size of 77 participants was required for five variables, to 
account for 49% of the variance in 6MWD in a sample of healthy Canadian adults 
(24). In order to have a similar number of predictor variables (i.e. age, height, 
weight, gender and ∆HR) to account for a similar proportion of variance in the 
2MWD, the target sample size for this study was 77 participants (α = 0.05, 1-β = 
0.8). This number was inflated by 15% to take into account the fact that some of the 
participants, especially those aged ≥ 70 years, may not complete the assessments 
required for this study (e.g. two 2MWTs in a session or spirometry). Therefore, the 
recruitment target for this study was 91 participants. This sample size was consistent 
with the sample sizes used in several other studies that developed regression 
equations to estimate the 6MWD in healthy individuals, even in those with a greater 
number of predictor variables (19, 33, 39).  
4.3.2 Sampling 
Stratified sampling was used to ensure an equal number of male and female 
participants were recruited in each decade of age (i.e. 40 male vs. 40 female 
participants) and that the sample was representative of the three major ethnicities in 
Malaysia (i.e. Malay, Chinese and Indian). As data shows that the Malaysian 
population comprises approximately 50% Malay, 23% Chinese and 7% Indian (43), a 
sample comprising a 6:3:2 ratio for Malay to Chinese to Indian for each decade from 
40 to 69 years was recruited. As the age range for those aged between 70 and 75 
years was half of a decade, a sample comprising half the target sample size for that of 
a full decade (i.e. 3:2:1 ratio) was recruited (Appendix 6).   
4.3.3 Statistical analyses 
Statistical analyses were performed using SPSS software (Version 19, SPSS Inc., 
Chicago, IL, USA). The distribution of data was examined by graphical (frequency 
histograms and box plots) and statistical methods (Kolmogorov-Smirnov test).  
A paired samples t-test was used to compare the differences between the repeated 
2MWDs. The best 2MWD was used for further analyses. Comparison of the 2MWDs 
between males and females was performed using the independent t-test. If the 
difference in the 2MWDs between males and females was significant, gender was 
added as one of the independent variables in the regression analysis. Comparison of 




the 2MWDs among the age groups (i.e. 40 to 49 vs. 50 to 59 vs. 60 to 69 vs. 70 to 75 
years) was performed using one-way analysis of variance (ANOVA).  
Associations between age, height, weight and ∆HR with the 2MWD were examined 
using Pearson’s correlation coefficients. To develop the regression equations, 
stepwise multiple regression analysis was performed using the variables that were 
significantly correlated with the 2MWD as the independent variables, with the best 
2MWD as the dependent variable. If ∆HR was retained as one of the predictors of 
the 2MWD in the regression analysis, a second regression equation, without this 
variable was planned, a priori. The latter equation is important as any equation that 
includes a measure of cardiac response during the 2MWT may be of limited use 
when estimating the 2MWD in people with a limited chronotropic response to 
exercise (e.g. heart failure patients or beta-blocker use).  
Assumptions that underpin regression analyses were assessed. Specifically, 
collinearity was assessed using variance inflation factors (VIF) and condition indices 
derived from eigenvalues, with values ≤ 5 (283) and ≤ 30 respectively considered to 
be acceptable. The presence of both univariate and multivariate outliers were 
identified and were either removed or ignored depending on their impact on the 
regression model (284). The normality, linearity, and homoscedasticity of the 
residuals were assessed by examining the normal P-P plot of regression standardised 
residuals and distribution of the standardised predicted values plotted against the 
standardised residuals. The standard deviations (SDs) of the residuals from both 
equation models were reported to allow for the calculation of the lower limit of 
normal (LLN) for the estimated 2MWD (i.e. estimated 2MWD – 1.64 x residual SD) 
(285). 
The 2MWDs measured in this study were compared with the 2MWDs estimated 
using the equations derived from a sample of Brazilian (17) and American adults 
(18) using paired samples t-tests. The method described by Bland and Altman (259) 
was also used to examine the agreement between the measured and the estimated 
2MWDs (17, 18). For all analyses, a p value < 0.05 was regarded as statistically 
significant. All data are expressed as either mean ± SD or mean difference (MD) 
with 95% confidence interval (CI) unless otherwise stated. 





Of the 91 participants who were screened, four did not meet the study criteria (2 had 
a FEV1/FVC < 0.7, 1 walked with a marked limp and reported a swollen ankle, and 1 
was unable to complete the spirometry). Almost half (n = 43 [49%]) of the 
participants were on regular medications for common conditions (i.e. n = 37 [43%] 
for hypertension, n = 19 [22%] for hypercholesterolemia and n = 18 [21%] for 
diabetes mellitus). The characteristics of the 87 participants (males = 43 [49%]) and 
the results of the 2MWTs are summarised in Table 4.1.  
4.4.1 2MWD 
None of the participants required a rest during either of the 2MWTs. The mean 
2MWDs recorded during the two consecutive 2MWTs were 193 ± 33m and 199 ± 
34m respectively, and the best 2MWD was 200 ± 34m. The 2MWD increased by a 
mean of 6m (3%); 95% CI, 4m (2%) to 8m (4%) with test repetition. Four 
participants (5%) walked the same distance on both 2MWTs, whereas 21 (24%) and 
62 (71%) participants achieved their best 2MWD on the first and second tests, 
respectively. The 2MWDs for the males and females were 217 ± 31m and 184 ± 
28m, respectively. Males walked 33m (18%) further than females (p < 0.001) (Figure 
4.2). There was a reduction in the 2MWD with increasing age (p < 0.001) (Figure 
4.3). 




Table 4.1: Characteristics of the participants and results of the 2MWT 
 Total group  
(n = 87) 
Male  
(n = 43) 
Female  
(n = 44) 
Age, yr 57.1 ± 9.6 58.0 ± 9.7  56.2 ± 9.5 
Height, m   1.59 ± 0.77   1.65 ± 0.53       1.54 ± 0.57** 
Weight, kg   67.8 ± 13.0   73.1 ± 13.4       63.1 ± 11.1** 
BMI, kg/m2 26.8 ± 4.4 26.7 ± 4.2 26.8 ± 4.6 
Spirometry    
 FEV1, L 2.22 ± 0.58 2.61 ± 0.45     1.83 ± 0.41** 
 FEV1 %pred 90 ± 15 90 ± 13 91 ± 17 
 FVC, L 2.77 ± 0.73 3.30 ± 0.51     2.25 ± 0.49** 
 FVC %pred 92 ± 15 92 ± 13 92 ± 16 
 FEV1/FVC  0.80 ± 0.05 0.79 ± 0.05   0.82 ± 0.05* 
Smoking history    
 Smoker, n (%) 0 (0) 0 (0) 0 (0) 
 Ex-smoker, n (%) 15 (17) 15 (35) 0 (0) 
 Non-smoker, n (%) 72 (83) 28 (65) 44 (100) 
2MWT data    
2MWD, m (test 1) 193 ± 33 (112-261) 210 
 ± 30 (112-239) 
 177 ± 28 (118-261)** 
2MWD, m (test 2) 199 ± 34 (117-260) 216 ± 31 (117-237)  183 ± 29 (126-260)** 
Best 2MWD, m 200 ± 34 (117-261) 217 ± 31 (117-239)  184 ± 28 (126-261)** 
Resting HR, bpm    83 ± 10 82 ± 10  84 ± 10 
Peak HR, bpm  133 ± 20         134 ± 19            132 ± 20 
∆HR, bpm   51 ± 22 53 ± 22 50 ± 23 
%pred HRmax   80 ± 11 83 ± 11 80 ± 11 
End-test dyspnoea   2.0 ± 1.2 2.1 ± 1.2 1.9 ± 1.2 
End-test leg fatigue   1.4 ± 1.3 1.4 ± 1.3 1.3 ± 1.2 
Data are presented as mean ± SD (range) or number (percentage). 
*p < 0.05 and **p < 0.001 for comparisons between males and females. 
Abbreviations: ∆HR, peak measured HR during the 2MWT – resting HR; 2MWT, 
two-minute walk test; 2MWD, two-minute walk distance; %pred HRmax, peak HR 
as a % HRmax (220-age); bpm, beats per minute; BMI, body mass index; FEV1, 
forced expiratory volume in one second; FEV1 %pred, percentage of predicted FEV1 
(282); FVC, forced vital capacity; FVC %pred; percentage of predicted FVC; HR, 
heart rate; kg, kilograms; L, litres; m, metres; yr, years.







Figure 4.2: Differences in 2MWD between genders.  
Data are shown as box plots. The horizontal line in the box indicates the median 
value of the data. The upper edge of the box indicates the 75th percentile while the 
lower edge of the box indicates the 25th percentile of the data set. The upper limit 
represented by the whisker lines is Q3 + 1.5 × IQR. The lower limit represented by 
the whisker line is Q1 – 1.5 × IQR. Circles correspond to outliers.  
**p < 0.001 
Abbreviations: 2MWD, two-minute walk distance; IQR, interquartile range; m, 
metres.  
 






Figure 4.3: Influence of age on 2MWD.  
Data are shown as box plots. The horizontal line in the box indicates the median 
value of the data. The upper edge of the box indicates the 75th percentile (Q3) while 
the lower edge of the box indicates the 25th percentile (Q1) of the data set. The upper 
limit represented by the whisker lines is Q3 + 1.5 × IQR. The lower limit represented 
by the whisker line is Q1 – 1.5 × IQR. Circle corresponds to outliers.  
**p < 0.001 
Abbreviations: 2MWD, two-minute walk distance; IQR, interquartile range; m, 
metres; NS, non-significant; yr, years.  
 




4.4.2 Regression equations 
Correlation coefficients between age, height, weight and ∆HR with the 2MWD are 
shown in Table 4.2. The predictor variables that explained the largest proportion of 
variance in the 2MWD were gender, age and ∆HR (Table 4.3). The model that 
explained the greatest proportion of the variance in the 2MWD, without violating the 
assumption of collinearity was: 
2MWD = 196 - (1.1 × age) + (1.0 × ∆HR) + (31.2 × gender) 
with the 2MWD measured in metres, age in years, ∆HR in bpm, females = 0, and 
males = 1. Together, these variables accounted for 73% of the variance in the 
measurement of the 2MWD. The SD of the residuals from this equation model was 
17m. Therefore, the LLN = predicted 2MWD – (1.64 × 17m). The normal P-P plot of 
the regression standardised residuals and the scatterplot of standardised residuals 
against the standardised predicted values for this regression model are provided in 
Figure 4.4a and Figure 4.4b, respectively. Given that ∆HR was retained in the first 
model, a second model that excluded ∆HR was also derived from this sample. This 
equation was: 
2MWD = 279 - (1.7 × age) + (35.9 × gender) 
with 2MWD in metres, age in years, females = 0, and males = 1. These variables 
accounted for 47% of the variance in the measurement of the 2MWD. The SD of the 
residuals from this equation model was 24m. Therefore, the LLN = predicted 2MWD 
– (1.64 × 24m). The normal P-P plot of the regression standardised residuals and the 
scatterplot of standardised residuals against standardised predicted values for this 
regression model are given in Figure 4.5a and Figure 4.5b, respectively. 
4.4.2.1 Additional analyses 
Predictors for the 2MWD were gender, age and ∆HR. However, exploration of the 
data set revealed a strong correlation between height and the 2MWD in females (r = 
0.50; p = 0.001) but not in males (r = 0.001, p = 0.996). Due to this, further analyses 
were conducted to determine whether adding an interaction term to the model for 
gender with height, weight or a combination of height and weight (i.e. BMI) 
improved its performance. That is, an interaction term would allow the association 
between anthropometrics in females only to be considered in the final model. When 




an interaction term between gender and height was included as one of the 
independent variables in the regression analysis, the regression equation explained an 
additional 0.2% of the variance in the 2MWD. When two interaction terms were 
included in the regression analysis (height × gender and weight × gender), the 
regression equation explained an additional 2.3% of the variance in the 2MWD. 
When BMI (i.e. weight adjusted for height) was included in the regression analysis, 
the regression equation explained an additional 1.4% of the variance in the 2MWD 
(Figure 4.6). Given that these interaction terms explained only a small proportion of 
the variance in the 2MWD, they were not included in the final model. In other words, 
it can be concluded that the strong association between height and the 2MWD in 
females did not have an important impact on the regression model to estimate the 
2MWD among females.




Table 4.2: Correlation coefficients between participant characteristics and the 
2MWD 
 Total group 
(n = 87) 
Male 
(n = 43) 
Female 
(n = 44) 
Age, yr -0.43** -0.55** -0.55** 
Height, m 0.50** 0.001 0.50* 
Weight, kg 0.12 -0.001 -0.16 
∆HR, bpm 0.62** 0.66** 0.68** 
*p < 0.005, and **p < 0.001 
Abbreviations: 2MWD, two-minute walk distance; ∆HR, change in heart rate 
(i.e. peak – resting); bpm, beats per minute; kg, kilograms; m, metres; n, 
number; yr, years.





















      
Table 4.3: Predictor variables for the 2MWD obtained from multiple linear regression analyses 
Model 1 (R2 = 0.73)     
 Unstandardised  
coefficient (B) 
Standard error p value Partial R2   
Constant 196.38 14.63 < 0.001 - 
Age (yr) -1.07 0.21 < 0.001 0.08 
Gender 31.22 3.83 < 0.001 0.18 
∆HR (bpm) 0.996 0.11 < 0.001 0.47 
 
Model 1 (R2 = 0.47) 
 Unstandardised  
coefficient (B) 
Standard error p value Partial R2  
Constant 278.61 16.03 < 0.001 - 
Age (yr) -1.68 0.28 < 0.001 0.23 
Gender 35.94 5.31 < 0.001 0.24 
Abbreviation: ∆HR: change in heart rate; 2MWD, two-minute walk distance; bpm, beats per minute; yr, year 
a) 






Figure 4.4a: Normal P-P plot of regression standardised residuals for Model 1: 
2MWD = 196 – (1.1 x age) + (1.0 x ∆HR) + (31.2 x gender).  
The points were clustered tightly along the diagonal line (i.e. line of identity) 
indicating that the residuals were normally distributed. 
 
 
Figure 4.4b: Scatterplot of standardised predicted value (x-axis) vs. standardised 
residual value (y-axis) for Model 1: 2MWD = 196 – (1.1 x age) + (1.0 x ∆HR) + 
(31.2 x gender).  
Mean values equal to zero and few data points extended beyond a standardised 
residual value of 2 indicating that the model was a good fit.  
Abbreviations: 2MWD, two-minute walk distance; ∆HR, change in HR. 
a) 
b) 





Figure 4.5a: Normal P-P plot of regression standardised residuals for Model 2: 
2MWD = 279 - (1.7 x age) + (35.9 x gender).  
The points were clustered tightly along the diagonal line (i.e. line of identity) 
indicating that the residuals were normally distributed. 
 
 
Figure 4.5b: Scatterplot of standardised predicted value (x-axis) vs. standardised 
residual value (y-axis) for Model 2: 2MWD = 279 - (1.7 x age) + (35.9 x gender). 
Mean values equal to zero and few data points extended beyond a standardised 
residual value of 2 indicating that the model was a good fit. Abbreviations: 2MWD, 
two-minute walk distance. 
a) 
b) 






Figure 4.6: Contribution of each predictor variable to the 2MWD. 

















4.4.3 Comparison with the 2MWD estimated using a previously published 
equation 
Figure 4.7a and Figure 4.7b illustrate the comparisons between the 2MWD measured 
in this study with the 2MWD estimated using the equations derived from both the 
Brazilian and American samples (17, 18). The MD; 95% CI between the 2MWD 
measured in the current study and that estimated using the equation derived from a 
sample of Brazilian and American adults were 4; -1 to 10m (17) and 23; 18 to 29m 
(18), respectively. In the Bland and Altman plots (Figure 4.8a and Figure 4.8b), the 
upper and the lower limits of agreement were not calculated. This was due to the 
presence of proportional bias in the differences between the measured and estimated 
2MWDs in both plots (286). 







































      
a) b) 
Figure 4.7a: Scatterplot of the 2MWD measured in a Malaysian sample (y-axis) vs. the 2MWD estimated using equation 
derived in a Brazilian sample (x-axis). 
Figure 4.7b: Scatterplot of the 2MWD measured in a Malaysian sample (y-axis) vs. the 2MWD estimated using equation 
derived in an American sample (x-axis). Lines of identity for both plots are shown. 
Abbreviations: 2MWD, two-minute walk distance; m, metres. 
 
Line of identity is shown. 
























Figure 4.8a: Bland and Altman plots showing agreement between the 2MWD measured in a Malaysian sample and the 2MWD estimated 
using equation derived in a Brazilian sample.  
Figure 4.8b: Bland and Altman plots showing agreement between the 2MWD measured in a Malaysian sample and the 2MWD estimated 
using equation derived in an American sample.  
The solid line corresponds to the mean difference (i.e. bias) between the two 2MWDs. Due to the presence of proportional bias in the 
measurement error, the limits of agreement between the measured and the estimated 2MWD were not calculated in both plots. 
Abbreviations: 2MWD, two-minute walk distance; m, metres. 
b) a) 






This is the first study to derive equations to estimate the 2MWD in Malaysians adults 
without significant disease. This study found that 73% of the variance in the 2MWD 
was explained by gender, age and ∆HR during the test, and when ∆HR was excluded 
from the regression equation, the combination of gender and age explained 47% of 
the variance in the 2MWD. The values for the SD of the residuals for the estimated 
2MWD were presented for both equations, which allowed calculation of the LLN for 
the estimated 2MWD. 
4.5.1 The influence of gender, age and cardiac response on the 2MWD  
On average, male participants walked 18% further than the females. The difference 
in the 2MWD between genders in the present study is of a similar magnitude to that 
found in previous studies on the 2MWD (17) and the 6MWD (20, 22-24, 27, 33, 36) 
in healthy adults. The finding that male participants walked a greater distance than 
females can be best explained by the fact that males are generally taller than females 
(Table 4.1) and taller individuals walk with a longer stride length as opposed to 
shorter individuals (287). Other than the difference in height, males also have greater 
muscle mass and strength than females. Both, height and muscle strength have been 
identified in a previous study as two of the most important predictors of gait speed in 
healthy individuals (288). 
The present study also demonstrated that the 2MWD decreased with increasing age. 
This finding is consistent with that of most studies that measured the 2MWD (17) or 
6MWD (17, 20-24, 27, 28, 34-36) in healthy adults. This can be explained by the 
decline of muscle mass (230, 231) and the increase in sedentary behaviour with an 
increase in age (289). Only two studies have reported non-significant associations 
between age and the 6MWD in healthy adults (30, 39). This negative finding 
probably relates to the relatively narrow age range in the study samples in these two 
studies (i.e. 55 to 75 years (39) and 45 to 65 years (30)) which may have reduced the 
influence of age on this outcome. As shown in Figure 4.3, the influence of age on the 
2MWD seen in the current study was not statistically significant between the age 
ranges of 40 to 49 and 50 to 59 years. This suggests that the influence of age on the 




2MWD is likely to be seen in samples which have a larger range in age, possibly 
more than two decades.  
The mean peak HR achieved during the better of the two 2MWTs was 81% of the 
predicted HRmax. This finding confirms that the 2MWT is a sub-maximal test for 
healthy adults, and is consistent with a previous study that reported a peak HR of 
70% predicted HRmax during the 2MWT (17). A similar HR response had also been 
reported during the 6MWT in healthy adults (20, 22, 25, 39).  
4.5.2 Effect of test repetition 
The small but significant increase in the 2MWD with test repetition documented in 
this study (i.e. 3%; 95% CI, 2% to 4%) is consistent with the finding of the study 
described in Chapter 3 among people with moderate to severe stable COPD (i.e. 4%; 
95% CI, 1% to 7%). The fact that the 2MWT in both studies was conducted using a 
similar test protocol and by the same investigator suggests that the magnitude of 
learning on the 2MWD with test repetition is small regardless of health status. Earlier 
work that has investigated the effect of test repetition on the 2MWD in other 
populations, such as in healthy Brazilian adults (17), or in other diseases such as in 
those with poliomyelitis (10) and heart failure (2), also reported a learning effect for 
the 2MWD of a similar magnitude. In contrast, the change in the 6MWD with test 
repetition has been reported to be lower in healthy individuals compared to those 
patients for whom dyspnoea plays a major role in exercise limitation, such as people 
with COPD (i.e. ranged from a mean of 9m to 24m [2% to 4%] in healthy individuals 
(20, 21, 24, 31, 36) vs. 27m to 37m [6% to 11% in people with COPD) (6, 262, 263, 
290). Therefore, it appears that, learning effect to some extent is influenced by the 
duration of the test. 
4.5.3 Regression equations 
In the present study, the inclusion of ∆HR in equation model 1 explained an 
additional 26% of the variance in the 2MWD. This finding corroborates the results of 
previous studies that have demonstrated a measure of cardiac response during the 
6MWT explains between 13% (19) and 27% (20) of the variance in the 6MWD. In 
contrast with earlier work which included the peak HR expressed as a % predicted 
HR maximum (HRmax) (19-22), this study included the measure of ∆HR during the 
2MWT in the regression analysis. This was done because the % predicted HRmax is 




calculated based on age (291), and age was identified as an independent variable in 
both prediction equations. Therefore, it is likely that the inclusion of % predicted 
HRmax may violate the assumption of collinearity and consequently result in over-
fitting of the regression model.  
4.5.3.1 Regression model 1 
Approximately 73% of the variance in the 2MWD could be explained by age, ∆HR 
and gender. Hence, it can be concluded that the data fits the model very well. 
Referring to the unstandardised beta (B) values in Table 4.3, this model shows that, 
for every 1 unit (year) of increase in age, the 2MWD would be decreased by 1m. In 
contrast, the 2MWD increases by 1m with an increase of 1bpm in ∆HR. Being male 
was also identified as having a positive influence on the 2MWD. Specifically, the 
model indicates that the 2MWD will increase by 31m in males. From the analysis 
undertaken to determine the overall fit of the model, it can be seen in Figure 4.4b that 
the highest standardised residual of 2.361 is smaller than ±3 and only 2% of the 
sample had standardised residual values greater than ±2. Therefore, it can be 
concluded that the sample appeared to conform to what was expected for a fairly 
accurate and reliable model. The model derived also generalises very well as shown 
by the close proximity between the adjusted R2 = 0.725 vs. observed R2 = 0.734. 
4.5.3.2 Regression model 2 
Regression model 2 shows that approximately 47% of the variances in the 2MWD 
could be explained by age and gender. Referring to the unstandardised beta (B) 
values for this model, as shown in Table 4.3, an increase in age reduced the 2MWD; 
every one unit (year) of increase in age led to a decrease in the 2MWD of 
approximately 2m. Similar to Model 1, the 2MWD increased, by 36m, in males. 
From the analysis undertaken to determine the overall fit of the model, it can be seen 
in Figure 4.5b that the highest standardised residual of 2.486 is smaller than ±3 and 
only 1% of the sample had standardised residual values greater than ±2. Therefore, it 
can be concluded that the sample appeared to conform to what was expected for a 
fairly accurate and reliable model. The model also generalises very well as shown by 
the close proximity between the adjusted R2 = 0.461 vs. observed R2 = 0.473. Neither 
the study by Selman et al. (17) nor the study by Bohannon et al. (18) reported data 
pertaining to the highest standardised residual values in their participants or the 




differences between the adjusted and observed R2 of their regression models and 
therefore comparison with existing literature is not possible. 
4.5.4 Comparison with the 2MWD estimated using previously published 
equations 
Both of the previously published equations were expected to over-estimate the 
2MWD in Malaysians adults. This is because Asians have been reported to have a 
lower percentage of lean body mass for a given BMI when compared to other 
ethnicities (232, 292-294), and lean body mass is positively associated with muscle 
strength (295), a known determinant of maximal walking speed in healthy 
individuals (288). However, the 2MWD estimated using both of the previously 
published regression equations did not over-estimate the measured 2MWD in 
Malaysian adults. There was no significant difference between the 2MWD measured 
in a sample of Malaysian adults and the 2MWD estimated for them using the 
regression equation derived from a Brazilian sample (17). This was despite the 
participants in the present study being comparatively older (age 57 ± 10 years vs. 
median [interquartile range] 52 [36 to 68] years), and shorter (height 1.59 ± 0.77m 
vs. 1.66 [1.58 to 1.72m]) than the Brazilian sample (17). On the other hand, the 
2MWD estimated using the equation derived from an American sample significantly 
under-estimated the 2MWD measured in the sample of Malaysian adults by 23 ± 
27m (p < 0.001) (18). This was also despite the fact that the American participants 
were younger (age 46 ± 18 years vs. 57 ± 10 years) and taller (height 1.68 ± 0.10m 
vs. 1.59 ± 0.77m) than the participants in the present study (18). Factors such as 
discrepancies in the 2MWT protocol used between these three studies and cultural 
differences among Malaysian, Brazilian and American may be able to explain this 
unexpected finding.  
4.5.4.1 Discrepancies in the 2MWT protocol used between the studies 
A factor related to the 2MWT protocol that could account for the lack of difference 
seen between the measured and estimated 2MWD (17) is that more frequent 
encouragement was given during the 2MWT in the present study compared to the 
Brazilian study (every 30s vs. 60s (17)). This may have resulted in a greater effort 
level during the test in the current study, as suggested by a greater magnitude in ∆HR 
(49 [36 to 68] bpm vs. 39 [25 to 55] bpm (17)). Encouragement has been shown to 
have a positive effect on walking test performance (2). Similar to the Brazilian study 




(17), encouragement was also given only once throughout the 2MWT in the study 
among Americans adults (18). Cardiac response during the test was not reported in 
the American study hence a comparison of effort level cannot be made. Other than 
the 2MWT protocol in the American study being conducted with a lower frequency 
of encouragement, the fact that their equation was derived from only one test 
compared to the best of two 2MWDs as was used in the present study, may also have 
led to an under-estimation of their 2MWD (18). As reported earlier (see subheading 
4.4.1), the 2MWD in the present study increased significantly by a mean of 6m; 95% 
CI, 4m to 8m on repeated tests. It is also possible that the use of a shorter walking 
track (15.2m) in the American study (18) may have compromised the 2MWD 
achieved in their study (see subheading 2.3.3.2.3).  
4.5.4.2 Cultural differences among Malaysian, Brazilian and Americans 
To date, there are no studies that have explored the potential influence cultural 
factors may have on the 2MWD. However, studies that have established prediction 
equations for the 6MWD across different cultures have shown that culture-specific 
factors such as parity, lifestyle, socioeconomic status and educational level 
significantly influence the 6MWD (36, 296). For example, Ben Saad et al. (36) in a 
study among 229 healthy North African adults demonstrated that issues of 
developing countries such as high parity and low socioeconomic status and 
educational level significantly influenced the 6MWD. Specifically, they found that 
the 6MWD was lower in high parity (≥ 6) vs. low parity (≤ 5) women and in people 
with low vs. high income and educational status (36). Although there are likely to be 
some cultural differences between Malaysian, Brazilian and American adults, it was 
beyond the scope of this study to examine the influence of any of the cultural-
specific factors on the 2MWD. Of note, given that all three studies would have 
recruited people who potentially have an interest in exercise (i.e. the walk test), 
perhaps cultural-specific factors would have less influence on the test result.  
4.5.5 Agreement between the measured and the estimated 2MWD  
The Bland and Altman plots for the agreement between the 2MWD measured in the 
present study and the 2MWDs estimated from both previously published regression 
equations showed the presence of proportional bias in the distribution of the error 
between the measurements (Figure 4.8). As explained in Portney and Watkins (225), 
the pattern of proportional bias indicates that the two measurements do not agree 




equally through the range of measurements. In the present case, the error was 
influenced by the size of the measurement whereby a greater estimated 2MWD was 
seen in cases of a low measured 2MWD, and a lower estimated 2MWD was seen in 
cases of a high measured 2MWD. Therefore, the two measurements could not be 
considered interchangeable with each other. Similar finding has also been reported in 
a previous study that compared the 6MWD measured in a sample of North Africans 
adults with the 6MWD estimated using regression equations derived from other 
populations (36). 
4.5.6 Strengths and limitations  
There are two main strengths of the present study. First, stratified sampling was used 
to ensure the sample was representative of the Malaysian population. Second, this 
was the first study in the Asian region to derive equations to estimate the 2MWD, 
which will be important not only to interpret the 2MWD in clinical populations in 
Malaysia but also in other Asian countries with similar cultural backgrounds and 
anthropometric characteristics to Malaysia, such as Indonesia, Singapore and 
Southern Thailand.  
The present study had some limitations. First, the participants in the present study 
were volunteers who responded to flyers distributed in their community, thus the 
results may be influenced by a possible selection bias (e.g. volunteers for research 
are usually healthier and better educated) (297). Second, the selection of participants 
within the age range of 40 to 75 years in the present study may limit the 
generalisability of the equations to estimate the 2MWD in all adults in Malaysia, 
especially in individuals younger than 40 years. However, the age range of 40 to 75 
years was selected as it is representative of people with COPD who have been 
referred to a PRP in Malaysia (275). Future studies should consider broadening the 
age range to allow for prediction of the 2MWD in people with diseases other than 
COPD. Third, this study aimed to produce equations to estimate the 2MWD in a 
general Malaysian population, not for specific ethnic groups in Malaysia. However, 
in the absence of regression equations for specific ethnic groups, the regression 
equation developed in this study included representation from the three main ethnic 
groups that reside in Malaysia and so is likely to provide the best estimate of the 
2MWD for the ‘average’ Malay.  





The equations produced in this study allows the main outcome of the 2MWT (i.e. the 
2MWD) in clinical populations in Malaysia to be interpreted as a percentage of the 
value estimated in a person with the absence of significant disease. Even though the 
inclusion of ∆HR in the regression model explained an additional 26% of the 
variance in the 2MWD, it is important to report both equations. This is particularly 
important when assessing exercise capacity in individuals who require medications 
that have the potential to influence the HR response to exercise. Furthermore, the 
inclusion of the ∆HR in the regression equation requires the measurement of HR 
during the test. This may also be a limitation in a busy healthcare setting when it 
necessitates an extra measure to use the regression equation. Therefore, in most 
clinical settings, the equation that does not include the ∆HR will be more appropriate 
to estimate the 2MWD. Future studies should examine the accuracy of the regression 
equations reported in this study.




CHAPTER 5  
A RANDOMISED CONTROLLED TRIAL OF EXERCISE 
TRAINING IN PEOPLE HOSPITALISED WITH AN 
AECOPD  
 
This chapter presents the randomised controlled trial (RCT) which evaluated the 
effectiveness of an exercise program initiated early during the hospitalisation of 
people with an acute exacerbation of chronic obstructive pulmonary disease 
(AECOPD). The research questions answered in this chapter are:  
i. does an exercise program, initiated within two days of hospital admission, 
that comprises walking and resistance exercise, produce additional benefits in 
exercise capacity, quadriceps muscle force (QMF), functional performance 
and physical activity (PA), over and above any changes seen with usual care? 
ii. is there a difference in the level of adherence between supervised and 
unsupervised exercise training sessions? 
 
The details of the study design are provided, including a description of the inclusion 
and exclusion criteria, recruitment strategies, assessment protocol, and randomisation 
process and blinding procedures. The assessments made at baseline and prior to 
discharge as well as the details of the data management and statistical analyses are 
described. The results are presented and discussed. 




5.1 Study design 
This study was a single blind randomised controlled parallel-group trial. Data 
collection was performed between July 2013 and August 2014. An overview of the 
study design is provided in Figure 5.1. Baseline (i.e. pre-intervention) assessments 
commenced after participants gave written, informed consent and were completed 
within two days of hospital admission. Participants then were randomised to either an 
exercise group (EG) or a control group (CG). Participants in both groups received the 
usual medical and physiotherapy care given to patients admitted with an AECOPD. 
Those in the EG also received one supervised and one unsupervised training session 
each day throughout their hospitalisation. Spirometry and re-assessment 
measurements were performed on the day of discharge. 
5.1.1 Approval from Human Research Ethics Committees and trial 
registration  
Approval to conduct the study was granted by the Human Research Ethics 
Committees of Malaysia Ministry of Health (approval number NMRR-12-12-971-
12644), Universiti Teknologi MARA (approval number 600-RMI [5/1/6]), and 
Curtin University (approval number HR 13/2013). The trial was registered with the 
Australian New Zealand Clinical Trials Registry (ANZCTR [registration number 
ACTRN12612000745842]). Written, informed consent was obtained from all 
participants prior to data collection.





Figure 5.1: Overview of the study design 
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5.1.2.1 Inclusion criteria  
Patients who were admitted to hospital with an AECOPD as their primary diagnosis 
were eligible to participate in this study.  
5.1.2.2 Exclusion criteria  
Exclusion criteria comprised: (i) admission to the intensive care unit, (ii) 
contraindications to exercise testing (Appendix 7) (167), (iii) presence of any 
comorbid condition thought to compromise safety during the assessments and 
exercise sessions, (iv) severe musculoskeletal/ neurological condition thought to 
adversely influence performance during the assessments and exercise sessions, (v) 
hospitalisation within the previous 14 days, (vi) any requirement for non-invasive 
ventilation (NIV) during waking hours, (vii) unlikely to be admitted for at least five 
days and (viii) inability to understand English or Malay.  
5.1.3 Recruitment 
Patients admitted to two general hospitals: Hospital Selayang (HS) and Institute of 
Respiratory Medicine (IRM), Kuala Lumpur, Malaysia were screened daily through 
the hospital database. Those who were admitted with an AECOPD as the primary 
diagnosis were told about the study by the medical professionals’ in-charge of the 
patients (i.e. nurses or medical doctors). They were asked if they would like to hear 
more about the study from the investigator. Those who expressed an interest to hear 
more about the study were approached by the primary investigator (PhD candidate) 
who provided a verbal explanation about the study and sought written informed 
consent from each participant to participate in this study. Information about the study 
was provided to participants prior to randomisation and therefore, all participants 
received identical information regardless of group allocation. 
5.1.4 Assessment protocol 
During the baseline assessment, measurements were collected of exercise capacity 
(two-minute walk test [2MWT]), QMF and functional performance (i.e. Sit to Stand 
Test [STST] and Timed Up and Go [TUG] test). The participants also completed 
questionnaires pertaining to health status (chronic obstructive pulmonary disease 
[COPD] assessment test [CAT]) (298) and the magnitude of their functional 




limitation resulting from dyspnoea (modified Medical Research Council Scale 
[mMRC]) (151, 152). These tests were performed in the following order: CAT, 
mMRC, 2MWT, STST, TUG and QMF. The 2MWT was performed along the ward 
corridor, while the other three tests (i.e. STST, TUG and QMF) were performed in 
the ward’s meeting room. Participants were given a PA monitor (StepWatchTM 
Activity Monitor [SAM]; OrthoCare Innovations, Seattle, Washington, USA) to be 
worn continuously throughout the hospitalisation period. Re-assessment 
measurements comprised spirometric measures of lung function, followed by the 
2MWT, STST, TUG and QMF. 
5.1.5 Randomisation 
On the same day that all baseline assessments were completed, participants were 
randomly assigned to either the EG or CG. The randomisation sequence was 
generated using a computer-based program (http://www.random.org/) and concealed 
using sequentially numbered opaque envelopes. The sequence was stratified 
according to the hospital from which the participants were recruited (i.e. HS or 
IRM), and participants’ baseline two-minute walk distance (2MWD [i.e. < 100 m or 
≥ 100 m]). The sequence was also blocked so that for every two participants 
randomised, one was allocated to the EG and one to the CG.  
5.1.6 Blinding   
Complete blinding of all study personnel and participants was not feasible. The 
primary investigator, who was responsible for the collection of baseline 
measurements and training of the participants in the EG, was aware of each 
participant’s group allocation. However, re-assessment measurements were 
performed by a qualified physiotherapist who was unaware of the participant’s group 
allocation. All participants were aware of the existence of the two study groups, but 
they were not informed about what treatment the other group was receiving.  
5.2 Measurements 
5.2.1 Primary outcome measures 
5.2.1.1 2MWD  
Exercise capacity was measured using a 2MWT. Absolute contraindications to 
performing the test were taken from published guidelines for cardiopulmonary 




exercise testing (Appendix 7) (167). Additional relative contraindications comprised: 
(i) pre-exercise heart rate (HR) of > 125 beats per minute (bpm) and, (ii) resting 
percutaneous oxygen saturation (SpO2) of < 90%. Participants who required 
supplemental oxygen performed the test breathing oxygen supplied at their 
prescribed flow rate for exercise, delivered through nasal prongs with the oxygen 
cylinder transported by the participant using a trolley. As supplemental oxygen has 
been demonstrated to increase exercise capacity and reduce dyspnoea on exertion 
(299-301), for each participant, any use of supplemental oxygen during the baseline 
2MWT was kept identical during the re-assessment 2MWT. 
 
The 2MWT was carried out in accordance with a protocol adapted from the 
European Respiratory Society (ERS)/American Thoracic Society (ATS) Technical 
Standards for the 6MWT (226) with the following modifications: (i) standardised 
encouragement every 15s instead of 30s to recommence walking if the participant 
rested during the test, (ii) standardised phrases of encouragement every 30s instead 
of every minute and (iii) the instruction ‘to walk as fast as you can’ instead of ‘to 
walk as far as possible’ (see subheading 2.3.3.2.3).  
 
The test was performed over a 30m straight course within the ward corridor. The 
course was marked with a cone at either end. Chairs were placed at both ends and at 
the mid-way point to allow seated rests if required. Standardised instructions were 
read aloud to the participants in either English or Malay before the test. They were 
informed that they could slow down or rest if necessary. Participants were also told 
to stop walking and inform the investigator if they experienced any chest pain or 
dizziness. Participants who demonstrated profound oxygen desaturation, defined as 
SpO2 < 80%, were instructed to stop walking immediately and to recommence 
walking if SpO2 recovered to ≥ 80% (226). 
 
Percutaneous oxygen saturation (Masimo Rad-5v, Masimo Corporation, Irvine, 
California, USA) and HR (Polar a1, Polar Electro Oy, Kempele, Finland) were 
monitored throughout the 2MWT with the values recorded before the test, every 30s 
during the test, and at test completion. The investigator walked behind the participant 
and care was taken to avoid influencing the walking speed of the participant. 
Following test completion, participants remained in the testing area, and SpO2 was 




monitored until it returned to ≥ 90%. In participants who needed to rest during the 
2MWT, the frequency, duration and reason for resting were recorded. In participants 
for whom a rest was imposed because of profound oxygen desaturation (SpO2 < 
80%) (302), the nadir SpO2 was also recorded. Dyspnoea was assessed using the 
Borg category ratio scale (0-10) (147) at rest, upon test completion, and at the start of 
any rests taken during the test, with the highest dyspnoea score used in the analyses. 
Leg fatigue was recorded on test completion (147). The main outcome of the 2MWT 
(i.e. 2MWD) was expressed in meters and as a percentage of the predicted value for a 
healthy Malaysian sample, using the regression equation presented in Chapter 4 of 
this thesis. 
5.2.1.2 QMF 
The strength of the quadriceps muscles of the dominant leg was assessed during an 
isometric maximum voluntary contraction (MVC) using a force transducer (digital 
force gauge [BFG1000, Mecmesin Limited, Slinfold, West Sussex, UK]). The device 
(Figure 5.2a) contains a highly accurate load cell (± 0.2% of full scale [1000 Newton, 
N]) that converts tension/compression force into an electrical signal. The built-in 
software in the device converts this electrical signal into a force value (N) that is 
displayed on the screen of the device. The force transducer has been shown to 
provide a very sensitive measurement of strength and has the ability to detect even 
small differences in isometric forces (131, 132) when compared to the two most 
commonly used method of assessing muscle strength in the clinical setting (i.e. 
manual muscle testing [MMT] and hand-held dynamometer [HHD]). The force 
transducer and accompanying apparatus is also lighter and can be transported more 
easily than the isokinetic machines (i.e. the gold standard in measuring muscle 
force). The force transducer was mounted on a steel support affixed to a purpose-
built chair (Figure 5.2b). The position of the participant was standardised (i.e. seated 
with hips and knees flexed to 90o and feet not touching the floor). External 
stabilisation was provided at the pelvis, trunk and the lower extremities of the leg not 
being tested (non-dominant side) (Figure 5.2c). A force plate was attached to the 
force gauge and was held perpendicular to the distal third of the tibia (Figure 5.2d). 
A high-density foam pad was placed at the front part of the force plate to protect the 
participant’s skin. The device was factory calibrated, and zeroed before each 
measurement in accordance with the manufacturer’s recommendations.  





With the arms folded across the chest, participants were instructed to gradually 
increase the force exerted against the force plate to produce a MVC that was 
maintained for 5s. This duration (5s) has been shown to be adequate to generate a 
maximum force in older adults (303, 304). The participants were also reminded to 
avoid a rapid and explosive type of contraction. The protocol included a 
familiarisation period, and followed with three to five trials with a minimum of 30s 
rest between each contraction (305). Standardised verbal encouragement was given 
during the test. The highest value that was within 10% of at least one other measure 
was used in the analyses (72). Outcomes were expressed in kilograms (kg) and as a 
percentage of the predicted value in a healthy population (306).  
 
























Figure 5.2a: Force gauge 
Figure 5.2b: Force gauge chair 
Figure 5.2c: Position of the participant during the test 









5.2.2 Secondary outcome measures  
5.2.2.1 STST 
The STST was used to measure functional performance in this study as it: (i) reflects 
many common activities of daily living such as rising from a chair/bed or getting out 
of a car and (ii) requires little instrumentation (i.e. a stopwatch and a standard chair). 
The protocol used for the STST was based on the 30s chair raise protocol described 
by Rikli and Jones (174). Specifically, the test was performed using a standard height 
chair (45cm) without arm rests. With the arms folded across the chest, participants 
were instructed to move between sitting and standing upright as many times as 
possible within a 30s period. Prior to commencing the test, the investigator 
demonstrated the task and the participant was asked to complete a practice trial of 
two repetitions. During the test, participants were permitted to rest and no 
encouragement was given. A position that was more than halfway up from sitting to 
standing at the end of the 30s was counted as a full stand. The number of stands 
performed within 30s was counted as the test result. The score was also expressed as 
a percentage of the predicted value in a healthy population (307). 
In people with stable COPD, the number of repetitions achieved during the STST has 
demonstrated moderate to strong associations with measures such as QMF (r = 0.46, 
p = 0.01) (308) and six-minute walk distance (r = 0.75, p < 0.001) (177). The test has 
demonstrated the ability to detect change following a pulmonary rehabilitation 
program (PRP) in people with stable COPD (175).  
 
5.2.2.2 TUG test 
The TUG test was used to measure functional performance in this study as it is a 
measure of basic mobility (309) that has been shown to be safe even in people aged > 
70 years (173). The TUG test protocol was based on the protocol described by 
Podsiadlo and Richardson (182) with modification of the test instruction ‘to walk as 
quickly as you can’ instead of ‘to walk at a comfortable and safe pace’ (see 
subheading 2.2.3.2). The test was performed using a standard straight-backed chair 
with arm rests. The test required the participant to stand up from the chair, walk a 
distance of 3m as quickly and as safely as possible, turn around at the cone, and 
return to the sitting position. Participants were permitted to push up with their arms 




to get into the standing position. No encouragement was given during the test. The 
time (s) taken to complete the task was measured as the test result. As earlier work 
has suggested that the performance during the TUG test differs between individuals 
of different ethnicities (184), the test result (i.e. time) in this RCT was interpreted 
based on the reference values developed in elderly Thai (310) rather than Caucasians.  
 
The time taken to complete the TUG test has demonstrated moderate to strong 
associations with measures of balance (e.g. Berg Balance Scale [r = -0.72]), gait 
speed (r = -0.55) and functional capacity (e.g. Barthel Index [r = -0.51]) (182) in 
older adults. In people with COPD, the TUG test has been shown to have high test-
retest repeatability (186) and is responsive to change following a PRP (187).  
5.2.2.3 PA 
Physical activity was measured in terms of the number of steps taken each day 
throughout the duration of hospitalisation and was recorded using the SAM. Prior to 
data collection, the SAM (Figure 5.3a) was initialised for each participant by 
entering their (i) height (cm), (ii) selecting the range of walking speed (moderate), 
(iii) leg motion (normal), (iv) time zone (Malaysia), and (v) number of days over 
which measurements were to be made (15 days). This small (75 x 50 x 20 mm) and 
light-weight (38g) device was attached to the participant’s right ankle using a 
Velcro® strap (Figure 5.3b). The device was set to flash a red light for the first 40 
steps taken by the participants to indicate that it had started detecting steps. During 
this time (i.e. the first 40 steps taken by the participant), the investigator monitored 
that the red flashing light blinked one time for every step taken by the participant to 
ensure that the device was working (212). Participants in both groups were instructed 
to wear the device continuously, day and night, and were told not to remove the 
device even when showering and during sleeping. The SAM was only removed from 
the participant’s ankle on the day they were discharged from hospital.  
 
Data from the SAM were downloaded using the accompanying software 
(StepWatchTM 3.1; OrthoCare Innovations, Seattle, Washington, USA) via a docking 
station (Figure 5.3c). The device detected the total number of steps taken by only one 
leg (i.e. right leg). Therefore, this value was doubled to calculate the total number of 
steps taken by the participant. The device also provided data pertaining to the total 




time which the participant spent being sedentary (i.e. 0 steps/min), walking at low (≤ 
60 steps /min) and moderate (> 60 steps/min) intensities (311). The SAM has been 
shown to be accurate in recording steps in people with COPD, including those who 
walk very slow or use a walking aid (211). The step rate derived from the SAM has 
shown excellent agreement with the step rate derived via direct observation in people 
with COPD (211).

























Figure 5.3a: StepwatchTM Activity Monitor 
Figure 5.3b: StepwatchTM Activity Monitor attached to the right leg 
Figure 5.3c: Docking station 
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5.2.3 Descriptive measures  
5.2.3.1 Participant’s details 
Body weight (kg) and height (m) were measured and used to calculate body mass 
index (BMI [kg/m2]). The participant’s medical history (e.g. current medication use, 
comorbidities and smoking history) was recorded. The number of smoking pack-
years was calculated by dividing the average number of cigarettes smoked per day by 
20 (i.e. the number of cigarettes in a pack), then multiplying by the number of years 
that the participant had smoked (84). 
5.2.3.2 Health status 
The impact of COPD on each participant’s health status was assessed using the 8-
item CAT in either English or Malay (298). The CAT score has demonstrated a 
strong association (r = 0.80, p < 0.001) with the COPD-specific version of the St 
George’s Respiratory Questionnaire (SGRQ) (298).  
5.2.3.3 Functional limitation 
Participants were asked to rate their functional limitation resulting from dyspnoea 
using the modified mMRC dyspnoea scale (151, 152). This scale comprises five 
statements each of which is assigned a grade that ranges from zero “I only get 
breathless with strenuous exercise” to four “I am too breathless to leave the house or 
I am breathless when dressing”. The participant selects the statement which best 
describes their level of limitation in daily activities due to breathlessness. The 
mMRC scale has been shown to be a valid method of categorising people with 
COPD in terms of their level of functional disability (255).  
5.2.3.4 Spirometry  
Spirometry was performed at hospital discharge according to standard procedures 
(256) using a portable Microloop II (Micro Medical Ltd, Rochester, Kent, UK) 
device, which was calibrated every six months. Testing was conducted by the 
primary investigator who was trained and certified to standards which aligned with 
those of the ATS/ERS standards. Participants were required to perform a minimum 
of three acceptable forced vital capacity (FVC) manoeuvres (256). The largest forced 
expiratory volume in one second (FEV1) and FVC from any of the three manoeuvres 
that met the acceptability and repeatability criteria were selected as the test results. 



















Both FEV1 and FVC were expressed as a percentage of the predicted normal values 
(282). 
5.2.3.5 Adverse events 
Adverse events (Table 5.1) were recorded during both assessment and training 
sessions. If an adverse event occurred, the investigator immediately ceased the 
session and sought appropriate help as per hospital protocols.  
5.3 Interventions  
Participants in both groups who required supplemental oxygen during activity were 
provided with portable oxygen to use during their hospitalisation.  
5.3.1 Control group  
Participants in the CG received the usual medical and physiotherapy care given to 
patients admitted with an AECOPD according to the Malaysian Clinical Practice 
Guideline (CPG) (89). Usual physiotherapy care comprised airway clearance 
techniques (e.g. active cycle of breathing techniques, percussion and vibrations, 
gravity assisted drainage positions [if required]), strategies to minimise dyspnoea 
(e.g. pursed lip breathing and positioning [if required]), and encouragement to 
mobilise in the ward. Participants in the CG did not receive any exercise program but 
were not restricted in their physical activities throughout the period of 
hospitalisation. The primary investigator also visited all participants in the CG on a 
daily basis. They were asked about their condition and were free to ask any questions 
related to their health. This daily meeting was a strategy to minimise the difference in 
attention from the primary investigator between the EG and the CG (312).  
5.3.2 Exercise group 
The participants in the EG received usual medical and physiotherapy care given to 
patients admitted with an AECOPD according to the Malaysian CPG (89). In 
addition, they performed two individual training sessions (one supervised and one 
unsupervised) each day throughout their hospitalisation period. The duration of the 
exercise training was 30min per session, and the supervised training was conducted 
by the primary investigator. The training commenced on the day following 
randomisation and continued until the participant was discharged. At the beginning 
of each supervised exercise session, measurements were made of BP (Omron M10-
IT, Omron Healthcare Europe, Hoofddorp, The Netherlands), pulse rate and SpO2 



















(Masimo Rad-5v, Masimo Corporation, California, USA). Criteria for postponing an 
exercise program were a pre-exercise (i) systolic BP > or < 20% of resting value, (ii) 
pulse rate > 125bpm and /or (iii) SpO2 < 90%. Prior to commencing the training, 
participants were familiarised with both the Borg scale (0-10) (147) to rate dyspnoea 
and leg fatigue, and the visual analogue scale (VAS) (313) to rate any symptoms of 
delayed onset muscle soreness (DOMS). The VAS consisted of a 10cm horizontal 
line with one descriptor at each end (i.e. no pain – worst possible pain) (313). 
Dyspnoea and leg fatigue were measured at the end of each supervised training 
session, whereas any symptoms of DOMS were measured prior to the exercise 
session on the following day. During each supervised session, pulse rate and SpO2 
were monitored intermittently. Criteria for ceasing an exercise session were defined 
as an adverse event, and have been summarised in Table 5.1. 
The intensity and progression of the exercises were titrated based on the participants’ 
levels of dyspnoea and leg fatigue. As such, if the participant could complete the 
designated exercise intensity with reported dyspnoea and leg fatigue of ≤ 5 on the 
Borg scale, progression was made on every second day of training session. If the 
participants reported a Borg score of ≥ 6, progression was delayed until the next 
exercise session. During exercise training, supplemental oxygen was administered, as 
required, to maintain SpO2 of > 88%. Each training session comprised walking and 
functional resistance exercises. For all participants, training took place on their ward.  
5.3.2.1 Walking training 
The initial prescription for the walking exercise was based on the baseline 2MWD. 
Specifically, if a participant could walk 100m on the baseline 2MWT, he/she was 
instructed to walk 100m twice a day (once supervised, once unsupervised). 
Progression was then made on every second day of training (symptoms permitting) 
by increasing the distance walked by 20%. For example: 
Baseline 2MWD = 100m 
Prescription on the first exercise session = 100m 
Prescription on the third exercise session 
(if symptoms permitted) 
= 100m + (20% × 100m) = 120m 
 
Prescription on the fifth exercise session  
(if symptoms permit) 
= 120m + (20% × 120m) = 144m 
 



















5.3.2.2 Resistance training 
The resistance component of the training program comprised three exercises, namely 
sit to stands, step ups, and half squats. Detailed descriptions of these exercises are 
given in Table 5.2. For all three exercises, the initial prescription was based on the 
baseline measurement of the STST. Specifically, if the participant achieved 10 sit to 
stands during the baseline STST, he/she was instructed to perform one set of 10 sit to 
stands, 10 step ups, and 10 half squats exercise twice a day (one supervised and one 
unsupervised). Progression was then made on every second day of training 
(symptoms permitting) by increasing the repetition of each exercise type by one set. 
The achievement of three sets of number of repetitions of the STST completed at 
baseline indicated that the participants had completed the target progression for the 
training program. For example:  
Baseline STST = 10 repetitions  
Prescription on the first exercise session = one set of 10 repetitions of each 
exercise 
Prescription on the third exercise session 
(if symptoms permitted) 
= two sets of 10 repetitions of each 
exercise 
Prescription on the fifth exercise session 
(if symptoms permitted) 
= three sets of 10 repetitions of each 
exercise 
 
5.3.2.3 Adherence to the training session 
Each day, the participants in the EG were given a diary card to monitor their 
adherence to the unsupervised training sessions (Appendix 8). Adherence was 
measured as the percentage of scheduled sessions that were completed. Reasons for 
not participating in the training sessions were documented.   



















Table 5.1: Parameters used to define adverse events 
Signs Adverse events 
Heart rate > 85% of estimated maximum HR (i.e. > 85% of 210 – 
[0.65 × age]) (252) 
Angina pectoris Chest discomfort (i.e. pressure, heaviness, tightness, 
squeezing, burning or choking sensation) 
Oxygen desaturation SpO2 < 80%  
Blood pressure Change in systolic blood pressure (BP) > or < 20% of 
resting value 
Fall/ collapse Fall or collapse during the assessment or exercise session 
Abbreviations: HR, heart rate; SpO2, percutaneous oxygen saturation.  
 























Table 5.2: Description of the resistance exercises 
Type of exercise Description 
Sit to stands The exercise was performed with the participant seated in the centre of a straight-backed chair; feet were flat on 
the floor and slightly apart. Participants were instructed to stand upright and return back to a fully seated 
position with their arms folded across their chest. 
Step ups A step measuring 40cm × 25cm × 25cm was used. Participants were instructed to climb up and down the step 
following the sequence up-up-down-down leading with alternate leg for each set of repetitions. A chair was 
placed in front of the participant as a safety measure for them to hold onto if they felt they were going to fall 
(participants were not allowed to hold onto the chair during the exercise). 
Half squats In a standing position, participants were instructed to squat down until their thighs were parallel to the floor (or 
as far as they could), hold the position for one second, and return to the standing position slowly. Participants 
were reminded to keep their back straight during the exercise. A chair was placed in front of the participant as a 
safety measure for them to hold onto if they felt they were going to fall (participants were not allowed to hold 
onto the chair during the exercise). 



















5.4 Statistical analyses 
5.4.1 Sample size calculations 
As data on the change in 2MWD following exercise training in people hospitalised 
with an AECOPD were not available, sample size calculations were performed using 
data from a previous RCT of exercise training in people hospitalised with an 
AECOPD that reported change in QMF (72). In this earlier study, participants were 
allocated either to an EG that received resistance training for the quadriceps once per 
day or a CG that received usual care. Over the course of hospitalisation, participants 
in the EG demonstrated a mean change in QMF of +10 ± 16% from baseline 
measures while those in the CG demonstrated a mean change in QMF of -1 ± 13% 
from baseline measures (between-group difference of 11%). However, in the present 
study, participants allocated to the EG received training twice daily and therefore it 
was anticipated that the between-group difference in QMF would be greater than 
11%. Assuming a between-group difference of 15% ± 14% (α = 0.05, 1 - β = 0.8), a 
sample size of 15 participants per group was needed (30 in total). This number was 
increased from 30 to 38 to allow for a 20% attrition rate (314). This sample size also 
provided sufficient power to detect a between-group difference of 17 ± 14m in the 
2MWD, which was a change reported by people with stable COPD on completion of 
a five-week PRP (8). 
5.4.2 Statistical analyses 
Statistical analyses were performed using SPSS software (Version 19, SPSS Inc., 
Chicago, IL, USA). The distribution of data was examined by graphical (frequency 
histograms and box plots) and statistical methods (Kolmogorov-Smirnov test). At 
baseline, between-group comparisons of continuous data were undertaken using 
independent t-tests. For data that were skewed from normal distribution, analyses 
were undertaken using a Mann-Whitney U test. Pearson’s Chi-square tests were used 
for between-group comparison of categorical data (e.g. comorbidities and 
medications).  
 
Progression in the training load for walking and resistance exercise were assessed 
using paired t-test and Wilcoxon Singed Ranked Test, respectively. Specifically, for 
the walking training, the distance walked at the initial supervised exercise was 



















compared with the distance walked at the final supervised exercise session. For the 
resistance training, the number of repetitions at the initial supervised exercise session 
was compared with the number of repetitions at the final supervised exercise session. 
Within- and between-group differences were analysed using a two-way repeated 
measures analysis of variance (two-way RM-ANOVA). Differences were expressed 
as mean difference (MD) and 95% confidence interval (CI). In the EG, adherence to 
the supervised and unsupervised training sessions was compared using the paired t-
test. Analyses were undertaken according to an intention-to-treat basis (315). That is, 
analyses were conducted using follow-up data from all participants irrespective of 
whether or not they completed the prescribed number of exercise sessions. There was 
no attempt to impute missing data or to account for participants without follow-up 
data. For all analyses, a p value < 0.05 was regarded as statistically significant. All 
data are expressed as either mean ± standard deviation (SD) or median (interquartile 
range [IQR]), unless otherwise stated. 
5.4.3 Management of PA data 
In people hospitalised with an AECOPD, no studies have investigated the minimum 
wear time needed to reliably measure PA. In people with stable COPD, Watz et al. 
(198) showed that two days of measurement was sufficient for a reliable 
measurement of PA in people with very severe disease. Similarly, the study by Pitta 
et al. (190) concluded that, in people with moderate to severe COPD, two days of PA 
measurement were necessary for the data to have acceptable reliability (i.e. intraclass 
correlation coefficient between 0.70 and 0.88). Therefore, the minimum requirement 
for a participant’s data to be included in the analyses of PA in this study was the 
availability of PA data over two days, with 100% wear time in each 24-hour period. 
Days in which less than 24 hours of PA data were available (i.e. the days when the 
SAM was applied and removed by a participant) were discarded. For participants 
who were included in these analyses, the total number of steps taken per day, time 
spent being sedentary and the time spent walking at low and moderate intensities (see 
subheading 5.2.2.3) were averaged over the number of assessment days (i.e. days 
with 100% wear time in each 24-hour period). Between-groups differences were 
compared using independent-samples t-tests. For data that were skewed from normal 
distribution, Mann-Whitney U tests were used. 




















During the period of recruitment, a total of 120 patients were screened across the two 
hospitals. Seventy-three (61%) patients did not meet the study criteria and 47 (39%) 
were invited to participate in the study. Of the 47 patients who were approached, 
nine (19%) declined participation: six (67%) refused to exercise during hospital stay, 
two (22%) were concerned that participation in this RCT would lead to a longer 
hospital stay, and one (11%) refused to participate in any kind of research study. 
Thirty-eight participants completed the baseline measurements and were randomised 
to either the EG (n = 20) or the CG (n = 18). At baseline, there were no significant 
differences between the EG and the CG in anthropometric or clinical characteristics 
(Table 5.3). Recruitment was similar at both sites (HS [n = 19], IRM [n = 19]). Four 
(20%) participants in the EG and two (11%) in the CG did not complete the re-
assessment measurements. Figure 5.4 shows the flow of screening, randomisation, 
and follow-up in the study. 



















Table 5.3: Baseline characteristics of the study participants (n = 38) 
 Variable  Total (n = 38) 
mean ± SD 
EG (n = 20) 
mean ± SD 
CG (n = 18) 
mean ± SD 
p value 
Age, yr  63.8 ±  7.5  62.3 ± 6.6 65.5 ± 8.2 0.18 
Weight, kg   55.6 ± 15.3   52.9 ± 13.9   58.6 ± 16.7 0.26 
Height, m   1.63 ± 0.07   1.63 ± 0.08   1.62 ± 0.07 0.56 
Body mass index, kg/m
2
 21.0 ± 6.1 19.7 ± 4.5 22.4 ± 7.4 0.17 
FEV
1
, L   0.87 ± 0.40  0.88 ± 0.36   0.87 ± 0.45 0.96 
FEV
1
 %pred   33 ± 14  33 ± 14   34 ± 14 0.89 
FVC, L   1.96 ± 0.60  2.01 ± 0.49   1.89 ± 0.72 0.54 
FVC %pred   58 ± 17  59 ± 15   57 ± 19 0.75 
FEV
1
/FVC   0.45 ± 0.14  0.44 ± 0.15   0.46 ± 0.13 0.64 
Smoking pack-years    47 ± 25  51 ± 27   45 ± 23 0.49 
CAT score 20 ± 5         21 ± 4 20 ± 6 0.45 
 n (%) n (%) p value 
Gender Male 20 (100) 17 (94) 0.29 
 Female 0 1 (6) 0.29 
Site HS 10 (50) 10 (56) 0.73 
 IRM 10 (50) 8 (44) 0.73 
GOLD  Grade I 1 (5) 2 (11) 0.49 
 Grade II 4 (20) 4 (22) 0.87 
 Grade III 10 (50) 8 (45) 0.73 
 Grade IV 5 (25) 4 (22) 0.84 
mMRC Grade 0 0 0  - 
 Grade 1 7 (35) 3 (17) 0.20 
 Grade 2 5 (25) 6 (33) 0.57 
 Grade 3 6 (30) 7 (39) 0.56 
 Grade 4 2 (10) 2 (11) 0.91 
Wheeled walker 0 0 - 
Supplemental oxygen# 14 (70) 11 (61) 0.56 
LTOT≠ 3 (15) 4 (22) 0.57 
Portable oxygen at home 0 0 - 
Smoking status Ex-smoker 12 (60) 17 (94) 0.01* 
 Current-smoker 6 (30) 1 (6) 0.05 
 Non- smoker 2 (10) 0   0.17 
*p < 0.05, ≠home oxygen, #oxygen therapy administered during the hospitalisation.  
Abbreviations: CAT, COPD assessment test; CG, control group; EG, exercise group; FEV1, forced 
expiratory volume in one second; FEV1 %pred, percentage of predicted FEV1 (282); FVC, forced vital 
capacity; FVC %pred, percentage of predicted FVC; GOLD, Global Initiative for Chronic Obstructive 
Lung Disease; HS, Hospital Selayang; IRM, Institute of Respiratory Medicine; kg, kilograms; L, litres; 
LTOT, long-term oxygen therapy; m, metres; mMRC, modified Medical Research Council; SD, 
standard deviation; yr, years. 




















Figure 5.4: Flowchart of randomised participants 
Abbreviations: CG, control group; EG, exercise group; ICU, intensive care unit; n, 



















Screened (n = 120) 
Excluded (n = 82) 
 
Contraindication to exercise testing (n = 15) 
Previous hospitalisation within 14 days (n = 5) 
Required NIV during waking hours (n = 12) 
Unlikely to be admitted for at least 5 days (n = 15) 
First seen after 48 hours of hospital admission (n = 26) 
 
Randomised (n = 38) 
Allocated to EG (n = 20) Allocated to CG (n = 18) 
Lost to follow-up (n = 4) 
 
Transferred to ICU after day 2 (n = 1) 
Early discharge (n = 1) 
Diagnosed endocarditis after day 2 (n = 1) 
Refused re-assessment (n = 1) 
 
 
Lost to follow-up (n = 2) 
 
Early discharge (n = 1) 





Analysed (n = 16) Analysed (n = 16) 
Declined participation (n = 9) 



















5.5.1 Medical treatment and co-morbidities 
During the period of hospitalisation, 31 (82%) of the 38 participants received oral 
corticosteroids (80% in EG vs. 83% in CG; p = 0.79) and 27 (71%) received 
antibiotics (80% in EG vs. 61% in CG; p = 0.20). A similar number of participants in 
the EG and the CG were on inhaled steroids before admission to hospital (25% vs. 
22%; p = 0.84). The participants were being treated for other common conditions 
such as hypertension (35% in EG vs. 44% in CG; p = 0.55), diabetes mellitus (25% 
in EG vs. 33% in CG; p = 0.57) and hypercholesterolemia (20% in EG vs. 22% in 
CG; p = 0.87). 
5.5.1.1 Safety and feasibility of the baseline and re-assessment measurements 
During baseline assessments, one participant demonstrated a decrease in SpO2 from 
92% at the end of the 2MWT to 69% within three minutes following the completion 
of the test. The participant was immediately given a short burst of 4L/min 
supplemental oxygen and the SpO2 recovered to ≥ 90% within half an hour. During 
baseline assessments, 13 (34%) participants required one or two rest(s) during the 
2MWT due to intolerable dyspnoea. No adverse events were observed during or 
following the QMF, STST and TUG tests.  
During the re-assessments, four participants (two from each group) rested during the 
2MWT due to intolerable dyspnoea. The two participants in the EG required between 
one and two rest(s), while the other two participants in the CG required only one rest 
during the test. No adverse events were observed during or following the 2MWT, 
QMF, STST and TUG tests.  
5.5.2 Exercise training program 
5.5.2.1 Adherence to the training sessions  
The 16 participants allocated to the EG performed 4 ± 1 (range 2 to 6) sessions of 
supervised exercise and 4 ± 1 (2 to 7) sessions of unsupervised exercise. On average, 
they completed 96 ± 9% of their scheduled supervised training sessions and 92 ± 
13% of their scheduled unsupervised training sessions. There was no difference 
between the level of adherence to supervised and unsupervised sessions (p = 0.22). 
Table 5.4 reports the number of missed sessions in both supervised and unsupervised 
training as well as the reasons given by the participants for not adhering to the 



















training session. No training sessions were missed because of unacceptable BP, pulse 
rate or SpO2 (see subheading 5.3.2).  
5.5.2.2 Safety and feasibility of the exercise program 
No adverse events were observed during the supervised training sessions and 
therefore no session was terminated by the investigator. Figure 5.5a-d displays the 
cardiorespiratory responses and level of symptoms recorded during the supervised 
exercise sessions. The mean levels of peak dyspnoea, leg fatigue and nadir SpO2 
across all training sessions were 2.6 ± 1.0, 0.5 ± 0.7 and 93 ± 3% during walking 
training and 2.5 ± 0.7, 1.0 ± 0.6 and 94 ± 3% during resistance training, respectively. 
The participants also reported a median (IQR) score of zero (0 to 2) for the intensity 
of DOMS symptoms following 24 hours of exercise sessions across the entire 
training period.  
5.5.2.3 Progression of the exercise program 
There was a significant increase in the distance walked during the first and final 
supervised training sessions (129 ± 30 vs. 160 ± 44; p < 0.001). Figure 5.5e presents 
the progression in the training load for walking exercise during the training period. 
There was a significant increase in the total numbers of repetitions of resistance 
exercise completed during the first and final supervised training sessions (12 ± 3 vs. 
20 ± 5; p = 0.001). Figure 5.5f presents the progression in the training load for each 
of the resistance exercises (i.e. sit to stands, half squats and step ups) during the 
training period. Figure 5.6a and 5.6b illustrate the highest distance and greatest 
number of repetitions achieved for both walking and resistance exercises compared 
to the final prescription in each participant. One (6%) participant did not achieve the 
final targeted prescription for walking exercise. For the resistance exercise, seven 
(44%) participants did not achieve the final targeted prescription. The reasons related 
to general fatigue and fear of over-exertion.



















Table 5.4: Missed training sessions and reasons for not participating in training 
sessions 
(n = 16) Supervised Unsupervised 
WT RT WT RT 
Total number of possible training sessions  61 59 67 67 
Total number of missed training sessions 3 3 6 7 
Reasons for not participating in the training sessions 
Dyspnoea - - 1 1 
Leg fatigue  - - 2 3 
Visitors interruption - - 1 1 
Feeling unwell  1 1 1 1 
Advised by covering doctor not to exercise  1 1 1 1 
Refused 1 1 0 0 
Abbreviations: n, number; RT, resistance training; WT, walking training





















Figure 5.5: Cardiorespiratory responses, levels of symptoms and progression in 
walking and resistance exercises.  
Peak dyspnoea (●) and leg fatigue (×) measured using the Borg scale at the end of 
each exercise session and DOMS (o) measured using the VAS 24 hours following 
the training session during a) walking and b) resistance exercise. Nadir SpO2 (□) 
recorded during c) walking and d) resistance exercise. Progression in the training 
load for e) walking and f) each of the resistance exercises. Data are mean ± SE.  
Abbreviations: 2MWD, two-minute walk distance; DOMS, delayed onset muscle 
soreness; SpO2, percutaneous oxygen saturation; VAS, visual analogue scale; STST, 
Sit to Stand Test. 
Chapter 5: Randomised controlled trial 
 























Figure 5.6: The progression in the prescription of a) walking exercise and b) resistance exercise (n = 16). Participant number 
15 exercised at the baseline prescription throughout hospitalisation due to one missed session (feeling unwell) and the 
participant was discharged after the third exercise session while participant 2, 6, 7, 10, 13 and 16 declined to exercise at the 
targeted final prescription for the resistance exercises. In Figure 5.6b, it can be seen that participant 10 had a comparatively 
high final prescription and this was due to this participant having the longest length of hospital stay. Abbreviations: m, 
metres; n, number.
a) b) 




















The number of participants in the EG and the CG who completed each of the 
baseline and re-assessment measurements is presented in Figure 5.7.  
5.5.3.1 Anthropometric and clinical characteristics 
At baseline, there were no significant differences between the EG and the CG in 
anthropometric or clinical characteristics (Table 5.5). The median [interquartile 
range] hospital length of stay were 8 [6 to 9] days in the EG and 7 [6 to 8] days in the 
CG (p = 0.64).  
5.5.3.2 2MWD 
With the EG and CG considered together, participants walked a mean of 129 ± 38m 
(62 ± 18%) during the baseline 2MWT. At baseline, there were no differences in any 
of the variables collected during the 2MWT between the EG and CG. 
Within-group differences: 
In the EG, the magnitude of change in the 2MWD between baseline and re-
assessment measurement was 33 ± 15m (p < 0.001). In the CG, the magnitude of 
change in the 2MWD between baseline and re-assessment measurement was 20 ± 
13m (p < 0.001). When compared with the coefficient of repeatability (COR) for the 
2MWD as estimated in Chapter 3 (see subheading 3.4.2), 14 (88%) and nine (56%) 
participants had an improvement of ≥ 14m in the EG and CG, respectively (Figure 
5.8). 
Between-group differences: 
Compared with the CG, the EG demonstrated a greater change in the 2MWD (MD; 
95% CI, 13m; 3m to 23m) (Figure 5.9a). Table 5.6 presents the baseline and re-
assessment measurements for measures collected during the 2MWT. There were no 
between-group differences in the change in peak HR, nadir SpO2, peak dyspnoea, 
end-test leg fatigue or the proportion of participants who rested during the test.  
5.5.3.3 QMF 
With the EG and CG considered together, the QMF of the participants at baseline 
was 20.3 ± 5.7kg (64 ± 14% predicted) (306). At baseline, there was no difference in 
QMF between the EG and CG. 




















In the EG, the magnitude of change in QMF between baseline and re-assessment 
measurement was 5.9 ± 3.4kg (p < 0.001). In the CG, the magnitude of change in the 
QMF between baseline and re-assessment measurement was 3.1 ± 3.6kg (p < 0.01). 
Between-group differences: 
Compared with the CG, the EG demonstrated a greater change in QMF (MD; 95% 
CI, 2.8; 0.3 to 5.3kg) (Figure 5.9b).  
5.5.3.4 STST  
With the EG and CG considered together, the number of repetitions in the STST at 
baseline was 12 ± 3 (46 ± 14%) (307). At baseline, there was no difference in the 
STST results between the EG and the CG.  
Within-group differences: 
In the EG, the magnitude of change in the STST between baseline and re-assessment 
measurement was 3 ± 3 repetitions (p < 0.01). In the CG, the magnitude of change in 
the STST between baseline and re-assessment measurement was 2 ± 2 repetitions (p 
< 0.001). 
Between-group differences: 
The magnitude of change in STST repetitions was similar between the two groups 
(MD; 95% CI, 1; -1 to 2 repetitions) (Figure 5.10a). 
5.5.3.5 TUG test 
With the EG and CG considered together, the time needed by the participants to 
perform the TUG test at baseline was 8.5 ± 2.8s. At baseline, there was no difference 
in the TUG test results between the EG and CG. 
Within-group differences: 
In the EG, the magnitude of change in TUG between baseline and re-assessment 
measurement was -1.5 ± 1.3s (p < 0.01). In the CG, the magnitude of change in the 
TUG between baseline and re-assessment measurement was -0.6 ± 1.9s (p = 0.21). 
Between-group differences: 
The magnitude of change in TUG was similar between the two groups (MD; 95% CI, 
-0.8; -2.0 to 0.4s) (Figure 5.10b).





















Figure 5.7: Number of participants who completed each of the baseline and post-
intervention assessments.  
#PA: n = 17 in each group including two participants (one in each group) with full 
SAM data but refusing all other re-assessment measurements. 
Abbreviations: 2MWT, two-minute walk test; n, number; CG, control group; EG, 
exercise group; QMF, quadriceps muscle force; STST, Sit to Stand Test; TUG, 






















EG (n =20) 
2MWT: n = 20 
QMF: n = 20 
STST: n = 20 
TUG: n = 20 
EG (n = 20) 
2MWT: n = 16 
QMF: n = 16 
STST: n = 16 
TUG: n = 16 
Spirometry: n = 16 
#
PA: n= 17 
Baseline assessment 
CG (n = 18) 
2MWT: n = 16 
QMF: n = 16 
STST: n = 16 
TUG: n = 16 
Spirometry: n = 16 
#
PA: n = 17 
CG (n = 18) 
2MWT: n = 18 
QMF: n = 17 
STST: n = 18 
TUG: n = 18 
Re-assessment 



















Table 5.5: Baseline characteristics of the study participants (n = 32) 
 Variable  Total (n = 32) 
mean ± SD 
EG (n = 16) 
mean ± SD 
CG (n = 16) 
mean ± SD 
p value 
Age, yr 64.2 ± 7.8  62.4 ± 7.2 65.9 ± 8.2 0.21 
Weight, kg   54.1 ± 14.9   50.8 ± 11.8   57.4 ± 17.3 0.22 
Height, m   1.62 ± 0.07   1.62 ± 0.07   1.62 ± 0.07 0.78 
Body mass index, kg/m
2
 20.7 ± 6.3 19.3 ± 4.1 22.1 ± 7.8 0.20 
FEV
1
, L   0.83 ± 0.33  0.87 ± 0.33   0.79 ± 0.34 0.47 
FEV
1
 %pred   32 ± 13  34 ± 14   31 ± 12 0.61 
FVC, L   1.88 ± 0.58  1.99 ± 0.49   1.77 ± 0.66 0.28 
FVC %pred   57 ± 17  60 ± 16   55 ± 18 0.39 
FEV
1
/FVC   0.45 ± 0.13  0.45 ± 0.15   0.46 ± 0.13 0.88 
Smoking pack-years    48 ± 22  49 ± 24   48 ± 21 0.93 
CAT score 21 ± 5         21 ± 4 21 ± 6 0.94 
 n (%) n (%) p value 
Gender Male 16 (100) 15 (94) 0.31 
 Female 0 1 (6) 0.31 
Site HS 9 (56) 9 (56) 1.00 
 IRM 7 (44) 7 (44) 1.00 
GOLD  Grade I 1 (6) 1 (6) 1.00 
 Grade II 3 (19) 3 (19) 1.00 
 Grade III 9 (56) 8 (50) 0.72 
 Grade IV 3 (19) 4 (25) 0.67 
mMRC Grade 0 0 0 - 
 Grade 1 6 (38) 2 (13) 0.10 
 Grade 2 3 (19) 5 (31) 0.41 
 Grade 3 5 (31) 7 (43) 0.47 
 Grade 4 2 (12) 2 (13) 1.00 
Wheeled walker 0 0 - 
Supplemental oxygen# 11 (69) 10 (63) 0.71 
LTOT≠ 2 (13) 4 (25) 0.37 
Portable oxygen at home 0 0 - 
Smoking status Ex-smoker 10 (63) 15 (94) 0.03* 
 Current-smoker 5 (31) 1 (6) 0.07 
 Non- smoker 1 (6) 0 0.31 
*p < 0.05, ≠home oxygen, #oxygen therapy administered during the hospitalisation.  
Abbreviations: CAT, COPD assessment test; CG, control group; EG, exercise group; FEV1, forced 
expiratory volume in one second; FEV1 %pred, percentage of predicted FEV1 (282); FVC, forced vital 
capacity; FVC %pred, percentage of predicted FVC; GOLD, Global Initiative for Chronic Obstructive 
Lung Disease; HS, Hospital Selayang; IRM, Institute of Respiratory Medicine; kg, kilograms; L, litres; 
LTOT, long-term oxygen therapy; m, metres; mMRC, modified Medical Research Council; SD, 
standard deviation; yr, years. 

























Figure 5.8: Change in the 2MWD from baseline. Dashed horizontal line represents the COR 
of 14m for the 2MWD. Abbreviations: 2MWD, two-minute walk distance; COR, coefficient 
of repeatability; m, metres. 
 
























Figure 5.9: Baseline and re-assessment measures for a) 2MWD and b) QMF 
between the EG and CG.  
Data are expressed as mean ± standard error. *p < 0.05 indicates a significant 
between-group difference, †p < 0.05 indicates a significant within-group difference. 
Abbreviations: CG, control group; EG, exercise group; 2MWD, two-minute walk 



























Table 5.6: Within- and between-group differences for measures collected during the 2MWT 
Variable EG (n = 16) 
mean ± SD 
 CG (n = 16) 
mean ± SD 
 Between-group 
difference  
 Baseline Re-assessment p value  Baseline Re-assessment p value  MD;      95% CI 
2MWD (%pred)   62 ± 16       77 ± 19 < 0.01    62 ± 20   72 ± 21 < 0.01  5; 0.4 to 10.3 
    Peak HR (bpm) 121 ± 17     120 ± 20 0.72  123 ± 12 124 ± 17 0.90  -2; -11 to 8  
    Peak HR (%pred HRmax) 72 ± 9       71 ± 11 0.73  74 ± 7   74 ± 10 0.96  -1; -6 to 5 
    Nadir SpO2 (%) 91 ± 5       94 ± 4 0.03  88 ± 6 91 ± 5 0.14  -0.2; -4.5 to 4.1 
    Peak dyspnoea   4.9 ± 2.3 2.6 ± 1.7 0.01    4.3 ± 2.3   3.5 ± 2.0 0.32  -1.5; -3.4 to 0.4 
    End-test leg fatigue   0.5 ± 1.0 0.6 ± 1.4 0.65    0.4 ± 0.8   1.0 ± 1.4 0.10  -0.4; -1.3 to 0.4 
    Rest duration (s)     8 ± 16  4 ± 11 0.12    10 ± 18   3 ± 8 0.04  4; -16 to 25 
 n (%) n (%)   n (%) n (%)   p value 
    Number of rests 0 11 (69) 14 (88) 0.08  11 (69) 14 (88) 0.18  0.94 
 1 4 (25) 1 (6) 0.56  5 (31) 2 (12) 0.18  0.46 
 2 1 (6) 1 (6) 1.00  0 0 1.00  1.00 
Between-group differences were calculated by comparing the change in the EG between baseline and re-assessment measures with the change in 
the CG between baseline and re-assessment measures.  
Abbreviations: 2MWD, two-minute walk distance; 2MWD (%pred), percentage of 2MWD estimated using the equation derived in Chapter 4; 
95% CI, 95% confidence interval; bpm, beats per minute; CG, control group; EG, exercise group; HR, heart rate; %pred HRmax, peak HR as % 
of HRmax (210 – [0.65 × age]) (252); MD, mean difference; n, number; s, seconds; SD, standard deviation; SpO2, percutaneous oxygen 
saturation.





















Figure 5.10: Baseline and re-assessment measures for a) STST and b) TUG between 
the EG and CG.  
Data are expressed as mean ± standard error. *p < 0.05 indicates a significant 
between-group difference, †p < 0.05 indicates a significant within-group difference.  
Abbreviations: CG, control group; EG, exercise group; n, number; s, seconds; STST, 
Sit to Stand Test; TUG, Timed Up and Go. 
a) 
b) 




















The total days of wearing the SAM were similar between the EG and the CG. 
Compared with the CG, the EG demonstrated less time spent being sedentary and 
more time spent walking at low intensity PA. Time spent walking at moderate/high 
intensity PA and the average number of steps taken per day were similar between the 
EG and the CG (Table 5.7).























Table 5.7: Between-group differences for measures of PA 
Variable Total  
(n = 34) 
EG  
(n = 17) 
CG  
(n = 17) 
Between-group 
difference 
 Median [IQR] Median [IQR] Median [IQR] p value 
Total wear time (day) 4  [3 to 5] 4  [3 to 5] 4  [2 to 5] 0.45 
Steps/day 3497  [1666 to 6134] 4215  [2133 to 6693] 2198  [1242 to 4857] 0.07 
Time being sedentary (min/day) # 1226  [1116 to 1311] 1154  [1082 to 1275] 1261  [1177 to 1342] 0.04 
Time walking at low intensity (min/day) # 169  [97 to 256] 248  [143 to 307] 126  [84 to 221] 0.03 
Time walking at moderate intensity (min/day) # 37  [17 to 69] 42  [30 to 77] 26  [11 to 53] 0.11 
Data are presented as median [interquartile range] and therefore #the sum of the time spent in each domain does not equal exactly 24 hours or 
1440 min.  
Abbreviations: CG, control group; EG, exercise group; IQR, interquartile range; min, minutes; n, number; PA, physical activity. 




















This is the first study in Malaysia to evaluate the effects of an exercise program 
initiated within two days of hospitalisation for AECOPD. This study found that 
individuals in the EG demonstrated greater gains in exercise capacity and QMF 
compared to the changes observed in the CG. No differences were detected between 
the EG and CG for the magnitude of change in functional measures (i.e. STST and 
TUG test). With regard to the measures of PA, individuals in the EG spent less time 
being sedentary and more time walking at low intensity PA when compared to the 
CG. Although there was no difference between the groups in average number of 
steps taken per day, this is most likely to reflect the large variability in this measure 
and a possible Type II error.  
5.6.1 Effects of an exercise program in people hospitalised with an AECOPD 
5.6.1.1 2MWD 
This is the first RCT of an exercise program initiated early during hospitalisation for 
an AECOPD that investigated changes in exercise capacity using the 2MWT. This 
study showed that in people hospitalised for an AECOPD, an exercise program that 
included both walking and resistance exercises improved functional exercise capacity 
over and above any change seen in the CG. Improvements in functional exercise 
capacity may be important in this population as previous cross-sectional studies have 
shown that low exercise capacity is one of the strongest predictors for outcomes such 
as greater disability (316), increased healthcare utilisation (317) and worse survival 
in people with COPD (318, 319). Nevertheless, data from RCTs that initiated 
exercise training during or shortly following hospitalisation for an AECOPD are 
inconsistent regarding the influence of this intervention on survival. To date, four of 
the RCTs that initiated exercise training during or shortly following hospitalisation 
for an AECOPD have reported data on both exercise capacity and mortality (67, 162, 
241, 244). With regard to exercise capacity, all four studies demonstrated significant 
between-group difference in favour of EG following exercise intervention. With 
regard to mortality, three (75%) of the four studies that reported survival data did not 
undertake any statistical analysis on this outcome (67, 162, 244). However, when 
data from these three studies were combined in a meta-analysis, there was a 
significant effect on mortality in favour of the EG (odds ratio [OR] 0.28; 95% CI 



















0.10 to 0.84) (239). In contrast to this finding, a large recent RCT demonstrated a 
difference in mortality between the EG and the CG, such that those in the CG had 
better 12 month survival (OR 1.74; 1.05 to 2.88) (241). The exact reason for this 
discrepancy in findings is unclear. Therefore, although cross-sectional studies have 
demonstrated that exercise capacity is related to survival, it is uncertain whether an 
exercise intervention, initiated during or shortly following hospitalisation from an 
AECOPD, which is effective at increasing exercise capacity, will influence survival. 
 
Although the overall dose of the exercise (i.e. 4 ± 1 supervised and 4 ± 1 
unsupervised sessions) in this study seems to be quite low to induce a training effect, 
the fact that the participants in the EG could walk further during the re-assessment 
2MWT, with a similar peak HR, nadir SpO2, peak dyspnoea and end-test leg fatigue 
as measured during the baseline assessment, suggests that the training program was 
adequate to induce a physiological adaptations (see Table 5.6). Further, when 
compared to the CG, it can be seen in Figure 5.8 that more participants in the EG had 
an increase in the 2MWD ≥ the COR calculated for the 2MWD when two tests were 
performed on different days (i.e. 14m [see subheading 3.4.2]). This means that, 
participation in the training program appears to have the potential to improve 
functional exercise capacity beyond the threshold for changes that could have 
occurred due to measurement error or the natural variability inherent in the test. This 
finding corroborates data reported in one previous study of exercise training in 
people hospitalised with an AECOPD. Specifically, Borges et al. (71) demonstrated a 
significant between-group difference in the 6MWD following an average of only 5.6 
exercise sessions in people hospitalised with an AECOPD. In addition, there are data 
to suggest that providing six weeks of home-based exercise after discharge from 
hospital to patients who commenced the exercise training program during an in-
patient admission may be effective at sustaining the improvement in exercise 
capacity (241). 
 
Unlike the findings from the current study and the study by Borges et al. (71), four 
studies that investigated the effect of exercise training initiated within two to three 
days of hospitalisation for an AECOPD did not report significant between-group 
differences in exercise capacity on the completion of the exercise (70, 72, 240, 242). 
The reasons that these studies did not demonstrate significant between-group 



















difference in this outcome are likely to relate to factors such as small sample sizes, 
differences in the training approach and low levels of program participation. For 
example, Tang et al. (70) evaluated the differences in exercise capacity between 
three groups, each of which comprised a small sample of 10 or 11 participants. They 
found that the differences in exercise capacity between the three groups were not 
significant (i.e. p > 0.05) but reported small to moderate effect sizes (d = 0.4 and d = 
0.6). Therefore, it appears that this study lack adequate statistical power to detect 
changes in this outcome (70).  
 
In the study by Troosters et al. (72), the lack of between-group difference in exercise 
capacity may be attributable to the fact that the exercise program they used was very 
specific for an improvement in muscle strength but not exercise capacity. That is, 
there was no walking component in the training program and the standard care given 
to all participants did not include early mobilisation (72). It is also important to note 
that the re-assessment of exercise capacity in the study by Troosters et al. (72) was 
not undertaken at the end of hospitalisation period but was conducted four weeks 
following hospital discharge without any post-discharge intervention. Therefore, any 
changes that might have occurred during the training program could have been 
reduced during the four-week period. 
The lack of between-group difference in exercise capacity in the study by Eaton et al. 
(240) appears to reflect, at least in part, sub-optimal adherence with the exercise 
program. That is, in this study only 40% of the patients assigned to the rehabilitation 
group attended 75% or more of the out-patient sessions. The level of adherence to the 
in-patient exercise session was not reported. In contrast, in the present study, the 
participants completed more than 90% of their prescribed exercises. Of note, the 
participants in the present study were provided with one supervised and one 
unsupervised exercise training session daily on top of their standard usual care 
throughout their hospitalisation period. They were also given a diary card to monitor, 
on a daily basis, their adherence to the unsupervised training sessions. 
5.6.1.2 QMF  
The present study demonstrated that an early exercise program that included walking 
and resistance exercises improved QMF over and above any change seen in the CG. 
This finding is particularly important given that QMF has been identified as a 



















significant predictor for important outcomes such as the number of hospital 
admissions due to exacerbation (115), out-patients visits (115) and survival (116) in 
people with COPD. To date, only one RCT has investigated the effects of exercise 
training in people hospitalised for an AECOPD on both QMF and mortality (241). 
This study reported no significant between-group difference in the QMF following 
the training program, but, controversially, demonstrated a difference in mortality 
between the EG and the CG, such that those in the CG had better 12 month survival 
(241). Therefore, although QMF has been identified as a significant predictor for 
survival, it is unclear whether or not an exercise intervention initiated during or 
shortly following hospitalisation from an AECOPD, which is effective at increasing 
QMF, will influence survival. 
 
The improvement in QMF after a short period of training is most likely explained by 
the involvement of neural adaptation to the continuous increasing stimulus given to 
the skeletal muscle (320). In addition, Troosters et al. (72), being the only previous 
study with a consistent finding, found that a short period of exercise training also 
appeared to have the potential to counterbalance the negative consequences of an 
AECOPD on muscle function (72). Specifically, they performed skeletal muscle 
biopsies on 20 individuals hospitalised with an AECOPD who had participated in 
only 6 ± 1 sessions of quadriceps strengthening exercise and found that (i) the level 
of myostatin, a negative regulator of muscle growth was significantly lower in the 
EG compared to the CG; (ii) the anabolic/catabolic balance was in favour of 
anabolism in the EG; and (iii) there was a trend for a higher myogenin/MyoD ratio in 
the EG compared to the CG (72). Myogenin is a transcription factor involved in the 
coordination, development and repair of skeletal muscle, while myoD is a protein 
that in a high dose suppresses cell renewal and induces apoptosis. Therefore, the 
improvement in QMF after only a short period of training in the present RCT may 
also be related to the changes that have occurred at the muscle level in addition to 
neural adaptation. 
 
Although the finding in the present study was consistent with the study by Troosters 
et al. (72), the magnitude of change demonstrated in the EG in the present study was 
relatively greater than that seen in the EG of Troosters et al. (72) (i.e. 30% vs. 10% 
from baseline measures). This could be explained in part by the fact that Troosters et 



















al. (72) prescribed a lower dose of exercise sessions (i.e. once daily knee extension 
exercises) and the standard usual care provided to both the EG and the CG was 
limited to airway clearance techniques and breathing exercises. This is in contrast to 
the present study where the participants in the EG performed two sessions of a 
combination of three functional resistance exercises and walking training each day 
throughout their hospitalisation period, and the standard usual care also included 
encouragement to mobilise in the ward. The encouragement to mobilise that was 
given as part of the usual care in the present study could also explain the within-
group improvement in QMF seen in the CG that was not observed in the study by 
Troosters et al. (72).   
 
Unlike the findings from the current study and the study by Troosters et al. (72), four 
other studies (70, 71, 240, 241) were unable to show that the implementation of an 
exercise program changed QMF in people hospitalised with an AECOPD. The 
reasons for this are likely to relate to factors such as the small sample size (70) and 
the use of less sensitive outcome measures to evaluate muscle force (i.e. manual 
muscle testing) (70). Further, the training approach used in these studies may have 
been insufficient to produce significant benefits on QMF (71, 240, 241). Borges et al. 
(71) provided a lower dose of exercise (i.e. 2 sets of 8 repetitions daily) when 
compared to the present study (i.e. 2 training sessions/day with quadriceps being the 
primary muscle worked in all 3 resistance exercises). In the study by Greening et al. 
(241), participants completed an average of only 3 ± 3 sessions of exercises during 
their hospital stay.  
5.6.1.3 STST and TUG test 
This study demonstrated that, on completion of the training program, no between-
group differences were observed in the STST and the TUG test. This finding is likely 
to be related to the fact that, at baseline, participants did not present with substantial 
impairment in either of these measures. Specifically, the mean STST of the 
participants at baseline were 12 ± 3 in the EG and 11 ± 4 in the CG. Although data 
pertaining to the STST in people hospitalised with an AECOPD are not available, the 
number of repetitions in STST in both the EG and CG in the present study were 
higher than that reported by Benton et al. (308) in people with stable COPD (i.e. 10 ± 
1). Similarly, the mean time taken to complete the TUG test (i.e. 7.9 ± 2.4s in the EG 



















and 9.2 ± 3.0s in the CG) was better than the commonly used cut-off value to 
identify individuals at high risk of falls (i.e. TUG ≥ 13.5s) (183), and were similar 
with that reported by Chang et al. (321) in people with stable COPD (i.e. 8.8 ± 2.0s). 
To date, there is only one study that has investigated the TUG test among people 
hospitalised with an AECOPD (322). In this study, Crisan et al. (322) reported that 
the mean times required to perform the TUG test were 15.9s in people with an 
AECOPD, 12.3s in people with stable COPD and 8.6s in healthy controls (322). 
However, the results from this study must be interpreted with caution because the 
authors did not describe the TUG test protocol used in their study and therefore it is 
unknown whether similar test protocol was used between this study and the present 
study. Earlier work has demonstrated that the use of different TUG test instruction 
(e.g. ‘to walk as fast as you can’ vs. ‘to walk at your comfortable pace’) produced a 
difference of more than 2s time in the TUG test (184). Although the difference could 
have been due to the change in the test protocol, their healthy controls, in the absence 
of airflow obstruction, required a similar time to perform the TUG test as required by 
the participants in the present study. This may suggests that the participants in the 
present study did not present with substantial impairment in this measure. 
 
The lack of effect of the exercise program on both of these measures may have also 
been influenced by the fact that the training program in the present study was not 
specific for improvement in these two outcomes. Specifically, during the resistance 
training, the participants were not given any set time to complete the prescribed 
number of exercises and were allowed to rest. Thus, the training may have had an 
effect on the participant’s endurance to perform the STST but not the speed to 
perform the task within a specified time. Likewise, with the TUG test, earlier work 
has shown that in order to see improvement in balance, a balance specific training 
program (e.g. single leg stance or tandem stance) is required (188).  
5.6.1.4 PA 
This is the first RCT of an exercise program in people hospitalised for an AECOPD 
that investigated changes in PA using measures such as time spent walking at 
different physical intensities and average number of steps taken per day. This study 
demonstrated that, on completion of the training program, there were significant 
between-group differences in the amount of time the participants spent being 



















sedentary and walking at low intensity PA. Although there was no between-group 
difference in the average number of steps taken per day over the hospitalisation 
period, the p value for this difference (p = 0.07) approaches the cut-off p value to be 
regarded as statistically significant (p < 0.05). It is also important to note that the 
average number of steps taken per day in the EG was twice as many as the CG and 
both groups demonstrated with large variability in this measure. Therefore, the lack 
of between-group difference in this measure is likely to reflect a Type II error in the 
analysis.  
An intervention that increases participation in PA in people with COPD is likely to 
be important given that low levels of PA has been identified in previous cross-
sectional studies as a significant predictor for important outcomes such as the 
number of hospital admissions due to exacerbation (201, 323) and survival in this 
population (323). To date, only one RCT has investigated the effects of exercise 
training in people hospitalised for an AECOPD on the levels of PA (71). In this 
study, Borges et al. (71) found that participation in an early exercise intervention did 
not change the amount of time their participants spent sitting, lying, standing and 
walking. Participants in both groups (i.e. EG and CG) were equally inactive (p > 
0.05). Further, this study did not report data in relation to survival. Therefore, it is 
unclear whether or not an exercise intervention initiated during or shortly following 
hospitalisation from an AECOPD, which is effective at increasing PA, will influence 
survival.  
Factors such as differences in the training approach between the study by Borges et 
al. (71) and the present study may in part explain the lack of effect observed in the 
study by Borges et al. (71) which is in contrast to the finding of the present study. 
For example, a walking training was not included in the study by Borges et al. (71) 
whereas the EG in the present study performed two sessions of walking per day 
throughout their hospitalisation. This difference in findings highlights the importance 
of including a walking training component to improve level of PA in this group of 
patients.  
5.6.2 Adherence to the exercise program and safety  
Participants in the EG completed more than 90% of their prescribed exercises 
irrespective of the level of supervision they received during the exercise sessions. 



















This means that an exercise intervention initiated within two days of hospital 
admission was well tolerated. The high adherence to the training in the present study 
may be explained, in part, by the fact that both walking and resistance exercises 
elicited only low levels of symptoms (i.e. peak dyspnoea, leg fatigue and muscle 
soreness) and modest oxygen desaturation (see Figure 5.5).  
 
Although earlier work has shown that, in people with COPD, aerobic exercise 
elicited higher cardiopulmonary stress and dyspnoea than resistance exercise (324), 
the present study demonstrated low levels of symptoms (i.e. dyspnoea, leg fatigue 
and DOMS) and only a small magnitude of oxygen desaturation not only in 
resistance exercise but also in walking (aerobic) exercise. However, comparison of 
the cardiorespiratory and symptom responses during the exercise training between 
the present study and the study by Probst et al. (324) must be made with caution 
because the training approach for both walking and resistance exercises between 
these studies were different. For example, the walking training program in the study 
by Probst et al. (324) was performed on a treadmill at 75% of the average walking 
speed during the 6MWT. In contrast, in the present study, participants were allowed 
to select their own walking speed and were also allowed to rest during the training 
session if required. The high level of adherence to exercise training in the present 
study also corroborates the finding from three other studies that reported the levels of 
adherence to exercise training were between 85% and 95% in people hospitalised 
with an AECOPD (70, 71, 241).  
 
With regard to the safety of the exercise program, no adverse event was identified 
during both walking and resistance exercises. During the assessments, only one 
participant exhibited marked oxygen desaturation (i.e. SpO2 < 80%) that resolved 
completely within half an hour after a short burst of supplemental oxygen. The 
incidence of adverse events in this study (i.e. 1 of 16 participants [3%]) was much 
lower than the incidence of adverse events previously reported by Tang et al. (70). 
Specifically, in their study, four (19%) of the 21 participants in the EG experienced a 
total of 11 adverse events of which 10 were regarded as not serious. The higher 
incidence of adverse events reported in the study by Tang et al. (70) compared to the 
present study could have been influenced by the differences in the criteria used to 
define adverse events between these two studies. For example, with regard to the 



















criterion used to define an adverse event of reaching the maximum HR during 
exercise, the formula used in the study by Tang et al. (70) (i.e. 85% of 220-age) 
produced a value for maximum HR that is lower than that produced using the 
formula used in the present study (85% of 210 – [0.65 × age]). Similarly, the 
criterion used to define an adverse event of oxygen desaturation, Tang et al. (70) 
regarded a decrease in SpO2 > 10% as an adverse event while the criterion used in 
the present study was SpO2 < 80%. These differences suggest that lower 
cardiorespiratory responses were regarded as adverse events in the study by Tang et 
al. (70) compared to the criteria used in the present study. 
5.6.3 Strengths and limitations 
The present study is the first RCT to investigate the effect of an early exercise 
program in people hospitalised with an AECOPD in a Malaysian context. The main 
strengths of the present study include: (i) robust methodological factors such as 
analyses being conducted based on the intention-to-treat principle, blinding of the 
outcome assessor and minimal loss to follow-up; (ii) the inclusion of a broad range 
of outcome measures including PA and functional performance measures such as the 
STST and the TUG test and (iii) the measurement of QMF using the force gauge; an 
outcome measure that has been shown to be more reliable than the HHD and the 
MMT.  
The present study also had some limitations. First, the method used for the 
prescription of the resistance exercise in this study (i.e. based on the baseline 30s 
STST) was found to be too intensive for a sample with a baseline STST as high as 12 
± 3. From Figure 5.6, it can be seen that the targeted prescription in the resistance 
exercise was not achieved by 50% of the participants despite high adherence to the 
training sessions. Second, due to the sample size being calculated to detect between-
group differences in the QMF and 2MWD, it is possible that the non-significant 
between-group differences observed for some outcomes, such as daily step count, 
may have been the result of a Type II error. However, the sample (n = 32) reached 
the sample size prospectively calculated for this study and the number of participants 
included in this study is similar to those previously studied (70-72).  




















This study has demonstrated that an exercise program that comprised walking and 
resistance exercise significantly reduced the deleterious effects of an AECOPD on 
exercise capacity and QMF. Participation in the exercise program did not 
significantly improve the STST and TUG test over and above any changes observed 
in the CG. With regard to the PA measures, although participation in the exercise 
program did not significantly increase the total number of steps taken per day, it did 
decrease the total time the participants spent being sedentary and increase the total 
time they spent participating in low intensity PA. Therefore, it can be concluded that 
participating in the exercise program did have a positive effect on PA level. The high 
level of adherence to the exercise training and the occurrence of only one adverse 
event that resolved relatively quickly supports the findings from previous studies that 
exercise training initiated within two days of hospitalisation for patients with an 
AECOPD is safe and feasible. The present study also extends the findings from 
Chapter 3 that the 2MWT is safe and responsive in people hospitalised for an 
AECOPD, and can be used to prescribe an effective, safe and well tolerated exercise 
program. 




CHAPTER 6  
SUMMARY AND CONCLUSIONS  
 
This program of research provides novel and important information pertaining to 
both the assessment and rehabilitation of people with chronic obstructive pulmonary 
disease (COPD) who are characterised by profound dyspnoea on exertion. Regarding 
assessment, data are provided pertaining to the measurement properties (i.e. effect of 
test repetition, validity and responsiveness), interpretation and feasibility of the two-
minute walk test (2MWT). Regarding rehabilitation, data are provided from a 
randomised controlled trial (RCT) that investigated the feasibility and effectiveness 
of an exercise program initiated within two days of hospital admission in people 
hospitalised with an acute exacerbation of COPD (AECOPD) on outcomes such as 
functional exercise capacity, quadriceps muscle force (QMF) and levels of physical 
activity (PA). 
6.1 Effect of test repetition, validity and responsiveness of the 2MWT  
Data presented in Chapter 3 demonstrated that the two-minute walk distance 
(2MWD) is repeatable in people with moderate to severe COPD. Specifically, the 
2MWD had a very small learning effect (i.e. mean difference; 95% CI, 4%; 1% to 
7%) which appears to be smaller than the learning effect for the six-minute walk 
distance (6MWD) as reported in a previous study among people with moderate to 
severe COPD (i.e. 11%; 9% to 12%) (6). This finding suggests that a practice walk 
for the 2MWT is less important than for the 6MWT, and may not be necessary in 
people with moderate to severe COPD. The choice not to do a practice walk in this 
population may result in only a small over-estimation of the magnitude of a treatment 
effect. A previous study has demonstrated that people who report higher levels of 
dyspnoea during the 6MWT are more likely to demonstrate an increase in the 
6MWD with test repetition (6). Future studies are needed to explore the 
characteristics of those who are most likely to increase their 2MWD with test 
repetition.  
Regarding validity, a strong linear relationship (r = 0.66, p = 0.003) was found 
between the 2MWD and the 6MWD. This finding supports the concurrent validity of 




the 2MWT as a measure of exercise capacity in people with moderate to severe 
COPD. Although reporting the concurrent validity of the 2MWD with the gold 
standard measure of exercise capacity (i.e. peak rate of oxygen uptake [VO2 peak] 
measured during a laboratory-based exercise test) would have strengthened the 
conclusions about the validity of the 2MWT, collection of such data was not feasible 
among the participants in the study described in Chapter 3 because of the high 
proportion of the participants who were on ambulatory oxygen. As earlier work has 
demonstrated a strong association between the 6MWD and VO2 peak (r = 0.73; p < 
0.001) in people with moderate to severe COPD, the 6MWD was used as a surrogate 
for VO2 peak in this study. The study described in Chapter 3 also found that people 
with moderate to severe COPD walked 31 ± 22m (27%) further during the 2MWT 
than one third of the distance walked during the 6MWT (p < 0.001). This 
information is particularly important for clinicians who evaluate the effect of an 
intervention (e.g. exercise program) using the 6MWT at baseline and are tempted to 
use the 2MWT on completion of the program in patients who develop an AECOPD 
or because the clinicians are under time pressure. Even though the 6MWT is three 
times as long as the 2MWT, comparing one third of the distance walked during the 
6MWT performed at baseline with the 2MWD measured post-intervention will lead 
to an over-estimation of the effects of the intervention on this outcome.  
With regard to the responsiveness of the 2MWD, data presented in Chapter 5 
demonstrated that the 2MWD in both an exercise group (EG) (123 ± 34m vs. 162 ± 
38m; p < 0.001) and control group (CG) (126 ± 44m vs. 146 ± 44m; p < 0.001) 
increased during the period of hospitalisation. This is consistent with the 
improvement seen in clinical status during the course of a hospital admission. More 
importantly, the 2MWD was shown to be responsive to exercise training in people 
hospitalised for an AECOPD. This is shown by the greater magnitude of increase in 
this outcome in favour of the EG (mean difference [95% confidence interval]: 13m 
[3 to 23m]). Further study is required to establish the minimal clinically important 
difference for the 2MWD. 
6.2 Interpretation of the 2MWD 
Data presented in Chapters 3 and 4 provides important and novel information to 
facilitate interpretation of the 2MWD. The study described in Chapter 3 calculated 
the coefficient of repeatability (COR) for the 2MWDs measured over two days in 




people with moderate to severe COPD, and the study described in Chapter 4 
developed regression equations to estimate the 2MWD in Malaysian adults without 
significant disease.  
The COR for the 2MWD measured over two days in people with moderate to severe 
COPD was 14m. This suggests that, for an individual patient, a change of ≥ 14m in 
response to an intervention is needed in order for the clinician to be 95% confident 
that the difference in the 2MWDs is not due to measurement error or the natural 
variability inherent in the test. The COR for the 2MWD also appears to be smaller 
than the COR for the 6MWD as reported in previous studies among people with 
moderate to severe COPD (51m (234) and 63m (269)). This means that, in people 
with moderate to severe COPD, clinicians can be confident of a true change in the 
2MWD with much smaller changes in the test result compared to the 6MWD.  
The regression equations presented in Chapter 4 to estimate the 2MWD were  
2MWD = 196 - (1.1 × age) + (1.0 × ∆HR [i.e. peak HR measured during the 2MWT 
- resting HR]) + (31.2 × gender) where females = 0 and males = 1 
2MWD = 279 - (1.7 × age) + (35.9 × gender) where females = 0 and males = 1.  
These equations will allow researchers and clinicians to estimate the 2MWD in the 
general Malaysian population and thereby express the 2MWD in a clinical 
population as a percentage of the estimated value (i.e. % predicted). Expressing the 
2MWD as a % predicted value provides patients and clinicians with an indication of 
the impact their disease has had on exercise capacity. Although there have been two 
previously published regression equations to estimate the 2MWD (17, 18), data 
presented in Chapter 4 demonstrated little agreement in the 2MWD measured in a 
Malaysian sample and the 2MWDs estimated using either of the two published 
equations. Therefore, these two previous equations are unlikely to be suitable for use 
in the Malaysian population. Given that the equations presented in Chapter 4 are the 
first to estimate the 2MWD in adults living in the Asian region, they are likely to be 
the most appropriate equations to facilitate interpretation of the 2MWD not only in 
Malaysia but also in other Asian countries with similar cultural backgrounds and 
anthropometric characteristics to Malaysia, such as Indonesia, Singapore and 
Southern Thailand. Future studies are needed to validate these equations in a larger 




sample of Malaysian adults and explore the differences in the 2MWDs (if present) 
between the three major ethnic groups in Malaysia (i.e. Malay, Chinese and Indian). 
6.3 Tolerance of the 2MWT 
The 2MWT appears to be better tolerated than the 6MWT among people with 
moderate to severe COPD. That is, data presented in Chapter 3 demonstrated that in 
participants with moderate to severe COPD, compared to the 6MWT, the 2MWT 
elicited a lower peak heart rate (112 ± 15bpm vs. 107 ± 13bpm; p < 0.001), less 
oxygen desaturation (82 ± 7% vs. 86 ± 6%; p < 0.001) and lower levels of dyspnoea 
(Borg score 5 ± 2 vs. 4 ± 2; p < 0.01). The proportion of participants who rested and 
the duration of rests were also lower during the 2MWT. Specifically, two (11%) 
participants rested once throughout the 2MWT while 13 (72%) participants required 
between one to three rest(s) during the 6MWT. The duration of rests for the 2MWT 
ranged between 7s and 13s while the duration of rest for the 6MWT ranged between 
3s and 167s. When the 2MWT was used to measure exercise capacity in people 
hospitalised with an AECOPD, data in Chapter 5 demonstrated that 13 (34%) of the 
participants required one or two rest(s) when the test was performed within the first 
two days of hospital admission. The proportion of those requiring a rest reduced to 
four (11%) when the test was performed on the day of hospital discharge. Therefore, 
it appears that people hospitalised for an AECOPD are likely to tolerate the 2MWT. 
The low proportion of those requiring a rest during the 2MWT as well as the low 
frequency of rest required when the test was performed as early as within two days of 
hospitalisation for and AECOPD may also suggest that the test make more efficient 
use of clinician’s time. 
6.4 Rehabilitation in people hospitalised with an AECOPD 
The study described in Chapter 5 was the first RCT to evaluate the benefits of an 
exercise program that comprised both walking and resistance exercise in people 
hospitalised with an AECOPD. The study design minimised the risk of bias by 
randomising the participants to the EG or CG, concealing the randomisation 
sequence, using a person who was blinded to group allocation to collect outcome 
measures, ensuring minimal loss to follow-up and analysing the data according to the 
intention-to-treat principle.  




Data presented in Chapter 5 demonstrated that in people hospitalised for an 
AECOPD, an individualised, progressive exercise program that comprised walking 
and resistance exercise was effective at improving the 2MWD and QMF. Further, 
those who completed the exercise program spent less time being sedentary and more 
time walking at low intensity PA compared to the CG. Of note, in this study, training 
was initiated within two days of being hospitalised, participants completed only a 
mean of 4 ± 1 sessions of supervised exercise and 4 ± 1 sessions of unsupervised 
exercise sessions and all training was completed using minimal equipment. This 
program was therefore inexpensive and can be easily replicated in countries where 
the length of hospitalisation for an AECOPD is short and healthcare funding is 
limited (e.g. Malaysia). 
Data presented in Chapter 5 were also the first to report no difference in the 
adherence to supervised and unsupervised exercise sessions among people 
hospitalised for an AECOPD. Participants in the EG completed 96 ± 9% of their 
scheduled supervised training and 92 ± 13% of their scheduled unsupervised training 
sessions (p = 0.22). The high adherence to the training sessions is likely to reflect the 
fact that the training program elicited low levels of symptoms (i.e. peak dyspnoea, 
leg fatigue and muscle soreness), no adverse events and was therefore well tolerated. 
The high adherence to the unsupervised sessions suggests that participants are likely 
to complete the training in the absence of direct supervision by a healthcare 
professional. This information is particularly relevant to clinicians working in a busy 
healthcare setting as it suggests that they do not need to provide two supervised 
sessions per day in order for participants to benefit from the exercise program 
described in Chapter 5. Future studies should explore the long-term effects of an 
exercise program initiated within two or three days of hospitalisation for an 
AECOPD on important outcomes such as exercise capacity, QMF, PA and 
readmission rate. 
6.5 Conclusions 
In people with COPD who are characterised by profound dyspnoea on exertion, such 
as those with severe COPD or those who are hospitalised for an AECOPD, the 
2MWT appears to be an appropriate alternative to the 6MWT for measuring 
functional exercise capacity. An exercise program initiated within two days of 
hospitalisation for an AECOPD is safe and feasible. A combination of walking and 




resistance exercise is effective at minimising the deleterious effect of an AECOPD 
on exercise capacity and QMF and appears to have a positive effect on PA. The three 
studies presented in this doctoral thesis have contributed important and novel 
information that both researchers and clinicians can use when developing a protocol 
to undertake a 2MWT in this population and to optimise the rehabilitation of people 
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These guidelines apply when testing patients with stable lung disease in a hospital 
out-patient setting; modifications to the guidelines and protocol are required when 
testing patients in community settings, during an acute exacerbation and for patients 
with pulmonary arterial hypertension (PAH). Contraindications, criteria for 
terminating the test and safety issues have been developed based on published 
guidelines. (ACSM 2006; ATS 2002; ATS/ACCP 2003). 
 
Contraindications for Exercise Testing 
: When information is available 
Absolute Contraindications Relative Contraindications* 
A recent significant change in the 
resting ECG suggesting significant 
ischemia, recent AMI (within 3-5 days) 
or other acute cardiac event 
Neuromuscular, musculoskeletal, or 
rheumatoid disorders that are 
exacerbated by exercise  
Unstable angina Moderate stenotic valvular disease 
Uncontrolled cardiac dysrhythmias 
causing symptoms or hemodynamic 
compromise 
Left main coronary artery stenosis  
Symptomatic severe aortic stenosis Tachydysrhythmia or bradydysrhythmia 
Uncontrolled symptomatic heart failure High-degree atrioventricular block  
Syncope Ventricular aneurysm 
Acute pulmonary embolus or 
pulmonary infarction 
Hypertrophic cardiomyopathy and other 
forms of outflow tract obstruction  
Acute myocarditis, pericarditis or 
endocarditis 
Acute systemic infection, accompanied 
by fever, body aches, or swollen lymph 
glands 
Suspected or known dissecting 
aneurysm 
Lower limb thrombosis (acute, 
untreated) 
Acute infections  Electrolyte abnormalities (e.g. 
hypokalemia, hypomagnesemia) 
Severe arterial hypertension at rest 
(SBP>200mmHg, DBP>120mmHg) 
Uncontrolled metabolic disease (e.g. 
diabetes) 
Severe pulmonary hypertension (if data 
available) 
Chronic infectious disease (e.g. 
hepatitis, AIDS) 
* may be superseded if benefits outweigh risks 
 
 





Appendix 2: Continued 
Additional Contraindications 
Unstable angina or AMI (Non STEMI) during the previous month. Stable 
exertional angina is not an absolute contraindication but the test should be 
performed after patient has taken anti angina medication and with rescue nitrate 
available 
Resting SpO2 ≤ 90% (check accuracy of reading and consider placing sensor on 
another finger/try ear sensor if available, warm sensor site, palpate pulse to ensure 
it is consistent with rate measured on oximeter) 
Pre-exercise heart rate > 125 (and irregular) 
Disability or impairment leading to safety concerns (e.g. orthostatic hypotension, 
balance problems, unsteady gait, require one assistant to walk) 
 
 
Criteria to terminate the test 
Participant requests to terminate the test 
e.g. intolerable dyspnoea not relieved by rest; onset of palpitations; severe leg 
pain/cramps; feeling of profound weakness/fatigue; severe wheezing; pain from 
comorbid condition e.g. lower back pain 
Any untoward medical occurrence, sign or symptom occurring during the test 
i. Onset of chest pain suggestive of ischemia 
ii. Abnormal heart rate response confirmed by palpitation (e.g. failure of HR to 
increase unless fixed rate pacemaker in situ; fall in HR); persistent 
tachycardia (HR > 210 – [0.65 × age]) 
iii. Signs and symptoms of poor perfusion (sudden pallor, dizziness or fainting) 
iv. Development of an abnormal gait/loss of coordination 
v. Signs suggestive of mental confusion 
 
 
Criteria to impose rest during the test 
Profound oxygen desaturation (SpO2 < 80% and falling). In this instance, 
immediately instruct the patient to rest. When SpO2 increases to >80% instruct the 
patient to recommence the test. Note that pulse oximeters are very accurate above 
90% but much less accurate below 80%. Check signal strength/perfusion 




Obtain history of patient’s comorbid conditions and medications 
Current CPR certification is a requirement of person conducting the test 
Perform test where rapid emergency response is available 
If patient is on oxygen therapy, test patient using prescribed flow rate and with 
usual method of O2 transportation if performing a walking test (check if 













Appendix 4: Standardised health screening form 
Participant No 
  




        
Age/gender/race   
 
Medications/ 
supplements   
 
Inclusion criteria: 









          Forced expiratory volume in one second (FEV1) ≥ 80% of the 






    Exclusion criteria 





          History of significant condition that may adversely affect 
performance: 
   Musculoskeletal (arthritis, recent joint replacement, amputee, do 




    
          Neurological (stroke, Parkinson's disease, multiple sclerosis, ever 




    
          Cardiovascular (angina on exertion, previous myocardial infarction, 




    





    Current medical status 















          An upper respiratory tract infection within the previous 4 week period   
 
  















Appendix 5a: Protocol for the 2MWT (English version) 
 
 
A standard protocol for the 2MWT was developed based on published guidelines. 
 
Instructions 
Introduce the Borg dyspnoea scale with its standard instructions and record pre-
exercise dyspnoea intensity and heart rate. Be consistent in using either right or left 
arm when measuring BP. Describe the walking course to participant (e.g. explain to 
turn in front of cones) 
 
Give the participant the following instructions: 
"You are now going to do a 2 minute walking test. The object of this test is to 
walk as fast as you can for 2 minutes so that you cover as much ground as 
possible. You may slow down if necessary. If you stop I want you to continue to 
walk again as soon as possible. You will be regularly informed of the elapsed time 
and you will be encouraged to do your best. Your goal is to walk as far as possible 
in 2 minutes. Please do not talk during the test unless you have a problem or I ask 
you a question. You must stop walking and let me know if you have any chest pain 
or dizziness. Do you have any questions?” 
 
Begin the test with “Start Walking Now” and use the following standard 
encouragements 
30 Seconds  1 ½ minute remaining (participant name) 
Do your best 
60 Seconds  Halfway (participant name) - 1 minute remaining 
You’re doing well, Keep it up! 
90 Seconds   30 seconds remaining (participant name) 
Do your best  
120 Seconds Stop there 
 
If the participant stops, record dyspnoea and give the following encouragement  
“Begin walking as soon as you feel able” 
(Repeat this encouragement every 15 seconds if necessary) 
 
Record: 
Number of completed lengths and distance of any incomplete lengths walked; 
number and duration of rest periods (if present). At the end of the test, record HR, 
dyspnoea, and leg fatigue.  
 





Appendix 5b: Protocol for the 2MWT (Malay version) 
 
 
Protokol Ujian Berjalan selama 2 minit ini telah diadaptasi dari protokol ujian 
berjalan selama 6 minit yang telah diterbitkan. 
Arahan: Memperkenalkan skala Borg dengan menggunakan arahan seperti di dalam 
garis panduan. Rekod kadar kesesakan nafas dan denyutan jantung sebelum ujian 
dimulakan. Tekanan darah harus diukur secara konsisten dengan hanya 
menggunakan sama ada tangan kanan atau tangan kiri sahaja. Terangkan jarak 
koridor (seperti peserta diminta pusing sebelum kon). 
Beri peserta arahan seperti berikut: 
“Anda akan menjalankan ujian berjalan selama dua minit . Di dalam ujian ini, anda 
diminta untuk berjalan secepat yang anda mampu untuk menghabiskan jarak yang 
lebih jauh. Anda dibenarkan mengurangkan kelajuan jika perlu. Sekiranya and perlu 
berhenti, anda diminta untuk sambung semula berjalan secepat yang anda mampu. 
Anda akan sentiasa dimaklumkan tentang masa yang telah berlalu dan diberi galakan 
untuk melakukan yang terbaik. Anda tidak dibenarkan bercakap semasa sesi ujian 
kecuali jika anda mempunyai sebarang masalah atau sekiranya saya bertanyakan 
sebarang soalan. Anda dimestikan untuk berhenti berjalan dan memaklumkan kepada 
saya sekiranya anda mengalami sakit di bahagian dada atau berasa pening. Adakah 
anda mempunyai sebarang soalan?” 
 
Mulakan ujian dengan arahan “Anda boleh mula sekarang” dan galakan: 
30 Saat  Anda tinggal satu setengah minit (nama peserta). Cuba yang terbaik!  
60 Saat Separuh masa telah tamat (nama peserta) Anda tinggal 1 minit. Anda 
melakukannya dengan baik! Gandakan usaha! 
90 Saat  Anda tinggal 30 saat (nama peserta) Cuba yang terbaik! 
120 Saat Berhenti  
 
Jika peserta berhenti, rekod kadar kesesakan nafas (jika ada) dengan menggunakan 
skala Borg dan beri galakan seperti berikut: 
 
"Mulakan berjalan apabila anda rasa mampu" 
(Ulangi galakan ini pada setiap 15 saat) 
 
Rekod: Bilangan ulangan 'lap' yang lengkap dan jarak ulangan yang tidak lengkap, 
bilangan dan tempoh setiap waktu rehat (jika ada). Semasa ujian berakhir, rekod 
kadar deyutan jantung, kesesakan nafas dan kepenatan pada otot kaki (jika ada). 
 
 









                    
Ethnicity 
Malay Chinese Indian TOTAL 
40-49 years 7 (54) 4 (31) 2 (15) 13 
50-59 years 7 (54) 3 (23) 3 (23) 13 
60-69 years 7 (58) 3 (25) 2 (17) 12 
70-75 years 3 (50) 2 (33) 1 (17) 6 
TOTAL 44 




                    
Ethnicity 
Malay Chinese Indian TOTAL 
40-49 years 7 (58) 3 (25) 2 (17) 12 
50-59 years 7 (54) 3 (23) 3 (23) 13 
60-69 years 7 (58) 3 (25) 2 (17) 12 
70-75 years 3 (50) 2 (33) 1 (17) 6 
TOTAL 43 











These guidelines apply when testing patients with an acute exacerbation of COPD in 
a hospital in-patient setting. Contraindications, criteria for terminating the test and 
safety issues have been developed based on published guidelines. (ACSM 2006; 
ATS 2002; ATS/ACCP 2003). 
 
Contraindications for Exercise Testing  
: When information is available 
Absolute Contraindications Relative Contraindications* 
A recent significant change in the 
resting ECG suggesting significant 
ischemia, recent MI (within 2 days) or 
other acute cardiac event 
Neuromuscular, musculoskeletal, or 
rheumatoid disorders that are 
exacerbated by exercise  
Unstable angina Moderate stenotic valvular disease 
Uncontrolled cardiac dysrhythmias 
causing symptoms or hemodynamic 
compromise 
Left main coronary artery stenosis  
Symptomatic severe aortic stenosis Tachydysrhythmia or bradydysrhythmia 
Uncontrolled symptomatic heart failure High-degree atrioventricular block  
Syncope Ventricular aneurysm 
Acute pulmonary embolus or 
pulmonary infarction 
Hypertrophic cardiomyopathy and other 
forms of outflow tract obstruction  
Severe arterial hypertension at rest 
(SBP>200mmHg, DBP>120mmHg) 
Electrolyte abnormalities (e.g. 
hypokalemia, hypomagnesemia) 
Severe pulmonary hypertension (if data 
available) 
Acute systemic infection, accompanied 
by fever, body aches, or swollen lymph 
glands 
Suspected or known dissecting 
aneurysm 
Uncontrolled metabolic disease (e.g. 
diabetes) 
Severe pulmonary hypertension Chronic infectious disease (e.g. 
hepatitis, AIDS) 
Acute myocarditis, pericarditis or 
endocarditis  
Lower limb thrombosis (acute, 
untreated) 
* may be superseded if benefits outweigh risks 
 
 
GUIDELINES FOR EXERCISE TESTING IN PEOPLE HOSPITALISED 





Appendix 7: Continued 
Additional Contraindications 
Unstable angina or AMI (Non STEMI) during the previous month. Stable 
exertional angina is not an absolute contraindication but the test should be 
performed after patient has taken anti angina medication and with rescue nitrate 
available 
Resting SpO2 ≤ 88% (check accuracy of reading and consider placing sensor on 
another finger/try ear sensor if available, warm sensor site, palpate pulse to ensure 
it is consistent with rate measured on oximeter) 
Pre-exercise heart rate > 125 (and irregular) 
Disability or impairment leading to safety concerns (e.g. orthostatic hypotension, 
balance problems, unsteady gait, require one assistant to walk) 
Requiring NIV during waking hours 
 
 
Criteria to terminate the test 
Participant requests to terminate the test 
e.g. intolerable dyspnoea not relieved by rest; onset of palpitations; severe leg 
pain/cramps; feeling of profound weakness/fatigue; severe wheezing; pain from 
comorbid condition e.g. lower back pain 
Any untoward medical occurrence, sign or symptom occurring during the test 
i. Onset of chest pain suggestive of ischemia 
ii. Abnormal heart rate response confirmed by palpitation (e.g. failure of HR to 
increase unless fixed rate pacemaker in situ; fall in HR); persistent 
tachycardia (HR > 210 − [0.65 × age]) 
iii. Signs and symptoms of poor perfusion (sudden pallor, dizziness or fainting) 
iv. Development of an abnormal gait/loss of coordination 
v. Signs suggestive of mental confusion 
 
 
Criteria to impose rest during the test 
Profound oxygen desaturation (SpO2 < 80% and falling). In this instance, 
immediately instruct the patient to rest. When SpO2 increases to >80% instruct the 
patient to recommence the test. Note that pulse oximeters are very accurate above 
90% but much less accurate below 80%. Check signal strength/perfusion 




Obtain history of patient’s comorbid conditions and medications 
Current CPR certification is a requirement of person conducting the test 
Perform test where rapid emergency response is available 
If patient is on oxygen therapy, test patient using prescribed flow rate and with 
usual method of O2 transportation if performing a walking test (check if 















Appendix 8: Diary card to monitor the adherence to the unsupervised training sessions 
ID  Date/ Day  


















Breathlessness 0 0.5 1 2 3 4 5 6 7 8 9 10 
Target Achieve 
 
 
S
tep
 u
p
s 
W
a
lk
in
g
 
H
a
lf sq
u
a
ts 
S
it to
 sta
n
d
s 
  
 
A
p
p
en
d
ices 
 
